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Abstract
Efficacy and safety of paediatric immunization-linked intermittent preventive treatment in 
infants (IPTi) in the prevention of malaria morbidity in rural western Kenya
Frank Ouma Odhiambo
Background: Intermittent preventive treatment in infants (IPTi) with sulphadoxine-pyrimethamine 
(SP) for the prevention of malaria has shown encouraging results in recent trials. However, 
resistance to SP is rising and alternative drugs for IPTi need to be evaluated.
Objectives: To evaluate the safety and efficacy of different drugs for IPTi and to better 
understand the role of treatment vs. prophylactic effect of IPTi by comparing short and long-acting 
antimalarials.
Methods: In an area of western Kenya with stable perennial malaria transmission and high usage 
of insecticide-treated nets, we conducted a randomized, double-blind, placebo-controlled trial with 
SP plus 3 days of artesunate [SP-AS3], 3 days of amodiaquine-artesunate [AQ3-AS3], or 3 days 
of chlorproguanil-dapsone [CD3]) administered at routine expanded programme of immunization 
visits (10 weeks, 14 weeks and 9 months). The primary endpoint was time to first or only episode 
of clinical malaria in the first year of life. Data was analysed using regression and survival analysis 
in SAS and STATA. The ClinicalTrials.gov identifier was NCT00111163.
Results: 1365 children received >1 dose of study drug and were included in the ITT analysis. The 
incidence of clinical malaria during the first year of life was 0.98 per PYAR in the placebo group 
and the median time to first episode was 196 days, compared to 204 (p=0.01), 208 (p=0.007) and 
196 (p=0.633) in the SP-AS3, AQ3-AS3, and CD3 group, respectively. The corresponding 
protective efficacies (PE) and 95% confidence intervals (Cl) against clinical malaria were: PE 
25.7% (6.3,41.1); 25.9% (6.8,41.0); and 16.3% (-5.2,33.5) forSP-AS3, AQ3-AS3, and CD3 
respectively. When multiple episodes of clinical malaria were considered the corresponding 
results were 22.2% (95% Cl: 2.5 , 37.8; p=0.029), 24.7% (95% Cl: 6.4,39.5; p=0.011), and 
10.5% (95% Cl: -11.6,28.2; p=0.324). A more specific case definition for clinical malaria (with 
>5000 par/pL of blood) showed much higher PEs; 48.9% (95% Cl: 12.2,70.3; p=0.015), 41.2% 
(95% Cl: 2.5,64.5; p=0.04), and 3.4% (95% Cl: -52.3,38.8; p=0.88). The PEs against the first or 
only episode of mild anaemia (Hb <11.0g/dL) was 16.4% (95% Cl: -0.6,30.4; p=0.057) in the SP- 
AS3 arm, 20.3% (95% Cl: 4.0,33.9; p=0.017) in the AQ3-AS3 arm, and 8.0% (95% Cl: -10.6 , 
23.5; p=0.375) in the CD3 arm. The corresponding figures for moderate-to-severe anaemia (Hb 
<8.0g/dL) were 27.5% (-6.9,50.8), 23.1% (-11.9,47.2), and 11.4% (-28.6,39.0) forSP-AS3, 
AQ3-AS3, and CD3 respectively. None of the regimens appeared to provide statistically 
significant protection against, all-cause out-patient visits, all-cause hospitalizations, malaria- 
related hospitalizations, or hospitalizations related to moderate-to-severe anaemia. A very high 
protective efficacy was found against the first or only episode of clinical malaria within a period of 
30 days after the first course of IPTi. Post-dose analyses suggested a significant protective effect 
for at least 4 weeks with SP-AS3 and AQ-AS3, and at least 2 weeks for CD3. Importantly, there 
was no evidence of a sustained effect of IPTi after this initial period for any of the three drug 
combinations. There was no evidence for a consistent rebound effect in the second year of life. All 
regimens were well tolerated. Out of a total of 11,568 drug doses administered, only 2.1% were 
vomited. The total rate of vomiting across the 3 courses was significantly higher with each drug 
intervention than with placebo. There were 593 serious adverse events (SAEs) recorded during 
the 1st year of life. Of these, 55 were deaths, and 538 were hospitalizations. There was no 
significant difference in the number of SAEs recorded between the treatment and the placebo 
arms. There were no cases of severe haemolysis recorded. Further analysis showed that being a 
G6PD deficient male in the CD3 arm significantly increased ones’ chances of having moderate-to- 
severe anaemia in the first year of life, -166.8% (95% Cl: -497.5 , -19.1; p=0.017). Serologic 
responses to EPI vaccines are pending.
Conclusion: The results suggest that long-acting regimens are more suitable for IPTi than short­
acting regimens in areas with high ITN usage and perennial malaria transmission, and the 
evidence suggests that the post-treatment prophylactic effect of the long-acting regimens provide 
an important component of the protective effect of IPTi, and appears to last as long as the direct 
pharmacological effect of the drug. There was no evidence for a sustained beneficial or harmful 
effect beyond this immediate period of protection.
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Chapter 1: Preface
Introduction
In the late 1990s, the resurgence of malaria across sub-Saharan Africa led 
to the formation of the Roll Back Malaria partnership that set goals to halve 
the burden of malaria worldwide by the year 2010 and halve that again by 
2015, using techniques that already existed or which could be rapidly 
developed (WHO, 1998). A major political turning point for sub-Saharan 
Africa was realised during the summit held in Abuja, Nigeria in 2000 where 
African leaders adopted the Abuja declaration committing their respective 
governments to achieve set goals in malaria control and prevention 
(WHO/CDS/RBM, 2002). Since that summit, there has been an increased 
emphasis on malaria prevention through various strategies, including 
intermittent preventive treatment in pregnant women (WHO, 2004b).
Intermittent preventive treatment is a strategy, which aims to gain most or 
all of the benefits of chemoprophylaxis, while avoiding its main drawbacks. 
Intermittent preventive treatment can be defined as drug administration, in 
curative doses, given at regular intervals to asymptomatic individuals 
already attending facility-based care (for example ante-natal visits), with the 
objective of preventing malaria. Drugs are provided irrespective of the 
presence of parasites or symptoms. The main difference from 
chemoprophylaxis is the fact that in the latter, anti-malarial drugs are given
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regularly at sub-therapeutic doses with the objective of sustaining a 
protective drug level that inhibits the development of the malaria parasite.
The strategy mentioned above has been broadened to include infants and a 
number of trials have demonstrated the benefits of intermittent preventive 
treatment in infants (IPTi) with sulphadoxine-pyrimethamine when given at 
the same time as childhood vaccinations (Schellenberg et al., 2002, 
Chandramohan et al., 2005, Macete et al., 2006, Kobbe et al., 2007, 
Grobusch et al., 2007b, Mockenhaupt et al., 2007)
The study described in this thesis was designed to further investigate 
alternative drug candidates to sulphadoxine-pyrimethamine and issues 
regarding the mode of action of IPTi which is a promising tool for malaria 
control and has the potential to boost the efforts to avert the senseless loss 
of life attributed to malaria.
Outline of the thesis
This thesis consists of the following seven chapters:
• Chapter 1 introduces the thesis.
• Chapter 2 reviews literature that is relevant to IPTi. The first section 
describes the burden of malaria morbidity in children, the second 
section gives a brief assessment of malaria control strategies, and 
the third section provides a more detailed account of the concept 
and rationale of IPTi, completed studies, the current body of
2
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evidence available, and the implications for its future as a malaria 
control strategy.
• Chapter 3 describes the country and site of study, with the first 
section giving a brief outlook of the country, and the second section 
providing more details about the study site and available research 
facilities.
• Chapter 4 gives an outline of the materials and methods used 
including a brief mention of study procedures and a comment on the 
rationale behind the choice of investigational drugs.
• Chapter 5 presents the results illustrated with figures and tables.
• Chapter 6 discusses the results within the context of the current 
body of knowledge and touches on relevant contemporary issues.
• Chapter 7 provides conclusions and recommendations based on the 
findings of this study.
3
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The burden of malaria morbidity
The burden of malaria in children
The global burden of malaria is estimated at over 500 million episodes of 
clinical malaria per year (Snow et al., 2005) resulting in a potentially 
preventable death toll of between 700,000 and 2.7 million deaths of children 
< 5 years of age each year, with sub-Saharan Africa contributing over 89% 
(WHO and UNICEF, 2005, Breman, 2001).
In 2002, it was estimated that over 800,000 deaths occurred among 
children <5 years of age in sub-Saharan Africa where malaria and anaemia 
are two of the leading causes of paediatric hospital admissions and acute 
febrile illnesses are responsible for 400 to 900 million hospitalizations per 
year (Breman et al., 2001, Slutsker et al., 1994, WHO and UNICEF, 2005).
In such hard-hit regions, repeated malaria episodes may impair a child’s 
physical and cognitive development and reduce the child’s attendance and 
performance at school (Bloland et al., 1999, Holding et al., 1999, Brooker et 
al., 2008, Clarke etal.,2008).
There is scanty information about the cost of malaria and the cost- 
effectiveness of different preventive measures but estimates suggest that 
Africa regularly sustains economic losses amounting to approximately 
US$12 billion per year and the disease may slow economic growth by 1.3
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percent per year as a result of lost life and lower productivity (Gallup and 
Sachs, 2001, Sachs and Malaney, 2002). Malaria thus contributes to 
poverty, which in turn exacerbates the disease burden, trapping many 
endemic communities in a vicious cycle of suffering from illness and poverty 
(Sachs and Malaney, 2002).
The burden of anaemia in children
Anaemia affects approximately one-quarter of the world's population and is 
concentrated in preschool-aged children and women. The most recent 
estimated global anaemia prevalence is 47.4 % in preschool-aged children, 
affecting 293 million children (McLean et al., 2008). Recent estimates for 
Africa are lacking but approximately three quarters of preschool children in 
eastern Africa suffer from anaemia, defined as haemoglobin (Hb) 
concentration below 11 g/dL (Arantxa Roca-Feltrer, 2008).
Anaemia in early childhood leads to impaired physical growth and mental 
development, decreased physical fitness and resistance to infections 
(Lozoff et al., 1987, Lozoffetal., 1991, Idjradinata and Pollitt, 1993,
Lawless et al., 1994, Chwang et al., 1988), increased risk of subsequent 
obstetric complications in girls (Gillespie et al., 1991, Brabin et al., 2003) 
and, when blood transfusions are needed, increased risk of HIV infection 
and other blood-borne pathogens (Kerouedan et al., 1994).
Iron deficiency and malaria have been regarded as the predominant causes 
of anaemia among African children. Their relative contribution depends on 
age, season and geographical area, reflecting local and time-dependent
5
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patterns in the availability of iron-containing foods and malaria 
transmission. Children are at highest risk for either iron deficiency anaemia 
or malarial anaemia between 6 and 36 months of age. In preschool 
children, iron deficiency predominantly results from a poor dietary intake of 
iron coupled with rapid body growth. For African children < 5 years of age, 
the overall incidence of severe malarial anaemia (Hb < 5 g/dl) is estimated 
at 15-60 cases per 1,000 children per year (Murphy and Breman, 2001). 
Although hookworm and schistosomiasis may be contributory factors in 
children in this age range, during infancy the prevalence and intensity of 
these infections is typically low. For example in western Kenya only 4.0% of 
infants were infected with hookworm and <1%with Schistosoma mansoni 
(Desai et al., 2005). Nevertheless, severe anaemia due to severe 
hookworm infections has been described even in very young children 
(Nkhoma et al., 2005).
Malaria-associated severe anaemia is an important cause of hospital 
admissions in malaria-endemic areas (Calis et al., 2008). In one hospital in 
Malawi, nearly 10% of admissions were for malaria-related severe 
anaemia; the peak prevalence occurred among infants aged 6-11 months 
(15%) (Slutsker et al., 1994). These rates were lower in children admitted to 
a hospital in an area not holo-endemic for malaria (Slutsker et al., 1994). 
Other studies have confirmed that the burden of malaria-related anaemia in 
areas with intense malaria transmission falls primarily on infants and young 
children (Shiff et al., 1996, McElroy et al., 1999).
6
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Although it is well know that malaria is associated with anaemia, the 
dynamics in infants is not well known. Most falciparum infections in infants, 
especially in young infants, are of low density and remain asymptomatic 
(i.e. are not associated with fever). In Kitua’s study in Tanzania, it was 
shown that the youngest infants up to 7 months of age are more sensitive 
to the impact of these low density infections on reducing levels of Hb than 
older infants; by the age of 12 months infants with low density infections 
had similar Hb levels to uninfected children (Kitua et al., 1997).
These data suggest that malaria related anaemia is an enormous public 
health problem in sub-Saharan Africa, that infants bear the greatest burden 
of the disease, and that because anaemia is often associated with 
asymptomatic malaria infection, prevention rather than treatment strategies 
are essential for combating the problem.
The global malaria control programme
Over the years, vector control has been and still remains the most generally 
effective measure to prevent malaria transmission. Initially, intensive control 
measures targeting larval control like sanitation and environmental 
modification were rigorously applied with great success in the well 
organised, highly urbanised and economically well endowed areas (Curtis, 
1996). In many tropical areas and especially sub-Saharan Africa, such 
control programmes were not feasible, so early diagnosis and prompt 
treatment using chloroquine was the mainstay for malaria control until 
recently (Curtis, 1996).
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The discovery of dichloro-diphenyl-trichloroethane (DDT) brought with it a 
formidable weapon that could be used to interrupt malaria transmission. 
DDT’s residual effect against adult stage mosquitoes resting on walls 
indoors, which required only one or two treatments per year, made it 
operationally feasible to extend vector control to cover extensive rural 
areas. Spectacular achievements were reported from southern Europe, 
North America and Taiwan among other countries, and so the malaria 
eradication campaign was launched in 1955 with indoor residual spraying 
(IRS) using DDT and later with other residual insecticides. By early 1970s, 
malaria had been eliminated from Europe, most of North America, the Near 
East, most of the Caribbean, Australia and some countries in the Far East 
(Bruce-Chwatt, 1980).
The African experience during the “Malaria Eradication Era”
The “eradication of malaria” was never formally recommended for the 
African continent (WHO, 1969), and the Malaria Conference in Equatorial 
Africa convened by WHO in 1950 in Kampala (Uganda) was probably the 
first coordinated attempt to find a strategy for malaria control in Africa 
guided by WHO (WHO, 1951). The “malaria eradication era” in Africa 
translated into applied field research activities in a large number of studies 
across the continent. The initial studies between 1950 and 1964 mainly 
involved the use of DDT and hexachlorohexane (HCH) for residual 
insecticide spraying, and targeted chemoprophylaxis in some programmes 
(WHO, 1984). Of all the studies, actual interruption of malaria transmission
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was only reported in 3 relatively small projects, two of them in forested 
areas of Liberia and Cameroon, and one in the western highlands of 
Uganda. In holoendemic areas, the most important projects that were 
conducted at the time were probably the Taveta-Pare Malaria Scheme 
(Wilson, 1960), in the savannah area adjoining Kenya and Tanzania, and 
the Western Sokoto Malaria Control Pilot project in northern Nigeria (Bruce- 
Chwatt, 1958). These projects demonstrated that malaria transmission 
could be considerably reduced and recorded dramatic reductions in the 
population of An. funestus (Gillies, 1977). However, by 1959 when WHO 
convened the Technical Meeting on Malaria Eradication in Africa in 
Brazzaville (Congo), it had become apparent that major financial, 
administrative and technical difficulties would have to be overcome in order 
to “eradicate malaria” in Africa (WHO, 1967). The studies carried out in the 
subsequent period between 1965 and 1974, recognized that any prospect 
of “eradicating malaria” were strongly associated with access to basic 
health services which was largely lacking in most countries. This led to the 
concept of pre-eradication programmes which attempted to develop basic 
health services concurrently with early eradication programmes. 
Unfortunately, the implementation of pre-eradication programmes turned 
out to be impracticable (WHO, 1967), and more realistic strategies were 
sought at the 22nd World Health Assembly (WHO, 1969). Evidence of the 
development of resistance to pesticides like DDT and drugs like 
chloroquine, and well documented studies like the Garki project in Sudan 
showed that there was no single affordable method that could be used to 
interrupt malaria transmission across the entire African continent
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(Molineaux, 1980). Therefore, different regions would have to adopt 
different strategies for malaria control. It also became clear, that it may not 
be possible to “eradicate malaria” in certain areas in Africa (WHO, 1974), 
given the conditions of ordinary life in rural areas, mobility of the population, 
lack of appropriate health services infrastructure, severely limited financial 
resources coupled with the tropical climate and environmental conditions 
that proved highly conducive for the survival of the vector. Furthermore, 
these tropical and sub-tropical areas had an abundant population of highly 
efficient vectors like Anopheles gambiae and Anopheles funestus with an 
estimated vectorial capacity >60%, which favoured stable malaria 
transmission in some areas and very high seasonal transmission in other 
areas (Snow, 2002). The emergence of resistance to DDT and the banning 
of its use in agriculture led to the abandonment of spraying in favour of 
case treatment. Indeed, the threat of malaria was greatly reduced 
worldwide as a result of the widespread use of chloroquine for treatment 
and chemoprophylaxis.
Re-emergence of Malaria in Africa
In the late 1990s, there was a strong resurgence of malaria in sub-Saharan 
Africa, resulting primarily from increasing rates of treatment failure to 
chloroquine due to a rapid rise in resistance caused by its indiscriminate 
and uncontrolled use for malaria control. In response to the worsening 
situation, a Ministerial Conference was convened in Amsterdam in 1992. A 
Global Malaria Strategy was agreed upon and endemic countries 
committed themselves to strengthening already existing malaria control
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efforts and initiating others in order to reduce the disease burden at every 
level. The strategy aimed to curb socio-economic loss due to malaria by 
preventing mortality and reducing morbidity and by progressively improving 
and strengthening the local and national capabilities for the control of 
malaria at all levels.
The two main objectives set were as follows:
1. appropriate malaria control programmes had to be implemented by 90%
of the countries affected by the year 1997
2. malaria morbidity was to be reduced by at least 20% compared to 1995
in at least 75% of the affected countries, by the year 2000 (WHO, 
1993).
Unfortunately, the strategy has not been successful for many of the 
countries involved. Most countries lacked adequate financial resources and 
appropriate technical capabilities necessary for the successful 
implementation of malaria control programmes (WHO, 1993).
In 1998, the Roll Back Malaria (RBM) partnership was initiated to provide a 
coordinated global approach to fighting malaria. RBM is a partnership 
between WHO, UNDP, UNICEF and the World Bank, whose aim is to 
mobilize support for local and national malaria control initiatives worldwide.
It seeks to work with governments, NGOs, and private sector companies to 
reduce the human and socio-economic costs of malaria. RBM is promoting 
strategies that are evidence-based, outcome focused and cost-effective 
(WHO, 1998). These include four main strategies as follows:
1. Prompt access to treatment
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2. Insecticide-treated mosquito nets
3. Prevention and control of malaria in pregnant women
4. Malaria epidemic and emergency response
The partnership set the following goals: to halve the burden of malaria 
worldwide by the year 2010 and halve that again by 2015 using control 
tools which already exist and need wider dissemination, or which can 
rapidly be developed (WHO, 1998). Consequently, African governments, 
including Kenya, held a summit in Abuja-Nigeria in 2000 and adopted the 
Abuja Declaration, including the target to protect at least 60% of children 
less than five years of age with the most suitable combination of personal 
and/or community protective measures such as ITNs by 2010 
(WHO/CDS/RBM, 2002).
Current Vector control strategies
In 2004 WHO launched the Global Strategic Framework for Integrated 
Vector Management (IVM). It provides a basis for strengthening vector 
control in coordination with national health systems. IVM advocates an 
evidence-based approach to the utilisation of national resources and 
encourages community engagement to ensure sustainability. It provides for 
integration with other disease control measures and the systematic 
application of a range of interventions for vector control (WHO, 2004a).
Use of ITNs
Most malaria-endemic countries in Africa have focussed their attention on 
scaling up the use of ITNs as the most reliable malaria prevention strategy
12
Chapter 2: Literature review
in children < 5 years of age. By the early 1990s, it had been shown that 
ITNs were safe to use and effective in reducing malaria transmission (Lines 
et al., 1987, Curtis et al., 1992, Lines, 1996). In the Gambia, an 
experimental study combining the use of chemoprophylaxis and ITNs 
reported a pronounced reduction in mortality in children less than five years 
of age. The study found that malaria-specific mortality was reduced by 70% 
and all-cause mortality was reduced by 63% (Alonso et al., 1991a, Alonso 
et al., 1991b). The fact that the overall mortality of a community could be 
markedly reduced by the use of ITNs was confirmed by several large-scale 
randomised controlled trials, which had child mortality as a primary 
endpoint (D'Alessandro et al., 1995, Binka et al., 1996, Nevill et al., 1996, 
Habluetzel et al., 1997, Phillips-Howard et al., 2003a). A Cochrane review 
concluded that the overall mortality in African children would be reduced by 
17% as a result of ITN use (Lengeler, 2004). Such a reduction translates 
into 6 lives saved in a year for every 1000 children aged between 1 and 59 
months. Furthermore, the mortality study in western Kenya (Phillips-Howard 
et al., 2003b), which was then an area of intense perennial transmission, 
demonstrated a 90% reduction in malaria transmission and the EIR was 
reduced from 60-300 to below 10 (Gimnig et al., 2003). In this same study, 
ITNs were also found to have a positive impact on birth weight and on the 
growth of infants (ter Kuile et al., 2003a, ter Kuile et al., 2003b). A recent 
systematic review of the impact of ITNs in pregnancy involving five 
randomized controlled trials in sub-Saharan Africa found that using ITNs in 
the first few pregnancies reduced the occurrence of low birth weight by 23% 
compared to non-use of nets (Gamble et al., 2007).
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ITNs generally need to be treated with insecticide approximately once a 
year, in order to maintain their effectiveness (Lines, 1996, Maxwell et al., 
2003). In a field situation, many difficulties are encountered in trying to 
maintain high re-treatment levels. Effectiveness projects in Africa have 
indicated an average re-treatment rate below 10%. The recent introduction 
of Long Lasting Treated Nets (LLTNs) has been a breakthrough in solving 
this problem. LLTNs can resist several washes and remain efficacious for 
their useful lifespan. Some brands of LLTNs recognized by the World 
Health Organization Pesticide Evaluation Scheme (WHOPES) include the 
Olyset Net (Sumitomo Chemical Co., Osaka, Japan), Perma-Net 
(Vestergaard Frandsen A/S, Kolding, Denmark) and Interceptor (BASF). 
The Permanet and Interceptor nets are made from polyester cloth and the 
nets are expected to last for 3-5 years. The Olyset net is made from 
polyethylene fibres and lasts >5 years (The Global Fund, 2007).
Increased national and international efforts have now boosted the 
deployment of ITNs. Most of the African countries, including Kenya, have 
waived taxes and tariffs on nets, netting materials and insecticides. Since 
2002, several countries have scaled up free of charge or subsidized 
provision of ITNs for children under 5 years of age and pregnant women 
(UNICEF, 2007). A new approach to increase net coverage has involved 
nationwide campaigns to boost measles vaccination and provision of 
vitamin A, coupled with the distribution of free LLTNs (Grabowsky et al., 
2005, Grabowsky, 2008). As a result, there has been a substantial increase
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in net coverage in the countries involved, according to household surveys 
that measured either ITN usage by children < 5 years of age or household 
ownership (WHO/GMP, 2007).
Use of IRS
IRS has been found to be highly effective to achieving a temporary, rapid 
reduction in malaria transmission. The main purpose of indoor residual 
spraying is to reduce transmission by reducing the survival of malaria 
vectors entering houses or sleeping units (Global Malaria Programme 
World Health Organisation, 2006). The information available suggests that 
its impact in areas of intense malaria transmission in reducing infant and 
child mortality is similar to that reported with ITNs (Curtis and Mnzava, 
2000) .
Despite its initial widespread use and contribution to the success of malaria 
eradication and control efforts, the use of IRS declined in most malaria 
endemic countries in the last decades, particularly in Africa. This was in 
part due to lack of government commitment and financing to sustain the 
logistically challenging efforts over the long term, but also due to concerns 
about insecticide resistance and community acceptance. One of the other 
reasons was the general disapproval of dichlorodiphenyltrichloroethane 
(DDT), the most widely used insecticide, due to fears of its harmful effects 
on the environment and on human health. In the past, DDT was widely 
used in agriculture and domestic hygiene, leading to massive release of the 
compound into the environment (Global Malaria Programme World Health
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Organisation, 2006). Some authors now have a renewed opinion that these 
fears are unjustified when DDT is used appropriately for IRS (Global 
Malaria Programme World Health Organisation, 2006, 2006, Mandavilli, 
2006, Rehwagen, 2006, Schapira, 2006, Guimaraes et al., 2007, 
Sadasivaiah et al., 2007, Curtis and Lines, 2000, Curtis, 2002). Whereas, 
others argue that DDT may do more harm than good in the long run and 
that it is not the only answer to malaria control (Berenbaum, 2005). In 2004, 
the Stockholm Convention on Persistent Organic Pollutants became 
operational in order to enforce strict control measures to reduce 
environmental damage from organic pollutants; however it stated that the 
use of DDT was still required in some countries for disease vector control 
(UNEP, 2001).
In the last five years IRS has received renewed attention and WHO now 
recommends that effective implementation of IRS with DDT, or one of the 
11 other recommended insecticides, should be a central part of national 
malaria control strategies where this intervention is appropriate. IRS is 
recommended only when the following conditions are met: a high 
percentage of the structures in an operational area have adequate 
sprayable surfaces, and can be expected to be well sprayed; the majority of 
the vector population is endophilic (rests indoors); and the vector is 
susceptible to the insecticide in use (Global Malaria Programme World 
Health Organisation, 2006). About half of African countries have included 
IRS as part of their malaria control strategies (WHO and UNICEF, 2005),
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and several more have now included 1RS as part of the President’s Malaria 
Initiative (PMI) funded malaria control initiatives.
The lack of progress in the development of new insecticide compounds 
suitable for public health use coupled with increasing vector resistance has 
resulted in a dwindling availability of alternative low-risk and cost-effective 
insecticides, which may threaten the sustainability of 1RS. The recognition 
that there is an urgent need to develop new and cheap alternative 
insecticide for public health use (WHO and UNICEF, 2005) has led to 
recent initiatives like the Gates funded Innovative Vector Control 
Consortium led by LSTM. In addition systematic monitoring for insecticide 
resistance is needed, requiring new levels of funding to set up or enhance 
existing insecticide resistance surveillance systems and new levels of 
international collaboration (Kelly-Hope et al., 2008).
Drug based control 
Treatment of malarial infections
The other cornerstone of malaria control programs has been case 
management of clinical or microscopy-confirmed malaria. The rapid spread 
of resistant strains of the malaria parasite to chloroquine in the 1980s in 
Africa resulted in a clear rise in recrudescence of infection and persistence 
of anaemia (Bloland et al., 1993, Ekvall et al., 1998). This link between 
resistance and chloroquine treatment failure is likely to have contributed to 
the increase in malaria-specific mortality that was observed in endemic 
countries in the 1990s (Trape et al., 1998, Snow et al., 2001).
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The arrival of highly-effective artemisinin-based drug combinations, 
although costly, brought desperately needed alternatives for case- 
management. WHO now strongly recommends that endemic countries 
change their policies to adopt artemisinin-based combination therapy as 
first line treatment for uncomplicated malaria (World Health Organisation, 
2006). The high cure rate achieved with these combinations (White, 1994, 
White, 2008c, Adjuik et al., 2004) and the prospect of sustained efficacy is 
likely to markedly reduce the malaria burden. This has been observed in 
Thailand (Carrara et al., 2006) and in South Africa (Barnes and White, 
2005). In the latter, the introduction of ACTs was also associated with other 
control measures such as the use of bed-nets and indoor residual spraying 
(Tren, 1999).
Most malaria-endemic countries have now switched their policies to use 
artemisinin-based combination therapy as first line treatment (World Health 
Organisation, 2006). In 1999, the WHO set itself the goal of halving the rate 
of malaria mortality worldwide by 2010. Improvement of accessibility and 
affordability of effective chemotherapy in general and artemisinin-based 
combinations in particular is more crucial than ever for reducing the malaria 
burden in endemic countries.
Mass drug administration to prevent malaria
Administration of anti-malarial drugs to an entire population has been used 
as a malaria-control strategy for decades (von Seidlein et al., 2003). Drugs
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were given to all individuals, whether infected or not, at specific points in 
time, either directly as a full therapeutic course of treatment or indirectly 
through the fortification of salt, with the main aim of minimizing the reservoir 
of infection (von Seidlein and Greenwood, 2003). In highly or moderately 
endemic countries where most infections are asymptomatic and go 
untreated, it seems unlikely that an impact on transmission could be 
achieved using only mass drug administration (MDA). In a recent 
comprehensive review, von Seidlein and Greenwood report that the first 
attempts of malaria control through MDA date back to the early 1930s in 
rubber plantations in Liberia, West Africa (von Seidlein and Greenwood, 
2003). In the 1950s, MDA was adopted by WHO as a control tool, until the 
1970s when it was finally dropped due to its failure to interrupt transmission 
of malaria and to the role it may have played in the spread of chloroquine 
resistance (WHO, 1993). Later in 1999 in the Gambia, a cluster randomized 
controlled trial attempted to reduce transmission of malaria at the start of 
the transmission season through one single administration of artemisinin 
plus sulphadoxine-pyrimethamine (von Seidlein et al., 2000). Residents 
living in 33 of 42 villages in the catchment area received a single dose of 
sulphadoxine-pyrimethamine combined with artesunate, whereas residents 
of 9 control villages received placebo. For the first two months following the 
MDA, the mean malaria incidence rate in treated villages was significantly 
lower than in the control villages. However, in subsequent months, the 
incidence was slightly higher in the MDA villages (rebound effect), and no 
overall cumulative benefit of MDA was detected over the course of the 
malaria transmission season.
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In summary, most MDA, which have been undertaken as part of an attempt 
to interrupt transmission, have failed. However, despite a failure to achieve 
this objective, many MDA projects led to a marked reduction in parasite 
prevalence and probably had a marked transient effect on malaria-related 
morbidity and mortality, although this was rarely measured. Currently the 
use of MDA is mostly restricted to special situations such as epidemics as 
was the case in Burundi in 1999 (Etchegorry et al., 2001, Evans, 2001).
Anti-malarial chemoprophylaxis
There is clear evidence that chemo-prophylactic use of anti-malarial drugs 
can substantially prevent the consequences of malaria in at-risk groups in 
pregnant women and children under five years of age (Geerligs et al., 2003, 
Meremikwu et al., 2008, Garner and Gulmezoglu, 2006). Chemoprophylaxis 
can be defined as the administration of anti-malarial drugs to targeted 
groups of people, at sub-therapeutic dosages, so as to obtain sustained 
protective blood levels over the period at risk. This implies that the drugs 
are used before infection occurs or before it becomes patent, with the aim 
of preventing either the occurrence of the infection or any of its symptoms. 
Some drugs act on the early stages of the parasite, while it is still confined 
to the liver, and destroy these stages before merozoites are liberated into 
the blood stream and infect red blood cells. In such cases, Bruce-Chwatt 
defines the relevant drug as a true prophylactic (Bruce-Chwatt, 1980).
When the drug is unable to achieve this effect and yet, if given for a 
prolonged period (exceeding the normal duration of the incubation period), 
it is able to keep the number of malaria parasites in the blood at such low
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levels that they will not cause any clinical symptoms, then it acts, as a 
suppressive (or clinical) drug (Bruce-Chwatt, 1980). In practice, this means 
that when the drug administration is discontinued, any parasites remaining 
in the blood start multiplying again and this may lead to a renewed attack of 
the disease. The rapid excretion of most drugs that have been used for 
chemoprophylaxis means that frequent administrations are needed (e.g. on 
a daily, weekly or fortnightly basis). For this reason, anti-malarial drugs 
used for chemoprophylaxis should have a long half-life so that the dosing 
interval can be extended. Until recently, the drugs available for 
chemoprophylaxis were limited to chloroquine, proguanil, pyrimethamine + 
dapsone, mefloquine, atovoquone-proguanil and doxycycline. The latter 
three are now the most commonly used options for travellers in the 
prevention of falciparum malaria.
Chemoprophylaxis in children
Several studies have investigated the impact of chemoprophylaxis on the 
health of young children living in malaria-endemic areas. The first data were 
reported in 1956 from the Gambia (McGregor et al., 1956). In that study, 
chloroquine was given to children under three years of age. The strategy 
significantly improved malaria morbidity. Other studies came to the same 
conclusions; chemoprophylaxis reduced the incidence of clinical episodes 
of malaria, and increased haemoglobin concentration whilst improving 
nutritional indices (Bradley-Moore et al., 1985a, Bradley-Moore et al.,
1985b, Bradley-Moore et al., 1985c).
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Chemoprophylaxis also substantially reduced mortality. In a study of 
Gambian children aged between three months and five years conducted in 
1988, Maloprim (pyrimethamine + dapsone) given every 2 weeks 
throughout the transmission season resulted in a marked reduction in the 
incidence of overall deaths, deaths attributed to malaria and in the 
incidence of clinical episodes detected through active surveillance 
(Greenwood et al., 1988). In that study, the protective effect of 
chemoprophylaxis was sustained over a period of five years until the study 
was stopped, when it was considered to be unethical to continue (Menon et 
al., 1990). The impact of chemoprophylaxis was reviewed in detail recently, 
the results suggested fewer episodes of clinical malaria, and a reduction in 
severe anaemia and hospital admissions (Meremikwu et al., 2008).
Chemoprophylaxis in pregnant women
In areas with stable malaria transmission, immunity to malaria develops 
after exposure to the parasite for a number of years and complications in 
the adult population are rare. During pregnancy however, women become 
more susceptible to malaria, and may present with different clinical features 
of malaria infection during pregnancy, depending on the degree of immunity 
that they may have acquired by the time they became pregnant. In areas of 
high transmission, malaria infection in pregnant women tends to be 
asymptomatic and associated with maternal anaemia and low birth weight 
(Desai et al., 2007).
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The use of anti-malarial drugs for chemoprophylaxis to prevent P. 
falciparum infection in pregnant women was first reported from Nigeria in 
1964 using pyrimethamine (Morley et al., 1964). Though this was initially 
highly effective, high levels of parasite resistance finally rendered this 
approach ineffective. Weekly chloroquine prophylaxis was proposed as an 
alternative, but with increasing levels of resistance and poor adherence, 
this has been found to be inadequate in the majority of the countries where 
it has been tried (Mola and Wanganapi, 1987). Proguanil was found to be 
safe in pregnancy but needed to be given daily, and needed to be preceded 
by effective parasite clearance (Mutabingwa et al., 1993). Fortnightly 
Maloprim has been shown to be effective in increasing birth-weight and 
reducing anaemia in primigravidae in the Gambia (Greenwood et al., 1989). 
Weekly and fortnightly chemoprophylaxis during pregnancy with efficacious 
anti-malarial drugs was shown to reduce maternal anaemia and the 
proportions of low birth weight babies within controlled trials (Garner and 
Gulmezoglu, 2006). In the Gambia, reduction of low birth-weight by 
chemoprophylaxis led to an estimated reduction in the neonatal death rate 
by 42% and infant mortality by 18% among primigravidae, and by 6% and 
4% respectively among children of multigravidae (Greenwood et al., 1992). 
The most recent Cochrane meta-analysis also suggest that successful 
prevention of malaria during pregnancy results in significant reduction in 
peri-natal deaths by 27% (which includes pregnancy loss from 28 weeks 
gestation onwards and neonatal death within the first 7 days) (Garner and 
Gulmezoglu, 2006).
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Limitations of chemoprophylaxis
Sustaining a high compliance with chemoprophylaxis in either children or 
pregnant women has proved difficult to achieve within national control 
programmes. Furthermore, concerns about the possible impact of long-term 
chemoprophylaxis on the development of natural immunity to malaria have 
been one of the main reasons for reluctance to pursue this strategy. It 
would not be sensible to protect a child from malaria for a period of time if 
the risk of dying from the disease is increased to the same degree after the 
drug administration is stopped. It has been shown by several authors that 
children who received repeated drug administration for a long term had 
lower titres of anti-malarial anti-bodies compared to children who did not 
(Bradley-Moore et al., 1985a). Menendez and others during a study 
conducted in 1995 in Ifakara, in South-eastern Tanzania showed that 
chemoprophylaxis during the first year of life was effective in prevention of 
malaria but impaired the development of natural immunity as there was a 
rebound in the incidence of clinical malaria and anaemia in the second year 
of life (Menendez et al., 1997, Aponte et al., 2007). Other authors 
suggested that the impairment of the natural immunity is strongly 
dependent on the duration of the prevention. According to Otoo and others, 
chemoprophylaxis can act to reduce but not prevent exposure to the 
parasite, and this can overcome some suppressive effects of malaria on 
cell-mediated immunity, and thus induce a better development of cellular 
immune response to malaria antigens (Riley et al., 1988, Otoo et al., 1989).
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In the late 1990s WHO dropped their recommendation for implementation 
of chemoprophylaxis on a large scale due to its potential for a rebound 
effect; logistical challenges to delivery, relatively high cost of 
implementation; low compliance with long-term regimens and the potential 
impact on the spread of drug resistance.
IPT in pregnancy (IPTp)
History
In 1994 in Malawi, it was shown that sulphadoxine-pyrimethamine given 
only twice during pregnancy (one dose in the second trimester and one 
dose in the third trimester) was more effective at reducing placental 
parasitaemia than weekly chloroquine (Schultz et al., 1994). A 72% 
reduction in placental malaria (from 32% to 9%) in primigravidae and 
secundigravidae was observed. Subsequent studies in Kenyan 
primigravidae living in Kilifi district showed a 39% (95% Cl 22-52%) 
protective efficacy of intermittent preventive treatment with sulphadoxine- 
pyrimethamine in preventing severe anaemia (Shulman et al., 1999). Parise 
and others came to the same conclusions as they found intermittent 
sulphadoxine-pyrimethamine treatment in the second and third trimester to 
be a highly efficacious way to prevent placental malaria infection in Kenyan 
primigravidae (Parise et al., 1998). On the basis of these results, the WHO 
recommended that all pregnant women resident in areas of moderate to 
high malaria transmission should be given intermittent preventive treatment 
with sulphadoxine-pyrimethamine throughout the second and third 
trimesters of pregnancy (WHO, 2004b, WHO, 2005). This recommendation
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has been adopted by most of the malaria-endemic countries in Africa and 
replaced weekly chloroquine chemoprophylaxis which had been used until 
then as the drug based strategy for prevention of malaria during pregnancy 
(WHO, 2007).
Concept
Intermittent preventive treatment during pregnancy consists of 
administration of treatment doses of an efficacious antimalarial drug given 
at predefined intervals at least 1 month apart, regardless of the presence of 
malaria parasitaemia at the time of treatment. Intermittent preventive 
treatment during pregnancy provides intermittent clearance or suppression 
of existing asymptomatic infections from the placenta (treatment effect) and 
when drugs with a long elimination half-life like sulphadoxine- 
pyrimethamine are used they may prevent new infections from occurring for 
several weeks due to the slow elimination of suppressive drug levels in the 
body (prophylactic effect). Another possibility is that sulphadoxine- 
pyrimethamine may not fully prevent the establishment of new blood-stage 
infections post-treatment but is able to suppress parasite multiplication to 
low-density infections that may induce persistent immunity (ter Kuile et al., 
2007, Greenwood, 2007). Intermittent preventive treatment during 
pregnancy is delivered at the time of routine ante-natal visits and currently 
sulphadoxine-pyrimethamine is the only anti-malarial recommended for 
use. The World Health Organization recommends that at least 2 curative 
doses of sulphadoxine-pyrimethamine be given during the second and third 
trimesters of pregnancy in areas of stable P. falciparum malaria 
transmission (WHO, 2004b).
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Ter Kuile and colleagues recently conducted a systematic review of 
currently available data to determine the effect of increasing resistance to 
sulphadoxine-pyrimethamine on the efficacy of intermittent preventive 
treatment during pregnancy in Africa. The pooled studies showed that in 
areas in which 1 of 4 treatments with sulphadoxine-pyrimethamine fail in 
children by day 14, the 2-dose IPT regimen with sulphadoxine- 
pyrimethamine continues to provide substantial benefit to Human 
Immunodeficiency Virus (HlV)-negative semi-immune pregnant women. 
They also showed that more frequent dosing is required in HIV-positive 
women not using Cotrimoxazole prophylaxis for opportunistic infections, (ter 
Kuile et al., 2007). The studies which were reviewed in the above 
mentioned article had been used by WHO’s Regional African Office to issue 
a statement on the continued use of sulphadoxine-pyrimethamine for 
intermittent preventive treatment during pregnancy in Africa (WHO, 2005). 
However, high priority must be given to determining safe and affordable 
alternatives due to the emerging spread of high-grade resistance to 
sulphadoxine-pyrimethamine. A series of multicentre trials are planned in 
that regard (Menendez et al., 2007a) but it will take several years before the 
results of these trials will become available.
IPT in Children (IPTc)
The concept of intermittent preventive treatment in children or IPTc (also 
labelled seasonal sIPTc when provided in the malaria transmission seasons 
only) has been proposed as an alternative mechanism for malaria
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prevention in areas with highly seasonal transmission (Greenwood, 2006). 
One published trial of intermittent preventive treatment in children has been 
published to date. The study was based in Senegal and used a single dose 
of sulphadoxine-pyrimethamine plus a single dose of artesunate given at 
monthly intervals for three months during the malaria transmission season. 
The intervention resulted in an 86% protective efficacy against clinical 
malaria in children 2 to 59 months of age (Cisse et al., 2006). A subsequent 
study in the same region compared 4 drug combinations; one dose of 
sulphadoxine-pyrimethamine (SP) plus one dose of artesunate (AS) 
(SP+1AS), one dose of SP plus 3 daily doses of AS (SP+3AS), one dose of 
SP plus three daily doses of amodiaquine (AQ) (SP+3AQ) or 3 daily doses 
of AQ and AS (3AQ+3AS) (Sokhna et al., 2008). Participants were treated 
once a month for 3 months during the peak malaria season. The study 
found that all 4 regimens reduced the incidence of malaria but SP+3AS was 
the most efficacious, and was recommended in order to minimize the 
spread of drug resistance allowing for AS to reserved for the treatment of 
acute malaria cases (Sokhna et al., 2008). In neighbouring Mali, another 
IPTc study with single dose of SP found 43% reduction in the annual 
incidence rate of clinical malaria (Dicko et al., 2008). The potential benefits 
of IPTc are substantial, particularly in areas with seasonal transmission 
where malaria affects children up to five years of age. More research is 
needed to determine if this is a practical approach to malaria control, 
particularly to address the feasibility of scaling up an intervention that does 
not build on any existing healthcare platform could prove challenging, and 
secondly, to address whether the administration of multiple closely spaced
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doses of antimalarial drugs covering a short transmission season impede 
the development of natural immunity to p. falciparum (Greenwood, 2006, 
Grobusch et al., 2007a).
IPT in infants (IPTi)
The concept and history of IPTi
Concept
In 2001, the IPT approach was adapted to the prevention of malaria in 
infants (IPTi) by Schellenberg and colleagues in the first IPTi trial in 
Tanzania (Schellenberg et al., 2001). IPTi was designed in an effort to 
harness the benefits of chemoprophylaxis while minimizing the problems.
By linking the delivery of the intervention to the already well established 
routine vaccination visits, the logistic and delivery considerations were 
considerably eased. It was also anticipated that, because fewer doses are 
given than would normally be used in chemoprophylaxis, the concerns 
about cost, drug resistance and immunological effects would be reduced.
In the first randomized, double-blind, placebo-controlled trial in Ifakara in 
Tanzania, a single dose of sulphadoxine-pyrimethamine (SP) was 
administered on three occasions during the first year of life at 2, 3 and 9 
months of age, at the routine vaccination visits in the Expanded Programme 
of Immunization (EPI). IPT was given regardless of whether or not the study 
subject had malaria symptoms or parasitaemia (Schellenberg et al., 2001).
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The study found the intervention to be highly effective. The rate of clinical 
malaria (events per person-year at risk) was 0.15 in the intervention arm 
versus 0.36 in the placebo arm, giving a protective efficacy of 59% (95% Cl 
41-72%). A 50% reduction of severe anaemia in the intervention arm was 
also observed at the end of the study. With the limitation of a small sample 
size, the trial did not show any adverse reactions to sulphadoxine- 
pyrimethamine and indeed, an extended follow-up of the trial participants 
until age 2 years showed a sustained reduction in the risk of clinical malaria 
extending well beyond the duration of the pharmacological effects of the 
drugs (protective effect 36%, 95% Cl 11-53%), (Schellenberg et al., 2005). 
Thus, study investigators were able to demonstrate a clinically and 
statistically significant decrease in malaria-related morbidity by linking IPTi 
delivery to existing public health interventions that serve as a routine 
contact point for health-workers and children world-wide.
In another study conducted also in Tanzania, Massaga and colleagues 
studied two hundred and ninety-one infants aged 12-16 weeks who 
attended Maternal and Child health clinics in a district where malaria is 
perennial (Massaga et al., 2003). For a period of six months, these infants 
were given a treatment course of amodiaquine or placebo every 60 days. 
The authors showed that the protective efficacy of intermittent treatment 
with amodiaquine in preventing malaria fevers was 64.7% (95% Cl 42.4- 
77.2%; p<0.001).
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The encouraging results of the first trial of intermittent preventive treatment 
led some healthcare workers to consider implementation on a wide scale 
(Schellenberg et al., 2006). Others suggested that it was important to 
balance the urgency of implementing a new, efficacious intervention on a 
public health scale against the need to acquire convincing evidence on 
safety and efficacy, and it was agreed that further evaluation of IPTi was 
necessary.
The IPTi Consortium
The evidence available by 2002 was reviewed by a group of research 
scientists and representatives from WHO and UNICEF. This group agreed 
that information was required in three key areas before intermittent 
preventive treatment could be recommended as a national malaria control 
strategy.
1. Firstly, better knowledge of its efficacy in reducing malaria morbidity in
different epidemiological settings.
2. Secondly, a clear demonstration that it had no adverse impact on
serological responses to EPI vaccines.
3. Thirdly, that all safety data available on intermittent preventive treatment
with sulphadoxine-pyrimethamine be consolidated and evaluated 
(Egan et al., 2005).
The IPTi Consortium was established in 2003 with support from the Bill and 
Melinda Gates Foundation to further the development and evaluation of 
IPTi. The Consortium comprises 14 institutions working as seven research
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collaborations (Table 1: Institutions currently participating in the IPTi 
Consortium) across Africa and Papua-New Guinea, and includes WHO and 
UNICEF.
Table 1: Institutions currently participating in the IPTi Consortium
1. Albert Schweitzer Hospital, Lambarene, Gabon
2. Centers for Disease Control and Prevention, Atlanta, USA
3. Hospital Clinic, University of Barcelona, Barcelona, Spain
4. Ifakara Health Research and Development Centre, Ifakara, Tanzania
5. Kenya Medical Research Institute, Kisumu, Kenya
6. Kilimanjaro Christian Medical Centre, Moshi, Tanzania
7. London School of Hygiene and Tropical Medicine, London, UK
8. Manhica Health Research Centre, Manhica, Mozambique
9. National Institute for Medical Research, Amani, Tanzania
10 Swiss Tropical Institute, Basel, Switzerland
11 Université Cheikh Anta Diop de Dakar, Dakar, Senegal
12 University of Copenhagen, Copenhagen, Denmark
13 University of Tubingen, Tubingen, Germany
14. United Nations Children’s Fund (UNICEF)
15. World Health Organization (WHO)
16. Papua New Guinea Institute of Medical Research
(Note: Trials are carried out in collaboration with local malaria control 
programmes and ministries of health.)
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Research Agenda IPTi Consortium
The IPTi Consortium aims to generate the scientific evidence required to 
support a policy recommendation on the intermittent preventive treatment of 
infants in a timely manner. Studies undertaken by the Consortium were 
planned to answer the above mentioned key questions and designed to run 
almost parallel to each other in order to facilitate rapid consolidation of the 
required information.
Studies with SP
The complexities of malaria epidemiology required an evaluation of 
treatment efficacy in settings with different transmission intensities. Sites 
were identified in West Africa (Gabon and Senegal), East Africa (Kenya and 
Tanzania), Southern Africa (Mozambique) and Papua New Guinea. The 
Consortium is also conducting a large-scale operational research project in 
southern Tanzania and, in conjunction with UNICEF, is carrying out limited 
implementation of IPTi in six other countries.
Alternative antimalarials
In addition, a set of Consortium studies were designed to identify the 
optimal characteristics of drugs and drug combinations suitable for use in 
IPTi, including the comparison of long-acting (e.g. mefloquine, 
sulphadoxine-pyrimethamine) and short-acting (e.g. chlorproguanil- 
dapsone) anti-malarial drugs, with and without the antimalarial artesunate.
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Other studies
The effect of IPTi on immunological responses to P. falciparum infection, 
the development of anti-malarial drug resistance, acceptability, cost and 
cost-effectiveness were also addressed as part of the various studies.
Working groups were set up to coordinate the different aspects being 
studied by the Consortium. All the studies were subject to clinical 
monitoring to ensure the quality and integrity of the data they generate.
Summary results from recent IPTi studies with SP
To date, a set of five IPTi trials have been completed that explored the 
safety and efficacy of using SP for IPTi in addition to the original trial by 
Schellenberg and colleagues (Schellenberg et al., 2001, Macete et al.,
2006, Chandramohan et al., 2005, Kobbe et al., 2007, Mockenhaupt et al.,
2007, Grobusch et al., 2007b). The studies were conducted across a range 
of different malaria-transmission settings in Mozambique, Ghana (3x) and 
Gabon.
Results from all studies are now available (Table 2, Page 37). The study by 
Macete et al. in Manhica in Mozambique used a 3, 4, and 9 month 
treatment schedule and reported a reduction in clinical malaria of 22% but 
no significant effect on anaemia (Hb <8g/dL). However, there were 
significant reductions in all- cause hospital admissions (19%) and anaemia 
hospital admissions after dose 1 and 2 (Macete et al., 2006). In Navrongo 
in Ghana, Chandramohan et al., administered 4 courses of IPTi at months
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3, 4, 9, and 12 and found a protective efficacy against all episodes of 
malaria of 25% up to 15 months of age, and a reduction in anaemia hospital 
admissions by 35%. The authors did not find an effect on the prevalence of 
anaemia (Hb <8g/dL) during the intervention period, however, and reported 
an increase in cases of high parasite density malaria (>5000par/pL) in the 
treatment group (-20%) during the period from 16 to 24 months of age 
(Chandramohan et al., 2005). Two other studies by Kobbe et al. in Kumasi 
in Ghana and by Mockenhaupt et al. in Tamale, also in Ghana, used a 3, 9, 
and 15 month schedule and reported a 20% (Kobbe et al., 2007) and 23% 
(Mockenhaupt et al., 2007) protective efficacy against clinical malaria 
respectively. The study in Kumasi did not see an effect on the prevalence of 
anaemia during the intervention period but reported an increase in anaemia 
in the treatment group after the last dose of study drug. The study in 
Tamale reported a 24% reduction in the prevalence of anaemia during the 
intervention period but also saw an increase in anaemia and high parasite 
density malaria in the treatment group after the last dose of study drug. A 
study in Lambarene in Gabon obtained a statistically non-significant effect 
against malaria and a 25% reduction in the prevalence of anaemia during 
the intervention period (Grobusch et al., 2007b).
With respect to adverse event monitoring, the trial in Kumasi, Ghana, 
reported two cases of severe skin reactions in the treatment group (both 
Stevens Johnson Syndrome (SJS)), and one moderate skin reaction in the 
placebo group, whereas Tamale reported one case of a moderate skin 
reaction in the treatment group. All the study subjects involved fully
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recovered. There were no reports of any other drug related adverse events 
or any adverse impact on serological responses to EPI vaccines.
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Table 2: Description of completed IPTi studies by the IPTi with SP
S tu dy
p aram eter
S ch e llen berg
e ta l.
C h an d ram o h an  
e t al.
M áce te  e t al. K o b b e  e t al. G ro bu sch  et 
al.
M o c k e n h a u p t  
et al.
Tria l, co u n try Ifakara,
T anzan ia
N avrongo,
G hana
M anh ica ,
M ozam b ique
K um asl,
G hana
L a m b a re n e , 
G abon
Tam ale ,
G hana
R ecru itm en t
year(s)
1 9 9 9 -2 0 0 0 2 0 0 0 -2 0 0 2 2 0 0 2 -2 0 0 4 2 0 0 3 -2 0 0 5 2 0 0 4 -2 0 0 5 2003
E IR /year 29 418 38 400 50 N A
T ransm iss ion P erennia l H igh ly  seasona l P erenn ia l w ith
seasona l
peaks
P erenn ia l P erennia l w ith
seasona l
peaks
P erenn ia l w ith
seasona l
peaks
Inc idence  rate  
per ye a r o f c lin . 
m a la ria * in PL
0.43 1.0 0 .55 1.29 0.22 0.88
In-vivo SP Rx- 
fa ilu re  by d a y  14
31 (1 9 9 9 - 
2000)
22 (2004) 21 (2001) N A 21 (2004) 1 4 (2 0 0 2 )
U se o f bed nets, 
% P L /S P  ITN 
(non-ITN )
67 /68 17/19 0 /0 (1 4 /1 5 ) 20 /20
e s tim a te
(39 /38 )
5/5 (80/80) <1%
Iron
su p p lem en ta tion
Y es Y es N one N one N one N one
A ges a t IPT 
dosing , m on ths
2, 3 ,9 3 ,4 ,  9 ,1 2 3, 4 ,9 3, 9 ,1 5 3, 9 ,1 5 3, 9 ,1 5
M ethod and 
du ra tion  o f 
fo llo w  up
PC D  to  24 
m on ths  o f age  
(C S S  a t 12 
and 18 
m on ths  o f 
age)
PC D  to  24 
m on ths  o f age 
(C S S  a t 2, 9 ,1 2  
and 18 m on ths 
o f age)
P C D  to  24 
m on ths  o f age 
(C S S  a t 12 
and 24 
m on ths  o f 
age)
A C D  m on th ly  
to  21 m on ths  
o f  age  and 
PC D
A C D  m onth ly  
to 30  m onths 
o f age and 
PCD
A C D  e ve ry  3 
m on ths  to  24 
m on ths  o f  age  
and PCD
enro lled  ch ild ren  
, p lacebo /R x- 
g roup
351/350=701 1242 /1243=2485 7 5 5 /748= 1503 5 3 5 /5 3 5 = 1 0 70 595 /594=1189 6 0 0 /6 0 0 = 1 2 00
PE, % (95%  C l) By 12 m on ths By 15 m on ths By 12 m on ths By 18 m on ths By 18 m onths By 18 m on th s
Clin, m a la ria  (all 
ep isodes)
62 .3  (4 4 .2 , 
74.6)
2 4 .8 (1 4 .3 ,
34.0)
2 2 .6 (1 .6 ,
39.2)
2 0 .3 (1 0 .6 ,
28 .9)
17.0 ( -2 4 .0 , 
44.0)
2 2 .5 (1 1 .8 ,
31.9)
C lin, m a la ria  
(high dens ity )
67 .8  (4 8 .8 , 
79.8)
2 3 .6 (1 1 .1  , 
34 .3)
2 6 .4 (5 .1  , 
42 .9)
1 8 .5 (5 .0 ,
30 .2)
1 7 .7 (2 .0 ,
30.9)
A ll-cause
h o sp ita lisa tions
3 0 .0 (8 .1  , 
46 .6 )
12.7 ( -4 .8 ,2 7 .3 ) 19.0 (4 .0 ,  
31.0)
8 .7  ( -2 3 .4 ,  
32 .4)
3 1 .3 (1 3 .1  , 
49 .9)
A ll-ca u se  seve re  
anaem ia
50 .3  (7 .6 ,  
73.2)
3 5 .5 (1 1 .2 ,
53.1)
12 .7  ( -1 7 .3 ,  
35.1)
N A 2 2 .0 ( -1 .0 , 
40.0)
23 .6  (4.1 , 
39.1)
R ebound  e ffe c t N one: 
susta ined  
e ffe c t (10 to  
24 m onths)
Yes: m ore  h igh- 
d ens ity
pa ra s ita e m ia  in 
16 to 24 m onth 
o ld  ch ild ren
N one: (10 to 
24 m on ths)
N one: (16  to 
24 m on ths)
None: Yes: m ore  
severe
m ala ria  (13  to 
24 m on ths)
IPTi, intermittent preventive treatment delivered to infants; ACD, active case detection; PCD, 
passive case detection; EIR, entomological inoculation rate; CSS, cross-sectional surveys; 
PL, Placebo: clinical malaria*, all episodes; Rx, Treatment; NA, Not applicable; high density 
(>5000par/pL).
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Meta-analysis
The IPTi Consortium has conducted a pooled safety and efficacy analyses 
of all six trials of IPTi with sulphadoxine-pyrimethamine conducted to date 
at 12 months of age (Breckenridge et al. and Aponte et al., in preparation).
Efficacy
The pooled analyses have shown a 30% protective efficacy against 
malaria, a 23% protective efficacy against all-cause hospital admissions, a 
38% protective efficacy against malaria-related hospital admissions, and a 
15% protective efficacy against anaemia (Hb <8g/dL), all in the first year of 
life (Grobusch et al., 2007a). The trials were not powered to measure the 
effect of IPTi on mortality but it was noted that the total number of deaths in 
the treatment groups and the placebo groups was similar (Breckenridge et 
al. in preparation). One death in the six trials was considered possibly 
attributable to sulphadoxine-pyrimethamine (Kobbe et al., 2007). Overall, 
there was a 19% significant reduction in the risk of serious adverse events 
(SAE) (which, by definition, included any hospital admissions and deaths) 
among the treatment groups compared to the placebo groups across all the 
trials. Only the skin reactions earlier mentioned above were noted.
Safety
WHO convened a committee to investigate possible interactions between 
IPTi and the serological response to EPI vaccines, which found no 
difference in the geometric mean titre between the treatment and placebo 
groups for measles, diphtheria, pertussis, tetanus, polio, hepatitis B and 
yellow fever. It concluded that IPTi with sulphadoxine-pyrimethamine
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administered at the time of routine vaccination does not have an adverse 
impact on the serological responses to EPI vaccines when co-administered 
with them (Grobusch et al., 2007a).
The Kumasi, Tamale and Navrongo trials that reported some rebound in the 
second year of life did not represent an overall consistent pattern of 
rebound. Navrongo reported some rebound in high density clinical malaria, 
Kumasi recorded rebound in the number of anaemia episodes (Hb <8g/dL), 
and Tamale observed rebound in severe malaria and severe anaemia (Hb 
<5g/dL) (Kobbe et al., 2007, Chandramohan et al., 2005, Mockenhaupt et 
al., 2007). Furthermore, in the pooled meta-analyses, there was no 
significant rebound in episodes of clinical malaria, anaemia, or all-cause 
hospital admissions or with parasites in the five month period after the IPTi 
schedule was completed.
Conclusions IPTi studies with SP
Thus, the interim results of these analyses suggest that IPTi with 
sulphadoxine-pyrimethamine offers a modest level of protection against 
malaria morbidity in the first year of life, and in contrast to earlier 
chemoprophylaxis trials, is not associated with a rebound effect based on 
the currently available evidence. Thus, it appears to offer protection against 
malaria and anaemia while not interfering with the acquisition of natural 
immunity to P. falciparum (Grobusch et al., 2007a). The Consortium already 
provided a considerable dossier of scientific evidence to a specially
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convened WHO study group as part of a platform for IPTi-related policy 
discussions. These findings are currently under consideration by WHO.
Remaining questions
Effect on development of immunity against malaria
Clearly another important question with regard to the mode of action is 
whether and how protection in the first year of life may affect the 
development of malarial immunity. It is not clear why the first trial showed a 
much higher protection in the first year of life (almost twice as much) than 
the subsequent trials and observed persistence of protection in the second 
year of life, whereas the subsequent trials did not (Gosling et al., 2008).
The six studies differed in transmission intensity; transmission seasonality; 
timing of dosing of the study drug; timing of the assessment of main end 
points; parasite resistance to the study drug; other illnesses or nutrient 
deficiencies affecting anaemia; coverage with other malaria prevention and 
treatment interventions, such as iron supplementation and the use of 
insecticide-treated bed nets; and other features not measured or reported 
(Ter Kuile and Steketee, 2006). Of note is that the initial study in Tanzania 
had the highest ITN coverage of all trials and had the highest level of 
sulphadoxine-pyrimethamine resistance. It has been hypothesized that that 
this initial study was conducted during a one-off situation with a unique 
combination of favourable factors like transmission intensity, ITN use, and 
moderate parasite resistance to the drug. Moderate resistance may have 
resulted in persistence of low grade parasitaemia that escaped drug action. 
This combined with reduced levels of transmission and thus potentially
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overwhelming re-infections may provide a vaccine type of effect that 
translated into long-lasting protective immunity that may not be readily 
reproducible in other situations (ter Kuile et al., 2007, Greenwood, 2007, 
Grobusch et al., 2007a). It may also be that the results were at the higher 
end of the normal variation of protective efficacy, with subsequent trials 
showing regression toward the mean. Similar observations were seen with 
the large-scale ITN trials that were conducted in the 1990s. An alternative 
explanation for the difference in observed effects of IPTi between sites and 
the extended period of protection into the second year of life observed in 
the Ifakara study may be a decrease in malaria transmission during the 
study period, as recently suggested by Gosling et al (Gosling et al., 2008).
It is hoped that the ongoing pooled analysis of the extended follow-up of the 
studies may help to shed some light on the complex interplay between the 
various potential determinants of protective efficacy such as transmission 
intensity and use of ITNs.
Drug resistance
Two concerns have been raised regarding IPTi and drug resistance.
Firstly, how the implementation of IPTi with sulphadoxine-pyrimethamine 
will affect parasite resistance to the drug. There is no doubt that widespread 
use of sulphadoxine-pyrimethamine for treatment led to selection of 
resistant parasites. Mutations found in the DHFR and DHPS genes involved 
in the parasite folate pathway are associated with parasite resistance to 
sulphadoxine-pyrimethamine (Roper et al., 2003). These mutations have 
been associated with reduced efficacy of sulphadoxine-pyrimethamine for
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treatment of uncomplicated malaria in children <5 years of age (Omar et al., 
2001, Kublin et al., 2002). This has been well documented in in-vivo studies 
right across the African continent (Schellenberg et al., 2002, Mockenhaupt 
et al., 2005, Abacassamo et al., 2004, Alloueche et al., 2004, Oduro et al., 
2005). The IPTi Consortium is currently investigating the relationship 
between widespread use of sulphadoxine-pyrimethamine for IPTi and 
molecular markers of drug resistance in a large-scale study in Tanzania 
involving 12,000 infants.
Secondly, how does the in-vivo measure of efficacy of a drug relate to its 
efficacy in intermittent preventive treatment in infant studies? It appears that 
sulphadoxine-pyrimethamine continues to be effective in IPTi despite high 
rates of resistant haplotypes and its reduced efficacy when used for 
treatment of symptomatic malaria. It seems that at the current levels of 
sulphadoxine-pyrimethamine resistance, there is no clear correlation 
between the protective efficacy of sulphadoxine-pyrimethamine used as 
intermittent preventive treatment and treatment efficacy. It has thus been 
hypothesized that the mechanism of action in sulphadoxine-pyrimethamine 
may be different in the context of prevention as opposed to treatment 
(Grobusch et al., 2007a). Although this is likely to be true, the studies to 
date in both infants and pregnant women have all been conducted at times 
of low to moderate resistance to sulphadoxine-pyrimethamine as measured 
from the treatment responses in concurrent treatment trials in children with 
acute falciparum malaria. It is unlikely that sulphadoxine-pyrimethamine will 
have much effect on clearing existing infections or preventing new
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infections once high grade resistance is well established (e.g. wide spread 
presence of the 164L mutation) (ter Kuile et al., 2007, White, 2005).
Alternative drugs for IPTi: Target Product Profile (TPP)
Thus, there are justified concerns about the longevity for sulphadoxine- 
pyrimethamine as the drug of choice for IPT in pregnancy or infants 
because of the increasing levels of antifolate resistance. Studies of 
alternative drugs are urgently required. One of the first steps in this process 
is the development of a target product profile (TPP) to determine the 
optimal and desirable characteristics of a drug regimen suitable for use in 
intermittent preventive treatment. Judging from the available literature and 
ongoing debate on IPTi, it would seem that a suitable drug would, as a 
pragmatic choice, have a dosing regimen <3 days (ideally a single dose), 
and would have to be efficacious, safe and well tolerated, whereas the 
optimal drug would have a single dose regimen, be very efficacious, very 
safe and extremely well tolerated.
Mode of action involved in IPTi
One of the other key questions in defining the target product profile is the 
mode of action of IPTi. For example, understanding how intermittent 
preventive treatment with sulphadoxine-pyrimethamine achieves its 
protective effect may help to address whether long or short acting drugs are 
required for IPT (Greenwood, 2007).
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Sulphadoxine-pyrimethamine prevents the establishment of new blood- 
stage infections by producing inhibitory blood concentrations for 
approximately 4 to 8 weeks after administration of each curative dose 
depending of the level of resistance of the parasites (White, 2005, Watkins 
et al., 2005, Watkins and Mosobo, 1993). Evidence from the recent pooled 
analyses of the IPTi consortium by month of follow-up suggests that the 
effect of intermittent preventive treatment could be largely related to 
intermittent chemoprophylaxis (the prophylactic effect) rather than 
clearance of parasitaemia only. A more detailed analysis of the study in 
Navrongo also suggests that this prophylactic effect does not last for longer 
than the pharmacological effect of sulphadoxine-pyrimethamine (Cairns et 
al., 2008). If the above is true then a long-acting alternative drug would be 
more suitable and efficacious for use in intermittent preventive treatment 
than a short-acting drug. It would be possible to demonstrate this concept in 
a study that would compare the efficacy of drug regimens with markedly 
different half-lives.
Studies comparing short versus long-acting drugs 
The IPTi Consortium has been investigating the safety and efficacy of 
alternative drugs and drug combinations to sulphadoxine-pyrimethamine for 
use in IPTi through other trials designed to explore those issues. Two of 
those trials, Kisumu in Kenya (described in this thesis) and Kilimanjaro in 
Tanzania, were designed to compare short-acting versus long-acting drugs 
when used for IPTi. In 2003, when these studies were being designed the 
following drugs were available and considered as suitable candidates:
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sulphadoxine-pyrimethamine plus artesunate, mefloquine, amodiaquine 
plus artesunate, and chlorproguanil-dapsone. The Kisumu trial chose to 
assess the following drugs: sulphadoxine-pyrimethamine plus artesunate, 
amodiaquine plus artesunate, and chlorproguanil-dapsone. The Kilimanjaro 
trial chose to assess the antimalarials sulphadoxine-pyrimethamine, 
mefloquine, and chlorproguanil-dapsone.
Whereas, a short-acting drug is rapidly eliminated from the body and 
therewith only able to provide a treatment effect (clearance of existing 
infections), a long-acting drug is one that is slowly eliminated from the body 
so that it has a suppressive effect on malaria re-infection for a period of 
time after treatment. The duration of that period (post-treatment 
prophylaxis) is determined by the dose, pharmacokinetic properties of the 
drug, and the level of parasite resistance to the drug (White, 2008a). For 
the short-acting drug, chlorproguanil-dapsone (CD) was selected based on 
demonstrated efficacy in Kenya (Watkins et al., 1988, Winstanley et al., 
1997) and northern Tanzania (Mutabingwa et al., 2005). CD has a terminal 
elimination half-life (ty2) of between 6 to 19 hours (Hietala et al., 2007). The 
two long-acting antimalarials given in combination with short-acting 
artesunate were AQ and SP. Amodiaquine had been shown to be 
efficacious for IPTi in neighbouring Tanzania (Massaga et al., 2003), and 
for treatment in western Kenya (Vreugdenhil et al., 2004). The desethyl 
metabolite of AQ, which accounts for nearly all antimalarial activity, has a ty2 
of between 3 to 12 days (Barnes et al., 2006). Sulphadoxine has a ty2 of 7 
days, whereas pyrimethamine has a ty2 of 3 days (Adjuik et al., 2002). 
Artesunate (AS) was added to both SP and AQ because of uncertainties of
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how rising P. falciparum resistance to SP and AQ alone might compromise 
efficacy if the primary action of IPTi was due to parasite clearance. 
Available data suggest that AQ plus AS is more efficacious than AQ alone 
in the treatment of uncomplicated malaria in symptomatic African children 
(Gupta et al., 2002, Doherty et al., 1999). Similarly, SP plus AS is more 
efficacious than SP alone (Obonyo et al., 2003, von Seidlein et al., 2000, 
Targett et al., 2001, Beutler et al., 1989). Artesunate is very short-acting 
and has a t% of approximately 1 hour (White, 2005), and was not added to 
CD because of the very high treatment success rate observed with CD in 
Kenya and northern Tanzania, and because at the time there were no 
published studies on the safety or efficacy of a CD plus AS combination.
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Chapter 3: Country and site of study
Introduction to the study country
Geography
Kenya is located in East Africa (Figure 1, Page 50) and lies between 
latitudes 4.21 0 N and 4.28 0 S and between longitudes 34 0 E and 42 0 E. 
It is bisected into almost half horizontally by the Equator and vertically by 
the 38 0 E meridian lines. The total land area is 592,909 square km which 
includes 11,230 km2 of inland water which is mainly comprised of Lake 
Turkana and Kenya's section of Lake Victoria (Snow, 1999).
Demography
The current population is estimated to be to 38 million in 2008 (CIA, 2008). 
The population distribution varies from 230 persons per square kilometre in 
agricultural high potential areas to 3 persons per square kilometre in arid 
areas. The population is relatively youthful with 41% of the population being 
under the age of 15 years on the basis of the 2004 population census. The 
number of persons aged over 65 years represented about 4% of the 
population in 2004 (compared to 18% < 15 years and 15.7% over 65 years 
in the United Kingdom in the same year (US Census Bureau International 
Data Base (IDB), 2008)).
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Climate
Kenya's climate varies from a tropical climate on the coast characterized by 
hot and humid conditions to a temperate climate inland and to a dry climate 
in the north. Over 70% of the country is arid and semi arid receiving little 
annual precipitation while rainfall is greatest in the highlands. Most parts of 
the country experience a bimodal pattern of rainfall, with the long rains 
coming in March- May and the start of the short rains occurring through 
October to December. Altitude is a major factor in variations in temperature 
between the different regions of the country. Average temperature ranges 
in the coastal town of Mombasa (altitude 17 metres) from 22°C to 30°C, in 
the capital city Nairobi (altitude 1680 metres) from 11°C to 28°C, and in 
Kisumu (altitude 1070 metres)on the shores of Lake Victoria from 17°C to 
35°C.
The epidemiology of malaria in Kenya
Malaria is a major public health problem in Kenya. The malaria burden and 
transmission patterns vary across the country from highly endemic to 
epidemic-prone. Overall, the diversity of the Kenyan climate lends itself to a 
wide variation in malaria risk and subsequent disease epidemiology. There 
are four principal groupings that can be used: endemic, highland (epidemic 
prone), arid (epidemic prone), and low risk districts (Snow et al., 1998). 
Modelling suggests that malaria accounts for approximately 30% of all 
outpatient attendance and 19% of all admissions to health facilities. It is 
reported to be one of the leading causes of death of children under age 5, 
responsible for an estimated 13.6% of deaths (Snow et al., 1998). Each
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year, an estimated 26,000 children (that is 72 per day) die from the direct 
consequences of malaria infection. An estimated 170 million working days 
are lost to the disease each year (Snow et al., 1998).
Malaria control in Kenya
The Division of Malaria control was established in the year 2000 as the 
operational arm of the National Malaria Control Programme at the national 
level. The objective of the Division at its inception in 2000 was to reduce the 
level of malaria infection and consequent death toll in Kenya by 30% by the 
year 2006 and to sustain that improved level of control to 2010.
To achieve this, four main strategic approaches have been used i.e.
1. Clinical management.
-Providing effective and prompt treatment 
-Management of malaria and anaemia in pregnancy
2. Vector control using ITNs and other methods
3. Epidemic preparedness and response (including indoor residual house­
spraying (IRS))
4. Supporting structure
1. Information, Education and communication (IEC)
2. Monitoring, evaluation and research.
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Figure 1: Map of Kenya
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Introduction to the study area
Location
The study took place in Asembo (Rarieda Division, Bondo District, Nyanza 
Province), western Kenya (Figure 2); the total population is approximately
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55,000 persons living in 76 villages in an area covering 178 square 
kilometres (Phillips-Howard et al., 2003a, Adazu et al., 2005). 
Figure 2: Location of Asembo in Western Kenya
The population is culturally homogeneous (more than 95% are of the Luo 
ethnic group and this proportion recently increased further due to the 
migration of internally displaced persons after the recent tribal clashes 
following the disputed general elections in December 2007) and they live in 
dispersed settlements. Most of the houses (Figure 3 and Figure 4) are built 
of mud, cement, or brick with roofs of iron sheets or thatch. Agricultural 
fields tend to lie adjacent to the compounds. The mainstay of the local 
economy is subsistence farming, occasionally boosted with meagre 
incomes from trading in the local food and livestock markets. Rainfall is
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seasonal with the heaviest (long) rains usually occurring from March 
through May and short rains falling between October and December. Local 
crops include maize, sorghum, cassava, and millet. Because employment 
opportunities are limited, many young adults temporarily migrate to the 
urban areas to seek employment.
Figure 3: Mud and cement houses with iron sheet roofing
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Figure 4: Mud-house with thatched roofing
Health care infrastructure
The area is served by 2 district hospitals (Bondo and Kisumu) between 10 
and 60 km from the study area, and 1 small mission hospital (without 
surgical facilities) located in the centre of the study area (Lwak). There are 
6 “health care units” located in Asembo. These units are comprised of 
government, community, and private facilities and are normally staffed by 
an enrolled community health nurse. Only one of the health care units (a 
government Health Centre) is staffed by a Clinical Officer and a registered 
nurse, and has diagnostic facilities for malaria.
Epidemiology of malaria in the study area
This lowland area around Lake Victoria experienced intense perennial 
malaria transmission (Beier et al., 1990). Although transmission occurs
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throughout the year there is clear seasonal variation with two seasonal 
peaks reflecting the normal bimodal rainfall pattern. The heaviest rains fall 
from March through May (long rains) with a smaller peak (short rains) in 
November and December (Figure 5) (Phillips-Howard et al., 2003a). Most 
transmission is due to Anopheles gambiae and An. funestus, with the 
proportion of infections attributed to each species varying both spatially and 
temporally. The small remaining balance of transmission is due to An. 
arabiensis.
Over the past 15 years, this area has been the site for a variety of malaria 
related research projects conducted by the KEMRI/CDC research unit in 
Kisumu, and the epidemiology of malaria has changed considerably. 
Transmission rates were reduced by 90% during an ITN efficacy trial (ITN 
population coverage > 70%) conducted from 1996 to 2002 (Gimnig et al., 
2003, Phillips-Howard et al., 2003b). The continued provision of free ITNs 
to the entire population has helped to maintain the low entomological 
inoculation rate (EIR), currently estimated at 7.2 infective bites per person 
per year (down from 60-300) (Lindblade et al., 2004, Adazu et al., 2005). 
Despite the reduced transmission level, cross-sectional surveys conducted 
in 1999, 2000 and 2001 (during the long rainy season when malaria 
transmission peaks) reported the prevalence of parasitaemia and 
moderately severe anaemia (Hb<7g/dL) among children < 5 years of age 
as 36% and 10% respectively (ter Kuile et al., 2003b, Lindblade et al., 
2004). The infant mortality rate changed from 176.1/1,000 live births in 
1992, to 110/1,000 live births in 2004, and 72/1,000 in 2007 (Adazu, 2007,
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McElroy et al., 2001). Based on verbal autopsy data approximately 30% of 
infant deaths are attributed to malaria (Adazu et al., 2005).
Figure 5: Trends in rainfall, sick child visits, and diagnoses of malaria 
and anaemia at seven peripheral health facilities, before and during 
the insecticide-treated bed net intervention in 1996 to 1999.
From (Phillips-Howard et al., 2003a).
Antimalarial treatment policy and drug resistance
SP became the first-line antimalarial drug for the treatment of 
uncomplicated malaria in Kenya in 1998. Data from 1999-2000 
demonstrated that the adequate clinical and parasitological response 
(ACPR) by day 28 for SP was 54% among children aged <5 years in 
neighbouring Bondo, western Kenya (Obonyo et al., 2003). In 2000, the 
treatment response to amodiaquine monotherapy in symptomatic children 
<5 years was reported as 89% in Bungoma, western Kenya (Vreugdenhil et
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al., 2004). A more recent study in 2007, in Bondo, western Kenya reported 
similar high (90%) ACPR for amodiaquine-artesunate (Thwing, 2007). The 
available data on chlorproguanil-dapsone sensitivity show 98% ACPR in 
coastal Kenya in 1997, but no data were available from western Kenya by 
the start of the study (Amukoye et al., 1997). However, chlorproguanil- 
dapsone was not readily available locally and its relatively limited use 
probably resulted in low drug pressure. In 2005, during the course of this 
trial, the Kenyan Ministry of Health (MOH) adopted artemether-lumefantrine 
(AL) as the first line treatment for uncomplicated malaria (Kenya, 2006), 
though implementation began in late 2006.
Vaccine coverage
EPI coverage in the study area is relatively poor: 55% of children receive all 
three doses of the pentavalent (diphtheria-tetanus toxoid-pertussis- 
hepatitis B- Haemophilus Influenza type b) vaccine and oral polio vaccine 
(OPV), 48% receive the measles vaccine and only 38% receive all the 
essential vaccines in the programme, as compared to the national statistics 
for Kenya which estimate that 73% of children receive the measles vaccine 
and 57% receive all the essential vaccines (Bureau of Statistics Kenya et 
al., 2004). The cold-chain required for the successful implementation of the 
EPI programme is not operational in some healthcare centres in rural 
western Kenya due to logistical problems forcing those centres to offer 
vaccination only on a couple of appointed days of the week, further 
exacerbating an already difficult situation with access to essential services. 
The ineffective utilisation of such a well established programme is a missed
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opportunity to improve primary healthcare and deliver potentially life-saving 
interventions like IPTi which easily fit into the EPI schedule.
Health and demographic surveillance system (HDSS) in study area
The Health and Demographic Surveillance System (HDSS) provides a 
platform that facilitates research activities, and allows scientists to measure 
the burden of infectious diseases and evaluate public health interventions.
All the households in the study area are visited every four months and data 
on the population (Figure 6) educational attainment, socioeconomic status, 
paediatric outpatient visits, causes of death in children, and malaria 
transmission are collected (Adazu et al., 2005).
Figure 6: Distribution of population by age (years) and sex in 2002
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Research facilities
The Research Station is located at the Centre for Global Health Research 
of the Kenya Medical Research Institute (CGHR / KEMRI) in Kisumu 
(Figure 7) (Kenya Medical Research Institute, 2008), Kenya and was 
established in 1979 by the Division of Parasitic Diseases (DPD), CDC from 
the US working in collaboration with KEMRI. Over the past 29 years, CDC's 
investment in the Research Station (Figure 8) has resulted in a well-trained 
group of staff members of Kenyan scientists, clinicians, laboratory 
technicians, and field workers. In the past, most of the activities were 
focused on malaria research. Although malaria research remains a priority 
at the station, activities have expanded rapidly over the last few years and 
currently include malaria prevention activities, as well as HIV research, TB 
Prevention, and HIV prevention and care program activities and are 
supported by the Global AIDS Program, the U.S. President’s Emergency 
Plan for AIDS Relief (PEPFAR) and the President’s Malaria Initiative (PMI). 
Another focal area is the International Emerging Infectious Diseases 
Program.
Laboratory and Communications Capabilities
The KEMRI/CDC Research Station has well-developed malaria and HIV 
laboratories that perform a range of standard diagnostic procedures 
(serology, haematology, microscopy).
The malaria laboratory (Figure 9) has the capability to perform 
sophisticated research assays such as polymerase chain reaction (PCR), 
gene sequencing and microsatellite work, lymphocyte sub typing, and
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cytokine measurement and is actively engaged in research on parasite 
diversity and the immunology of malaria in children under five years and 
pregnant women.
The HIV laboratory (Figure 10) conducts a range of HIV diagnostic tests, 
including rapid tests, enzyme-linked immunosorbent assay (ELISA), 
Western blot, BED HIV incidence testing, viral load and infant DNA PCR, 
CD4 immunology; a variety of chemistry and haematology assays; and 
diagnostic tests for sexually transmitted infections (Chlamydia, gonorrhoea, 
syphilis, HSV-2, Trichomonas vaginalis) and, using both rapid diagnostic 
tests and ELISA, hepatitis B and C. The HIV research laboratory also has 
the capacity to perform HIV drug resistance testing and HIV sub typing.
The microbiology laboratory performs primary isolation and identification of 
enteric organisms (Vibrio cholerae, Shigella) and respiratory organisms 
(Streptococcus pneumoniae) as well as antimicrobial susceptibility testing 
for these pathogens. Research on the immunology of schistosomiasis is 
also conducted.
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Figure 7: KEMRI director’s office
Figure 8: Main administrative office and IT centre
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Figure 9: Malaria Laboratory work-space
Figure 10: HIV Laboratory work-space
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Overview study design
We conducted a randomized double-blind, placebo-controlled efficacy trial 
(RCT) among children under longitudinal observation to estimate the 
efficacy and safety of IPTi with short and long-acting antimalarial drugs 
administered at the time of routine EPI vaccinations (at 10, 14 weeks and 9 
months), in order to understand the mechanism of action of IPTi (treatment 
vs. prophylactic effect). Children were recruited during the first EPI visit at 6 
weeks of age and were followed prospectively with collection of 
epidemiologic, clinical, and laboratory data. Routine EPI visits in Kenya 
occur at 6, 10, and 14 weeks, and again at 9 months of age. IPTi was 
provided under supervision at 10 and 14 weeks and again at 9 months with 
one of 3 drug regimens or a placebo. From ages 2.5-6.5 months, 
supplementation with ferrous sulphate was given as part of the intervention 
package.
The 4 arms of the study were as follows:
I Intermittent sulphadoxine-pyrimethamine+ three doses of 
artesunate treatment with daily iron supplementation;
II Intermittent chlorproguanil-dapsone treatment with daily iron 
supplementation;
III Intermittent amodiaquine+ three doses of artesunate 
treatment with daily iron supplementation;
IV Intermittent placebo treatment with daily iron supplementation.
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Morbidity surveillance was achieved through scheduled visits to the clinics 
and passive case detection, and anaemia and parasitaemia cross-sectional 
surveys at 12, 18, and 24 months of age. Figure 11 depicts the individual 
trial time-line.
Objectives
Primary objective:
To compare the efficacy of IPTi with one of 3 antimalarial regimens 
(sulphadoxine-pyrimethamine+ three doses of artesunate [SP-AS3], or 
amodiaquine+ three doses of artesunate [AQ-AS3], or chlorproguanil- 
dapsone [CD3]) given at routine immunization visits with that of placebo 
with respect to the prevention of clinical malaria in the first year of life.
Secondary objectives:
1) Compare the efficacy of IPTi with one of 3 antimalarial regimens (SP- 
AS3, AQ-AS3 or CD) given at routine immunization visits with placebo with 
respect to the prevention of moderate and severe anaemia in the first year 
of life.
2) Assess the impact of IPTi with the aforementioned regimens on serologic 
responses to vaccines (Polio, Diphtheria, Tetanus, Pertussis, Hepatitis-B, 
Haemophilias-lnfluenza type-B, and Measles).
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Pre-trial activities
Several meetings were held with local administration personnel, opinion 
leaders and village elders at “Barazas” (official Chiefs meeting at the sub­
location level). Meetings were also arranged with parents (mostly women 
were present) in villages within a 3.5 kilometre radius of each of the four 
clinics used as study sites. These meetings were designed to “request for 
permission” to engage the community in research activities, prepare them 
for mobilisation activities, explain the purpose of the study and answer any 
questions raised.
In order to achieve a high level of community acceptance for trial activities 
most of the support staff were hired from within the community after 
rigorous interviews to select the best candidates were conducted in 
Asembo. Conducting the trial at four different sites necessitated a larger 
than anticipated work force (Appendix I) and very intensive training in order 
to ensure compliance with standard operating procedures (SOPs) at all 
sites. Study staff was trained on how to follow GCP guidelines and how to 
fill in scan-ready study forms (Appendix II) among several other study 
activities. Training remained ongoing throughout the study and GCP 
refresher courses were given twice every year by the trial monitor. My 
training as the trial coordinator was even more rigorous, involving GCP 
requirements, preparation of SOPs, documentation of study activities, 
adverse event reporting, updating the study regulation files, preparing for 
monitoring visits among several other responsibilities.
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Study population
Infants aged 5 to 16 weeks attending any one of the 4 study clinics (Abidha, 
Ongielo, Lwak, and Saradidi in Asembo) for immunization at the 6-week 
visit was offered enrolment in the study if they fulfilled the inclusion and 
exclusion criteria
Inclusion and exclusion criteria
Inclusion criteria:
1. Age 5 weeks to 16 weeks (this extended period was allowed in 
consideration of a local cultural custom practiced by a section of the 
community belonging to the ‘Nomiya’ religious sect, which involves the 
detention of newborns indoors for up to 10 weeks).
2. Parent or guardian currently resident in Asembo (or Gem).
3. Parent or guardian has given permission for their child to participate
Exclusion criteria:
1. Known allergy to any of the study drugs
2. Current Cotrimoxazole prophylaxis
3. Concomitant disease requiring hospitalization or transfusion
4. Plans to be away from the study area for more than 6 months during the 
next year
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Study Schedule
Table 3: Study Schedule
6 w 10 w 14 w 18 w 6 m 9  m 1 2 m 1 8 m 24 m
E n ro lm e n t X
C lin ic  v is it X X X X X X X X
S ick le  C e ll s c re e n in g X
B lood  d ra w  fo r  G 6P D  
te s tin g
X
S tu d y  d ru g  g ive n X X X
M a la ria  B lo od  film X X X
H a e m o g lo b in X X X
A n th ro p o m e tr ic
m e a su re m e n ts
X X X X
V a c c in a tio n s X X X X
B lood  fo r  s e ro lo g y  
(a n tib o d y  te s tin g )
X X X X
N P sw a b  H ib X
Iron C o m p lia n ce X
F ilte r p a p e r b loo d  sp o t X X
Note: w, weeks; m, months; NP, nasopharyngeal swab; Hib, Haemophilus 
influenzae
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Figure 11: Individual trial time-line for participants of IPTi
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Note: Pent=diphtheria-tetanus toxoid-pertussis-hepatitis B-Haemophilus 
influenza type B; OPV=oral polio; EPI=expanded programme of 
immunization; IPTMntermittent preventive treatment of infants; Primary 
follow-up period lasted from approximately 2 months of age up to 12 
months of age.
Outcome measures
The primary outcome was time to the first or only episode of clinical malaria 
in the first year of life. An episode of clinical malaria was defined as an 
axillary temperature of at least 37.5°C or history of fever in the preceding 48 
hours together with asexual Plasmodium falciparum parasitaemia of any 
density.
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Secondary outcomes included: in the first year of life.
1. mild anaemia defined as Hb<11 g/dL
2. moderate-to-severe anaemia defined as Hb<8g/dL
3. serologic responses to EPI vaccines
4. clinical malaria with >5,000 parasites/pL of blood
5. all episodes of clinical malaria
6. all-cause outpatient visits
7. all-cause hospitalisations
8. hospitalisations with malaria illness
9. hospitalisations with moderate-to-severe anaemia.
Sample size and power calculations
This study primarily aimed to determine if routine intermittent treatment with 
antimalarials resulted in a reduction in childhood clinical malaria. The time 
to first episode of clinical malaria was used as the primary endpoint and 
used for sample size calculations.
The sample size required to detect a protective efficacy of 40% with 90% 
power and a a  of 0.017 was 250 per arm. The alpha value of 0.017 instead 
of 0.05 was used in order to account for multiple comparisons (3 arms each 
compared to the placebo group, Bonferroni adjustment 0.05/3 tests=0.017). 
Therefore, the study required a total sample of 1000 infants (250 in each of 
4 groups). We expected that 11% of infants would have the outcome 
measure at baseline and thus would be excluded from the primary analysis 
(Desai et al., 2003). Including this decrease and adjusting for a 10% loss to
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follow up and 13% mortality, the study required 1516 infants (379 in each 
arm).
Randomisation sequence generation
The randomisation code was prepared before the trial began by a 
statistician (Dr. John Williamson, CDC, Atlanta) using permuted block 
randomization with a block size of 8.
Randomisation implementation
Enrolment study forms were pre-printed with the already randomised 
unique study identification numbers and arranged sequentially. After written 
informed consent was obtained the registrar assigned the lowest available 
study identification number to the participant.
Randomisation allocation concealment
Each study drug combination was assigned to a colour and then packed 
into identical bottles labelled only with the colour, the IPTi course number 
(1,2, or 3), the day of treatment (day 1, day 2, or day 3), and whether the 
drug was drug A or B of the combination. In the case of SP/AS3, the first 
day had two bottles in the pack containing study drug (one containing SP 
and one containing AS), and the remaining days had one bottle with 
placebo (instead of SP) and one bottle with AS. In the case of AQ3/AS3, 
one bottle on each of the three days contained AQ and the other bottle 
contained AS. In the case of CD3, one bottle on each of the three days 
contained study drug, and the other bottle contained placebo. In the case of 
placebo, all the bottles contained placebo.
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All medications were dispensed as crushed tablets, in order to ensure 
accurate dosing. Mixing with cherry syrup was done at the moment of 
delivery to ensure drug quality and make the medicines more palatable. 
Labelling was performed by a scientist (Elizabeth Peterson) who was not 
involved in analyzing data from this trial. The colour-arm assignment of the 
study identification numbers remained concealed to everyone (including the 
technician) until the first intervention visit, after which it remained known to 
the technician only (Figure 12).
Figure 12: Study drugs were packed into identical bottles with 
different colour labels
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Blinding
Doses of the study drugs were prepared in an isolated and locked 
pharmacy room. The list of study identification numbers linked to a given 
colour was kept locked and was accessible solely to the pharmaceutical 
technician preparing doses. The colour-arm assignment of the study 
identification numbers remained concealed to everyone except the 
technician. The technician did not have access to names of participants. 
The key to the colour-arm assignment was kept by a scientist not 
associated with the study (Dr. Anja Van’t Hoog) and the Data and Safety 
Monitoring Board (DSMB). The key was obtained for analysis in exchange 
for the locked dataset and detailed analytical plan after the primary follow­
up period (the first 12 months of life).
Study procedures
Recruitment of participants
Infants were offered enrolment in the study when they attended a Mother 
and Child Health (MCH) clinic at any one of the 3 healthcare units in 
Abidha, Ongielo and Saradidi or the mission hospital in Lwak aged 5 to 16 
weeks and resident in Asembo at that time (Figure 13). Infants with known 
allergy to any of the study drugs, or HIV infected infants receiving 
cotrimoxazole prophylaxis for opportunistic infections, or infants suffering 
concomitant illness requiring hospitalization or transfusion, or planning to 
be away from the study area for more than 6 months were not enrolled. All 
enrolled children were provided with an ITN and the parent/guardian was
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instructed on effective use and maintenance of the net. Damaged nets were 
replaced during the course of the study.
Figure 13: Mothers attending an MCH clinic
Consenting procedure
All mother’s/guardians of children who were eligible for the study were 
informed about the reason for the study (Figure 14). Each activity and 
requirement of the study was explained to them. Informed consent forms 
which had been translated into the local language (Dholuo), and back- 
translated to check for accuracy were used. In the case of a literate 
parent/guardian, the entire informed consent form was read out to the 
parent and repeated if necessary to their satisfaction. The consenter 
responded to all questions or requested senior staff (like the Field
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Supervisor or PI) for further clarification where necessary. Comprehension 
was assessed using a standard set of questions, and the parent/guardian 
was requested to sign the form in duplicate for documentation of willingness 
to participate. The forms were also signed by a witness and the consented 
parent/guardian retained one copy, whereas the study retained the other. In 
case the parent/guardian was illiterate, then a literate witness (not 
connected with the research study) sat all through the consenting 
procedure and ensured that the consented understood all that was read to 
them, then the literate witness signed the forms alongside a thumb-print of 
the consented parent/guardian attesting to the fact that the permission was 
accurately read or interpreted, and that participation and thumb-printing 
were given willingly without coercion. All the parents/guardians who were 
approached were informed that their children’s entry into the study was 
voluntary and that they were free to withdraw from the study at any time.
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Figure 14: Mother undergoing consenting procedure
Follow-up procedures
Photographic identification was used to confirm identities at each visit. 
Malaria incidence was estimated through passive surveillance. Infants with 
any illness were instructed to return to one of the study clinics for care, 
which was provided free of charge. A rapid diagnostic test (RDT) 
(OptiMal®, DiaMed, Switzerland) for malaria was performed for all infants 
with a documented fever (>37.5° C by axillary measurement), history of 
recent fever in the previous 48 hours, or evidence of pallor. RDT results 
were used solely for clinical management and not for trial outcome 
measures. The DiaMed OptiMAL® detects the presence of Plasmodium 
lactate dehydrogenase (pLDH), an enzyme produced by all forms of the 
parasite. The presence of pLDH is revealed using monoclonal antibodies 
directed against isoforms of the enzyme. If the RDT was positive, the infant
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was treated with oral quinine (10 mg/kg three times daily for 7-day course) 
or artemether-lumefantrine (Coartem: 1 tablet twice daily for 3 days) for 
children >12 months of age weighing >5 kg. If the sick visit and positive 
RDT occurred at the 10- or 14-week or 9-month visit when study drug was 
due, then a paired 7-day treatment (prepared for each arm prior to trial 
commencement) was given such that the arms containing active study 
drugs were paired with placebo, whereas the placebo arm was paired with 
quinine. This arrangement ensured that all participants regardless of study 
arm received appropriate treatment for clinical malaria. In addition, Hb 
levels were checked and blood slides prepared. Any other childhood 
illnesses were treated according to the Integrated Management of 
Childhood Illnesses and MOH guidelines.
Participants who presented with serious adverse events suspected to be 
attributable to study drugs were withdrawn from receiving further study 
drugs but follow-up visits and healthcare continued. Those who migrated 
outside the study area for more than 3 months were suspended from the 
study but allowed to re-enter upon returning to the study area, or 
considered lost to follow-up if they failed to return.
Laboratory procedures 
Malaria smears
A thin and a thick smear were made on the same slide. The thin smear was 
used for species confirmation while the thick smear was used for 
examination and counting of the parasites. The thick smear has the
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advantage of concentrating the parasites by approximately 30 times 
compared with a thin smear.
Only the thin smear was fixed. The top part of the thin smear was not fixed 
if it was too close to the thick smear. The thin smear was completely 
covered in methanol for 2 to 3 seconds by dipping the slide in a coplin-jar 
filled with methanol. The thin smear was allowed to air dry for 2 minutes.
Staining of the blood smears
The slides were put into staining dishes or jars making sure that they were 
placed back to back in the staining jar to avoid smear-to-smear contact, 
which could lead to detachment. Working Giemsa solution was poured over 
the smears until completely covered. The smears were allowed to stain for 
the 15 minutes in 10% Giemsa (pH 7.2). Clean water was gently poured 
into the trough or staining jar to float off the scum on the surface of the 
stain. Care was taken not to wash off the blood smears. The remaining 
stain was gently poured off and rinsed again 2 times in clean water. The 
slides were removed from the staining dish or staining jar using forceps.
The slides were placed in a vertical position (standing on end) on a staining 
rack to drain and dry.
Reading and counting procedure
After the slides were completely dry, they were examined one by one under 
the microscope. After placing a stained slide on the stage, the 40x objective 
was used to scan the entire thick smear to get a general idea whether the 
smear was well prepared, well stained and free of debris and artefacts. A
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part of the thick smear that was populated with at least 8 White Blood Cells 
per High Power Field (WBCs/HPF) was selected, the 40x objective was 
moved from position and a drop of immersion oil applied. The 100x 
objective was moved into position and focused clearly. The slide was 
examined using the 100x objective and moved systematically across the 
field down 1 field and then backwards. This procedure was repeated until 
the entire blood smear had been examined. If parasites were found, a 
tentative species determination was made based on the thick smear, and 
then the thin smear was further examined to confirm the species. The thin 
smear is the appropriate sample for species identification. After the species 
had been identified, the asexual parasites (and gametocytes) were counted 
against 500 WBC on thick smears. Two tally counters were used (1 for 
parasites and 1 for WBCs). If only gametocytes were present and no 
asexual parasites, gametocytes were counted against 500 WBCs. The 
WHO recommends that at least 100 fields, each containing approximately 
10-20 WBCs, be screened before scoring a thick smear negative.
Assuming an average WBC count of 8,000 per microlitre of blood, this gave 
a threshold of sensitivity of 4 parasites per microlitre of blood. After 
examining the slide, it was gently wiped with a cotton wool ball soaked in 
Xylene, let to dry and stored in a slide cabinet at room temperature.
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Determination of parasitaemia
To quantify malaria parasites against WBCs, we counted the parasites in a 
thick smear. The number of asexual parasites per litre blood (assuming 
8,000 WBCs per litre of blood) was quantified by the mathematical formula: 
No of parasites x 8000 = Parasites per litre 
No of WBCs
Quality control for smear reading
All slides were read by two laboratory technicians independently, who were 
blinded to treatment arms. Slides with discrepant readings or with parasite 
density estimations that differed by >50% were sent to a senior technician 
for a third reading, the result of which was considered final. All the 
laboratory technicians involved passed their training organised by the 
Kenya Medical Research Institute and Walter Reed Project Centre of 
Excellence in Microscopy situated in Kisumu. The external quality 
assurance services for the Parasitology and Microbiology laboratories are 
contracted to the National Institute for Communicable Diseases in South 
Africa.
Rapid diagnostic test kit (RDT)
DiaMed OptiMAL-IT is an immuno-chromatographic test, using monoclonal 
antibodies against the metabolic enzyme pLDH (parasite lactate 
dehydrogenase) of Plasmodium species. These monoclonal antibodies are 
classified in two groups:
• one specific for Plasmodium falciparum
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• the other is a pan-specific monoclonal antibody which reacts with all 
species of Plasmodium which can occur in human beings (P. 
falciparum, P. vivax, P. ovale, and P. malariae).
It is important that you do not leave the material exposed to humidity and 
high temperature. Use the test, according to instructions, within 15 minutes 
of opening.
Validation of the test 
Results are valid if:
• the control band is clearly visible (dense line)
• the reaction field is cleared of blood 
Results are not valid if:
• the dipstick is not sufficiently cleared (reaction field remains red)
• the control band is not present
• the control band is not visible even if one or both of the diagnostic 
bands are present
• the control band and the band “P f are present while the band “P” is 
absent
If the results are not valid, repeat the test, following the test procedure 
precisely.
Interpretation of results 
Negative results
• no detectable line, other than the control band is visible 
Positive results
• If all three bands are visible, positive (for P. falciparum).
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• If the control band and the “P” band is visible, positive (for P. vivax,
P. ovale, or P. malariae)
Hb determination using Hemocue® photometers
Capillary blood was collected in micro-cuvettes and examined in 
Hemocue® photometers (Angelholm, Sweden) to determine Hb levels. The 
first step of haemoglobin determination begins with the finger stick, 
performed strictly according to the relevant SOP. Obtain an adequately 
filled cuvette following the correct procedures. The filled cuvette must be 
placed in the photometer within 10 minutes of sampling. Measurements 
made after 10 minutes may result in erroneous Hb estimation.
Daily Quality Control
1. Every day, the Clinic Coordinator or his/her designee tests the 
calibration control cuvette specific for the HemoCue photometer 
before patient testing, and after every 20 tests (if there are that many 
in one day). Values obtained should not deviate from the assigned 
value on the control cuvette card more than ±0.3g/dl. If the reading 
for the calibration control cuvette deviates from the stated reading, 
the Field Supervisor is notified immediately.
2. He/she records the date, Hemocue machine number, control cuvette 
value, reading, and ID code on the Daily Hemocue QC Log.
3. The photometer is designed to work for a long period without any 
direct service. No everyday preventative maintenance is needed for 
the electronic components of the photometer. However, the Clinic 
Coordinator or his/her designee cleans the cuvette holder daily with
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70% alcohol or a mild soap solution. The holder must be completely 
dry before being replaced in the photometer.
4. He/she also cleans the Calibration Cuvette holder on each day of 
testing and documents on the Daily Hemocue QC Log.
Monthly Quality Control
1. The Field Supervisor brings back the Hemocue machines to the 
Laboratory for additional quality control every month.
2. The Lab Assistant tests the HemoCue High, Medium, and Low liquid 
QC reagents monthly.
3. He/she records the date, Hemocue machine number, High, Medium, 
and Low readings, and their ID code on the Monthly Hemocue QC 
Log.
All Hemocues® were verified against a Coulter Counter® (Beckman 
Coulter, USA) at the monthly check-ups in the Laboratory. The external 
quality assurance services for the Haematology and Coulter Counter 
equipment are contracted to the United Kingdom National External Quality 
Assessment Service.
Blood specimens
Capillary blood was also collected at 12 months of age in tubes containing 
ethylene diamine tetra acetic acid (EDTA) for sickle cell status 
determination using a standard Hb electrophoresis technique. G6PD 
mutations at nucleotides 376 (A - G) and 202 (G - A) were detected by 
polymerase chain reaction followed by digestion with restriction 
endonucleases Fok\ and Nla\\\ respectively and phenotypes determined 
from the results (Beutler et al., 1989). Samples for glucose-6-phosphate
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dehydrogenase genotypes (G6PD) were collected at enrolment and 
analysed after all study subjects had completed the primary follow-up 
period. Table 4 shows how g6pd genotype results were mapped to 
phenotypes (Beutler et al., 1989).
Approximately, 500pL of whole blood was taken by finger prick sampling at 
the times indicated in Table 3: Study Schedule, Page 66. The samples 
were centrifuged, and the resulting sera frozen at minus 80 degrees 
Centigrade. Serum samples were subsequently transferred to the Health 
Protection Agency, UK for serological assays. The pre-vaccine samples for 
PENT/OPV were collected at enrolment and the post-vaccine samples one 
month after the third course of PENT/OPV vaccination and the second 
course of study drug. The pre-vaccine samples for measles were collected 
at 9 months of age immediately before the measles vaccination and the 
third course of study drug, and the post-vaccine samples at the following 
visit at 12 months of age.
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Table 4: G6PD genotypes mapped o phenotypes
MALES
Genotype Phenotype
G6PD B Normal
G6PD A Mild deficient
G6PD A- Hemizygous deficient
FEMALES
Genotype Phenotype
G6PD B B Normal
G6PD BA Normal
G6PD A A Mild deficient
G6PDB A- Heterozygous deficient
G6PDA A- Heterozygous deficient
G6PD A-A- Homozygous deficient
Investigational drugs
SP-Artesunate
Sulphadoxine-pyrimethamine has been the combination used for IPTi in all 
previous studies. Sulphadoxine-pyrimethamine has been extensively used 
in Africa over many years for both the treatment as well as prevention of 
malaria, and its safety in all age-groups and in later stages of pregnancy is 
well established (Peters et al., 2007, ter Kuile et al., 2007, Geerligs et al., 
2003). For IPTi, approximately 4000 infants received about 12,000 doses of 
IPTi-sulphadoxine-pyrimethamine in the six trials completed to date. 
(Grobusch et al., 2007a) Only one trial noted skin reactions considered due
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to IPTi; two in the sulphadoxine-pyrimethamine group (both SJS), and one 
in the placebo group; all three infants recovered fully (Kobbe et al., 2007).
SP was combined with artesunate as part of a loose combination treatment. 
The rationale for adding an artemisinin derivative was based on the studies 
that have shown the combination of SP plus artesunate to be more 
efficacious than SP alone in the treatment of uncomplicated malaria in 
symptomatic African children (Doherty et al., 1999, von Seidlein et al.,
2000, Targett et al., 2001) including in western Kenya (Obonyo et al.,
2003).
Amodiaquine-artesunate
AQ was included as an alternative to SP considering rising resistance to the 
latter and had been shown to be effective for IPTi in Tanzania (Massaga et 
al., 2003). Amodiaquine (AQ) is a 4-aminoquinoline, structurally related to 
chloroquine that has been used widely to treat and prevent malaria. It is 
more palatable than chloroquine and is easy to administer to children. It 
was first added to the World Health Organization (WHO) Essential Drugs 
List in 1977, but removed in 1988 for treatment or prophylaxis, because 
fatal adverse drug reactions were described in travellers using AQ for 
prophylaxis (Hatton et al., 1986, Neftel et al., 1986, Olliaro and Mussano, 
2003) Nevertheless, in the mid 90s amodiaquine was reintroduced in the 
WHO Treatment Guidelines after it was shown to have good safety and 
efficacy (Olliaro et al., 1996). Since then it has been widely used in
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chloroquine resistance areas as first line treatment of uncomplicated 
malaria, particularly in west-Africa.
Artesunate was added to amodiaquine because of uncertainties of how 
rising resistance could affect efficacy of amodiaquine. Amodiaquine is now 
increasingly deployed in combination with artesunate, one of the artemisinin 
derivatives. Amodiaquine plus artesunate is more effective than 
amodiaquine alone (Adjuik et al., 2002, Gupta et al., 2002) and is now used 
in many countries in loose combination (similar to that used in this study). 
Recently a fixed combination of artesunate plus amodiaquine was 
developed by the Drugs for Neglected Diseases initiative with Sanofi- 
Aventis as the industrial partner. It has been registered in Morocco (the 
country where the drug is manufactured). A prequalification dossier of this 
fixed combination has been submitted to the WHO. It is anticipated that the 
new co-formulation will increase the effectiveness of the combination by 
improving drug compliance (Sirima and Gansane, 2007). The WHO no 
longer recommends the use of amodiaquine as mono-therapy and it is 
anticipated that amodiaquine as mono-therapy will become increasingly 
difficult to obtain in the near future.
Chlorproquanil-dapsone (LapDap)
Chlorproguanil-dapsone (CD) was the short-acting drug of choice for this 
study. Chlorproguanil-dapsone is a non-artemisinin-containing fixed-dose 
antifolate combination similar to sulphadoxine-pyrimethamine and 
developed jointly by GlaxoSmithKline (GSK) and WHO/TDR (Tropical
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Disease Research) (Lang and Greenwood, 2003). It was briefly registered 
by the Medicines and Healthcare products Regulatory Agency (MHRA), the 
regulator in the United Kingdom, but was withdrawn in early 2008 by the 
manufacturer.
Chlorproguanil and dapsone were combined because they were known to 
be synergistic in combination and in order to obtain an antifolate 
combination with a more rapid elimination resulting in a shorter residence 
time in the body than sulphadoxine-pyrimethamine (Lang and Greenwood, 
2003). Chlorproguanil metabolises to chlorcycloguanil, which competes for 
the active site of dihydrofolate reductase (DHFR) and is also the mode of 
action of pyrimethamine. Dapsone competes for the active site of 
dihydropteroate synthetase (DHPS), also the mode of action of 
sulphadoxine. Chlorproguanil and dapsone have similar half-lives of around 
12 and 20 h. The two components of SP have half-lives of around 100 and 
200 h, respectively (Winstanley et al., 1997). The new combination was 
thus considered to exert less selective pressure for drug resistance than SP 
and hence a lower probability of selecting and spreading resistant parasites 
(Winstanley et al., 1997, Nzila et al., 2000).
Chlorproguanil-dapsone has been shown to be efficacious in Kenya 
(Watkins et al., 1988, Sulo et al., 2002) and northern Tanzania 
(Mutabingwa et al., 2001a, Mutabingwa et al., 2001b). There have been 
concerns about the life span of Chlorproguanil-dapsone when used 
because it shares similar genetic mechanisms of resistance as
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sulphadoxine-pyrimethamine. It was therefore further developed in 
combination with artesunate as chlorproguanil-dapsone-artesunate (CDA) 
by the Medicines for Malaria Venture (MMV), GSK and WHO/TDR.
Chlorproguanil-dapsone was chosen over CDA in our study, because at the 
time of the design of this study chlorproguanil-dapsone was only available 
as Lapdap, and CDA was not available, and there was no clinical 
experience with the combination in the treatment of malaria as it was still at 
an early phase of development and Phase I trials had just started (Olliaro 
and Taylor, 2003). It was therefore considered premature to use the 
combination with artesunate (loose or fixed) in the preventive use of malaria 
in a very young age group.
Interventions
The drug regimens were as follows:
1. SP_AS3 (DAFRA Pharma, Belgium): one SP paediatric-strength tablet
(250 mg sulphadoxine, 12.5 mg pyrimethamine) once on the first day 
of treatment (followed by a placebo SP tablet on days 2 and 3) and 
one paediatric artesunate tablet (25 mg) tablet, once daily for 3 days.
2. CD (GlaxoSmithKline, United Kingdom). One paediatric caplet (15 mg
chlorproguanil and 18.75 mg of dapsone) once daily for 3 days 
administered with a placebo for 3 days.
3. AQ3_AS3 (DAFRA Pharma, Belgium): one paediatric amodiaquine
tablet (67.5 mg), once daily for 3 days and one paediatric artesunate 
tablet (25 mg) once daily for 3 days.
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4. Placebo (DAFRA Pharma, Belgium). Participants in the placebo arm
received 2 placebo tablets co-administered once daily for 3 days.
5. Ferrous-sulphate (2 mg/kg/day) (Laboratory and Allied Ltd., Kenya) was
given at the first and second IPTi courses (1 month supply), and 1 
month later at the fourth scheduled visit (2 month supply) to the 
parent/guardian of all study participants for home administration 
during a 4-month period from approximately 2.5 to 6.5 months of 
age.
All study drugs were good manufacturing practice certified.
Administration of study drugs
All medications were dispensed as crushed tablets mixed -  to increase 
palatability - with pharmaceutical-grade flavoured syrup (Humco 
Corporation, Texarkana, Texas, USA) immediately prior to administration in 
an opaque syringe. The first dose of each course of study drug was 
administered and supervised at the healthcare unit by a study nurse, 
subsequent doses of each course were administered and supervised at 
home by study staff. All children were observed for 30 minutes; if vomiting 
occurred during that period a repeat dose was administered and supervised 
at the healthcare unit by a study nurse.
Iron was dispensed in bottles with a dropper device in the neck to facilitate 
accurate dispensing and with a childproof closure. The parent/guardian was 
instructed to bring along all the bottles of iron provided at the 14 week and 
18 week visits, and compliance with iron therapy was assessed by using a 
measuring stand to determine the quantity used by the 14 week, 18 week 
scheduled visits. In addition, a follow-up home-visit was scheduled at 6 1/4
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months to check iron compliance by which time the iron therapy was should 
have been completed.
Definition and assessment of adverse events
An adverse event (AE) was defined as any unexpected medical occurrence 
in a participant who was receiving or had received study drugs. An adverse 
event could therefore be any unfavourable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of the study drugs. It may or may not have been 
related to study drug. The intensity of each AE was also defined as 
belonging to grades 1-3, with 1 being the least severe.
A serious adverse event (SAE) was defined as any unexpected medical 
occurrence that:
1. results in death,
2. is life-threatening,
3. requires hospitalization or prolongation of existing hospitalization,
4. results in disability/incapacity,
5. Other medical events that may not be immediately life-threatening or
result in death or hospitalization but may jeopardize the subject or 
may require medical or surgical intervention to prevent one of the 
other outcomes listed in the above definition. These should also be 
considered SAEs. Examples of such events are intensive treatment 
in one of the study clinics for allergic bronchospasm or convulsions 
that do not result in hospitalization.
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NOTE: The term 'life-threatening' in the definition of 'serious' refers to an 
event in which the subject was at risk of death at the time of the event. It 
does not refer to an event which hypothetically might have caused death if 
it were more severe.
NOTE: In general, hospitalization signifies that the subject has been 
detained (usually involving at least an overnight stay) at the hospital or 
emergency ward for observation and/or treatment that would not have been 
appropriate in the physician’s office or out-patient setting. Complications 
that occur during hospitalization can be AEs or SAEs. If a complication 
prolongs hospitalization or fulfils any other serious criteria, the event is an 
SAE. When in doubt as to whether “hospitalization” occurred or was 
necessary, it should be considered an SAE.
NOTE: Hospitalization for elective treatment of a pre-existing condition that 
did not worsen from baseline is not considered an AE.
NOTE: The term disability means a substantial disruption of a person’s 
ability to conduct normal life functions. This definition is not intended to 
include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and 
accidental trauma (e.g. sprained ankle) which may interfere or prevent 
everyday life functions but do not constitute a substantial disruption.
Causality of all adverse events is defined in relation to the administration of 
study drugs:
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Definite (most probable) - Events occurring within a timely manner after 
administration of the interaction/intervention that are known sequelae of the 
interaction/intervention & follow a previously documented pattern but for 
which no other explanation is known. This category applies to those AEs 
that the investigator believes are incontrovertibly related to the 
interaction/intervention.
Probable - Any event occurring in a timely manner after administration of 
the interaction/intervention that follows a known pattern of reaction to the 
interaction/intervention & for which no other explanation is known. This 
category applies to those AEs that, after careful medical consideration at 
the time they are evaluated, are believed with a high degree of certainty to 
be related to the interaction/intervention.
Possible - Any event occurring in a timely manner after administration of the 
interaction/intervention that does not follow a known pattern of reaction & 
for which no other explanation is known. This category applies to those AEs 
that, after careful medical consideration at the time they are evaluated, are 
considered to be unlikely to be related but cannot be ruled out with 
certainty.
Unlikely - In general, this category can be considered applicable to those 
AEs that, after careful medical consideration at the time they are evaluated, 
are considered to be unrelated to administration of the 
interaction/intervention.
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Not related - Any AE for which there is evidence that an alternative 
aetiology exists or for which no timely relationship exists to the 
administration of the interaction/intervention & the AE does not follow any 
previously documented pattern. This category applies to those AEs that, 
after careful medical consideration, are clearly & incontrovertibly due to 
causes other than the interaction/intervention.
Unclassifiable (insufficient information) - There is insufficient information 
about the AE to allow for an assessment of causality.
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Table 5: Table for grading severity of adverse events
P A R A M E T E R G R A D E  1 G R A D E  2 G R A D E  3 SAE
H A E M A T O LO G Y (Life  T h rea ten ing )
H aem og lob in  
>3 m o to  <2 years
7 .1 -10 .9 5 .0-7 .0 <5.0 C ard iac  F a ilure  
S econda ry  to 
anaem ia
A b so lu te  N eu troph il 
C oun t (w ou ld  like ly  
on ly  be m easu red  in 
ch ild  ho sp ita lize d  fo r 
seve re  Illness)
7 5 0 -1200 4 0 0 -749 250-399 <250
P A R A M E T E R G R A D E  1 G R A D E  2 G R A D E  3 SAE
O TH E R
P ossib le  d rug  A lle rg y
(resp ira to ry
sym ptom s)
N one M ild w heez ing S evere  w heez ing , 
resp ira to ry  d ifficu lty
S evere  u rtica ria
A naphy lax is ,
A ng lo e d e m a
P ossib le  d rug  A lle rg y
(cu taneous
m an ifes ta tions)
P ruritis  w ith o u t R ash P ru ritic  Rash M ild  U rtica ria S evere  u rtica ria
A naphy lax is ,
A ng ioedem a
P ossib le  D rug F eve r 
(A xilla ry)
37 .5-39 >39.5 S usta ined  Fever: 
>39.5 , >5 days
Jaund ice N one N one M ild  ja u n d ice S evere  ja u n d ice  or 
ev idence  o f fu lm ina n t 
hepatitis
P ossib le  C u taneous  
reaction  to  s tudy 
drug
E ry th e m a  w ith  or 
w ith o u t p ru ritis
D iffuse
m acu lo p a p u la r rash, 
d ry  desquam a tion
V é s icu la tio n , u lcers, 
m o is t (w et) 
de sq ua m a tio n  o f 
<10%  o f body  
su rfa ce
E xfo lia tive  de rm atitis , 
M o is t (wet) 
desquam a tion  >10%  
o f  b ody  surface; 
(D iagnos is  o f 
S tevens-Johnson  o r 
T ox ic  ep iderm al 
necro lys is)
S tom atits M ild d isco m fo rt Pain fu l; d ifficu lty  
sw a llow ing , b u t ab le  
to  e a t and d rink
P a in fu l; un a b le  to 
sw a llo w  so lids
Pain fu l; requ ires  IV
NOTE: If any of the above symptoms appeared life-threatening, resulted in 
hospitalization, resulted in a permanent disability or incapacity, or resulted
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in death, the event was classified as a serious adverse event (SAE). All 
grade 3 or grade 4 AEs, all SAEs, and any other AEs that, in the judgment 
of the nurse could have been related to the administration of study drug, 
were reported to, and investigated by the clinical officer (Local Safety 
Monitor). Note that events categorized as grade 4 above were considered 
as life threatening, and reported as SAEs, even if hospitalization or death 
did not occur.
Data management and statistical methods
Data were entered using scan-ready Teleforms® and an optical scanner 
(Cardiff, Vista, California, USA). Data were checked for internal consistency 
and out of range values. The modified intention-to-treat (ITT) population 
included all the participants who received the first course of study drug 
regardless of whether they received all or part of the interventions. Only 
those who had received all three doses of IPTi or placebo (per-protocol) 
were included in these per protocol analyses.
We used Cox regression models to estimate the risk of the first or only 
episode of clinical malaria during the period starting from the first 
intervention visit and ending at 1 year of age or at censoring due to 
withdrawal or death. The protective effect (PE) was estimated as (1-hazard 
ratio) x 100%. The models’ assumption regarding the proportionality of the 
hazard ratio was analyzed by assessing the interaction between age and 
effect of treatment with a time-dependent Cox regression model. Kaplan- 
Meier curves were used to plot the time to event analyses.
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Multiple malaria episodes and hospital admissions were assessed using 
generalised estimating equations Poisson regression models were used to 
take into account intra-individual variations and to make any adjustments. 
During the 28 days after treatment was administered for an episode of 
clinical malaria, participants were considered not at risk for a new episode 
of malaria, and any positive blood smear during that time period was 
considered a recrudescence.
Post-dose analysis - 30 days after individual IPTi courses:
The person-time at-risk was calculated from the date of the given IPTi 
course until 30 days after that date or malaria was diagnosed or the 
participant exited the study before the 30 days ended, whichever occurred 
first. A Cox regression model was fitted to estimate the risk of the first or 
only episode of clinical malaria during the 30 day period. The PE was 
estimated as (1-hazard ratio) x 100%, adjusted for age and sex.
Post-dose analysis by week after individual IPTi courses:
The first IPTi course was excluded from this analysis because the period of 
post-treatment prophylaxis overlapped with the second IPTi course 
treatment. A Lexis expansion (Clayton, 1993) was used to obtain estimates 
within defined time strata at 7 day intervals after IPTi courses 2 and 3 by 
fitting a Cox regression model to estimate the time to first or only episode of 
clinical malaria within each time strata. The estimates were obtained by 
calculating PEs within each consecutive period of 7 days after each of the
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relevant courses of IPTi. Infants were excluded from the analysis for a 
period of 28 days after each event, i.e. if a child had clinical malaria in the 
middle of a 7 day time period, it was excluded for the next 4 week-strata 
until a total of 28 days exclusion period had been reached, after which the 
infant contributed again to the analysis.
Post-dose analysis -  biweekly time-interaction models:
The first IPTi course was excluded from this analysis as well because the 
period of post-treatment prophylaxis overlapped with the second IPTi 
course treatment. A Lexis expansion was used to obtain estimates within 
defined time strata at 14 day intervals after IPTi courses 2 and 3 by fitting a 
GEE time-interaction Poisson model to take into account intra-individual 
variations and to make any adjustments. Multiple episodes of clinical 
malaria were assessed, and PEs calculated as (1- incidence rate ratio) x 
100% within each consecutive period of 14 days after each of the relevant 
courses of IPTi. Infants were excluded from the analysis for a period of 28 
days after each event, i.e. if a child had clinical malaria in the middle of a 14 
day time period, it was excluded for the next 4 week-strata until a total of 28 
days exclusion period had been reached, after which the infant contributed 
again to the analysis.
The GEE time-interaction Poisson model analysis was pooled across the 
respective IPTi courses allowing for a more robust estimation of PEs over 
time. Biweekly intervals were preferred for analysis because some weekly 
intervals had very few episodes of clinical malaria or lacked them 
altogether.
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Log-binomial regression models were used to calculate prevalence rate 
ratios for the 12 month cross-sectional survey. Risk ratios involving count 
data were calculated using appropriate Poisson regression models.
Nutritional indices were generated using growth references from the 
National Center for Health Services, USA and the World Health 
Organization (CDC, 2005). The analysis was done using SAS version 9.1.3 
(SAS Institute, Cary, North Carolina, USA), and STATA version 8.2 (STATA 
corporation, College Station, Texas, USA).
Ethical approval
The study was conducted according to good clinical practice guidelines and 
monitored by a DSMB. Safety issues were also overseen by the safety 
panel of the IPTi consortium. The protocol was approved by the National 
Ethical Review Committee of the Kenya Medical Research Institute 
(KEMRI) in Nairobi, and the Institutional Review Board of the Centers for 
Disease Control and Prevention (CDC) in Atlanta, Georgia. The study is 
registered with ClinicalTrials.gov, identifier NCT00111163.
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Chapter 5: Results
Study site preparation
The recruitment of study personnel, their training in GCP and standard 
operating procedures (SOPs) was completed by February 2004. The trial 
started in March 2004 after a satisfactory site inspection by a team of 
investigators. Enrolment of potential study participants commenced at the 
four study sites within monthly intervals of each other in order to allow for 
effective logistical coordination (due to remoteness of some sites) and 
adequate response to community mobilisation. Some of the initial 
challenges, such as road access to the remote study sites and re­
establishment of cold-chain facilities required for safe vaccine storage were 
overcome with the collaboration and assistance of the Kenyan Ministry of 
Health, the local administration and community.
The trial profile
Recruitment started in March 2004 and was completed 24 months later in 
March 2006. One thousand five hundred and sixteen (1516) infants were 
enrolled over a period of two years. 1365 children were included in the ITT 
population, defined as all enrolled children who received at least one dose 
of study drug and had not reported to be ill with clinical malaria on or before 
their first intervention visit. The distribution of study participants within the 
four randomization arms was fairly balanced (Figure 15: Trial Profile, Page 
101). The remaining children were not included because they no longer
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fulfilled the inclusion criteria by the time they were scheduled to receive 
their first dose of study drug; within the one month period between the first 
immunization visit when the children were enrolled and the first course of 
intervention at the second immunization visit, 6 children had died, 41 had 
migrated outside the study area, 68 had withdrawn from the study, and 32 
had developed clinical malaria and received alternative antimalarial 
medication. An additional 12 children reported sick with clinical malaria on 
their first intervention visit.
Administration of all three courses of IPTi was completed by December 
2006. Over the duration of the entire study (follow-up to 24 months of age), 
1983 ITNs were issued to participants, 14596 sick visits were attended to, 
and 850 hospitalizations were facilitated.
Participant and baseline characteristics
The participant and baseline characteristics of the ITT population as 
assigned to the four randomisation arms are presented in Table 6 (Page 
102). The four study groups were comparable with regard to gender, Hb 
genotype, G6PD phenotype, weight-for-age, age at first, second, and third 
IPTi doses, use of ITNs, and loss to follow-up due to deaths (Table 6).
The average age was 2.7 months on enrolment in all 4 groups. About 1 in 
five children carried the sickle cell trait (Haemoglobin AS) and about 1 in 50 
had sickle cell anaemia. G6PD deficiency was present in about 1 in 4 
children, half of which was defined as mildly-deficient.
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Success rate of follow-up
A fairly high level of compliance was achieved to complete the 12 month 
follow-up. Of the 1365 children included in the ITT population, 100% 
received the first course of intervention (by definition of the ITT population), 
1317 (96.5%) received the second course of intervention and 1166 (85.4%) 
received the third course. Furthermore, 55 (4.0%) infants died, 38 (2.8%) 
withdrew consent, and 191 (14.0%) were lost to follow-up due to migration 
outside the study area; 1081 (79.2%) completed the 12 month follow-up 
period (Figure 15: Trial Profile, page 101). 1050 (76.9%) children were 
included in the per-protocol (PPT) population which was defined as all 
enrolled children who received all the three courses of the intervention 
within 28 days of their scheduled visits, had not reported ill on or before 
their first intervention visit, and stayed within the study area throughout the 
intervention period. The randomization of one study participant was un­
blinded due to the recommendation of the Local Safety Monitor and 
agreement of the DSMB chair, on suspicion of sensitivity to sulphur-based 
drugs because of a slight rash developed within 30 minutes of study drug 
administration. The child was withdrawn from receiving any more study 
drugs but was regularly followed-up and continued to benefit from free 
healthcare as promised until completion of the study. There was a 
differential loss to follow-up in the CD3 arm with a slightly higher number of 
migrations outside the study area within the five month period between the 
second and third courses of the intervention (Figure 15)
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Table 6 Characteristics of IPTi study arms
Parameter Placebo SP-AS3 AQ3-AS3 CD3
(n=337) (n=339) (n=347) (n=342)
Male sex [% ] 4 6 .9 53.1 5 3 .9 50 .6
Haemoglobin genotype: t
A A  [% ] 7 5 .3 76.1 7 8 .4 76 .7
A S  “ 23 .3 2 2 .9 18.9 2 1 .0
SS  “ 0 .4 0 .4 0 .7 0.4
O th e r “ 1.1 0 .7 2.1 2 .0
G6PD deficiency:
N o rm a l [% ] 7 3 .9 7 1 .6 6 8 .0 72 .2
M ild -d e fic ie n t 12.5 15.4 13.3 11.4
D e fic ie n t 13.6 13.0 18.7 16.4
Age at 1st IPTi [months] (m e a n ± S D ) 2 .7  ± 0 .4 2 .7  ±  0 .4 2 .7  ± 0 .5 2 .7  ± 0 .5
Age at 2nd IPTi [months] 3 .7  ± 0 .5 3 .7  ± 0 .5 3 .7  ± 0 .6 3 .7  ± 0 .6
Age at 3rd IPTi [months] 9 .2  ± 0 .3 9 .2  ± 0 .3 9 .2  ± 0 .3 9 .2  ± 0 .3
Weight-for-age z score at 1st IPTi “ 0 .3  ± 1 .1 0 .3  ±  1.1 0 .3  ±  1.1 0 .3  ±  1.1
Note: f  At 1 year of age. [%] - figure is presented as a percentage. 
(%) -  figure in brackets is a percentage.
1 0 2
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Protective efficacy (PE)
Intention to treat analysis
Surveillance during the study was conducted by passive case detection in 
addition to the regularly scheduled visits. The effects of IPTi on malaria and 
anaemia in the first year of life are shown in Table 7, Page 106.
Clinical malaria
A total of 918 episodes of clinical malaria were detected. The protective 
efficacy against the primary outcome of this study, i.e. the first or only 
episode of clinical malaria in the first year of life, was 25.7% (95% Cl: 6.3, 
41.1; p=0.012) in the SP-AS3 arm, 25.9% (95% Cl: 6.8, 41.0; p=0.010) in 
the AQ3-AS3 arm, and 16.3% (95% Cl: -5.2, 33.5; p=0.127) in the CD3 arm 
when compared to placebo. The median time to the first or only episode of 
clinical malaria during the first year of life was longer in the SP-AS3 arm 
(204 days; p=0.010) and the AQ3-AS3 arm (208 days; p=0.007) when 
compared to placebo but there was no difference in the CD3 arm (196 
days; p=0.633) when compared to placebo (196 days).
When multiple episodes of clinical malaria were considered the 
corresponding protective efficacy results were 22.2% (95% Cl: 2.5,37.8; 
p=0.029), 24.7% (95% Cl: 6.4,39.5; p=0.011), and 10.5% (95% Cl: -11.6 , 
28.2; p=0.324), for SP-AS3, AQ3-AS3 and CD3 respectively.
A more specific case definition for clinical malaria (with >5000 parasites/pL 
of blood) showed a much higher protective efficacy and yielded the
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following corresponding results for the first or only episode analysis 48.9% 
(95% Cl: 12.2,70.3; p=0.015), 41.2% (95% Cl: 2.5,64.5; p=0.040), and 
3.4% (95% Cl: -52.3,38.8; p=0.880), for SP-AS3, AQ3-AS3 and CD3 
respectively. Kaplan Meier survival plots of the above described data are 
shown in Figure 16, Page 108.
Anaemia
The protective efficacy against the first or only episode of mild anaemia (Hb 
<11 .Og/dL) was 16.4% (95% Cl: -0.6,30.4; p=0.057) in the SP-AS3 arm, 
20.3% (95% Cl: 4.0,33.9; p=0.017) in the AQ3-AS3 arm, and 8.0% (95% 
Cl: -10.6,23.5; p=0.375) in the CD3 arm. The corresponding figures for 
moderate-to-severe anaemia (Hb <8.Og/dL) were 27.5% (95% Cl: -6.9 , 
50.8; p=0.105), 23.1% (95% Cl: -11.9,47.2; p=0.170), and 11.4% (95% Cl: 
-28.6,39.0; p=0.525). Kaplan Meier survival plots of the above described 
data are shown in (Figure 17, Page 109 and Figure 18, Page 110). Multiple 
episodes of anaemia (incidence density) were not considered because of 
the long recovery times from malaria associated anaemia, even after 
effective antimalarial treatment (Price et al., 2001).
Participants, recorded as having had poor iron compliance were 16.7% in 
the SP-AS3 arm, 17.9% in the AQ3-AS3 arm, 15.8% in the CD3 arm, and 
16.0% in the placebo arm.
Sick child visits and hospital admissions
There was no evidence of any effect of the intervention on the frequency of 
all-cause sick child out-patient visits. None of the IPTi regimens appeared
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to provide statistically significant protection against, all-cause 
hospitalizations, malaria-related hospitalizations, or hospitalizations related 
to moderate-to-severe anaemia (Table 7).
Per protocol analysis
Of the 1365 enrolled infants, 1050 (76.9%) contributed to the per protocol 
analysis. The results of the PPT analysis have been presented in Table 8 
and are generally consistent with the ITT analysis. The results which 
achieved statistical significance for the PPT population, but not in the ITT 
population were the following: protective efficacy against the first or only 
episode of mild anaemia (Hb <11 .Og/dL) in the SP-AS3 arm, 22.6% (95% 
Cl: 4.8,37.1; p=0.015); protective efficacy against all-cause outpatient 
visits in the SP-AS3 arm, 9.4% (95% Cl: 2.2 , 16.0; p=0.011), other results 
came to similar conclusions as the ITT analysis (Table 8, Page 107).
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Table 7: Incidences of the main outcomes during the first year of life -
ITT
Outcome Placebo SP-AS3 AQ3-AS3 CD3
First or only 
episode of clinical 
malaria
(n=337) (n=339) (n=347) (n=342)
E ve n ts /P Y A R ; R a te 1 5 8 /1 6 1 .0 ;0 .9 8 1 3 0 /1 7 6 .3 ;0 .7 4 1 3 7 /1 8 1 .4 ;0 .7 6 1 3 6 /1 6 6 .2 ;0 .8 2
PE  %  (95 %  C l) R e fe re n ce 2 5 .7  ( 6 .3 ,4 1 .1 ) 2 5 .9  ( 6 .8 ,4 1 .0 ) 16 .3  ( - 5 .2 ,3 3 .5 )
P -va lue 0.012 0.010 0 .1 27
All episodes of 
clinical malaria
(n=337) (n=339) (n=347) (n=342)
E ve n ts /P Y A R ; R a te 2 6 3 /1 9 7 .0 ; 1 .33 2 0 9 /2 0 1 .1 ; 1.04 2 1 3 /2 1 2 .0 ; 1.00 2 3 3 /1 9 5 .0 :1 .2 0
PE  %  (95 %  C l) R e fe re n ce 2 2 .2  ( 2 .5 ,3 7 .8 ) 2 4 .7  ( 6 .4 ,3 9 .5 ) 10 .5  ( - 1 1 .6 ,2 8 .2 )
P -va lue 0 .0 2 9 0.011 0 .324
1st or only episode 
( >5000 par/pL)
(n=346) (n=350) (n=354) (n=347)
E ve n ts /P Y A R ; R a te 3 8 /2 0 6 .3 ;0 .1 8 2 0 /2 1 3 .1 ;0 .0 9 2 5 /2 1 9 .8 :0 .1 1 3 6 /2 0 3 .0 :0 .1 8
PE  %  (95 %  C l) R e fe re n ce 4 8 .9 ( 1 2 .2 ,7 0 .3 ) 4 1 .2  ( 2 .5 ,6 4 .5 ) 3 .4  ( -5 2 .3 ,3 8 .8 )
P -va lue 0.015 0 .0 4 0 0 .8 80
Mild anaemia 
(Hb<11g/dL)
(n=321) (n=335) (n=324) (n=326)
E ve n ts /P Y A R ; R a te 2 3 2 /1 1 4 .8 ; 2 .02 2 2 1 /1 2 8 .9 ; 1.71 2 1 4 /1 2 7 .3 ; 1.68 2 2 3 /1 1 8 .5 :1 .8 8
PE % (95 %  C l) R e fe re n ce 16.4  ( - 0 .6 ,3 0 .4 ) 2 0 .3  ( 4 .0 ,3 3 .9 ) 8 .0  ( - 1 0 .6 ,2 3 .5 )
P -va lue 0 .0 57 0.017 0 .3 75
Moderate-to-severe 
anaemia (Hb<8g/dL)
(n=350) (n=355) (n=357) (n=351)
E ve n ts /P Y A R ; R a te 5 9 /1 9 9 .3 ; 0 .3 4 5 /2 0 9 .5 ; 0.21 5 1 /2 1 3 .4 ;0 .2 4 5 2 /1 9 8 .7 :0 .2 6
PE  %  (95 %  C l) R e fe re n ce 2 7 .5  ( -6 .9 ,5 0 .8 ) 23.1 ( -1 1 .9 ,4 7 .2 ) 11 .4  ( - 2 8 .6 ,3 9 .0 )
P -va lue 0 .1 0 5 0 .1 7 0 0 .5 2 5
Out-patient visits (n=337) (n=339) (n=347) (n=342)
E ve n ts /P Y A R ; R a te 1 9 9 6 /2 1 0 .7 ;9 .4 7 1 9 4 7 /2 1 1 .1 :9 .2 2 2 1 2 5 /2 2 1 .5 ;9 .5 9 2 0 5 1 /2 0 6 .6 ; 9 .9 3
PE  %  (95 %  C l) R e fe re n ce 2 .6  ( - 4 .9 ,9 .7 ) -1 .3  ( - 9 .4 ,6 .2 ) -4 .8  ( -1 3 .2 ,2 .9 )
P -va lue 0 .4 82 0 .7 4 6 0 .2 29
All hospitalisations (n=337) (n=339) (n=347) (n=342)
E ve n ts /P Y A R ; R a te 1 3 7 /2 1 0 .9 ; 0 .65 1 2 7 /2 1 1 .4 ;0 .6 0 1 4 7 /2 2 1 .7 ;0 ,6 6 1 3 0 /2 0 6 .9 :0 .6 3
PE % (95 %  C l) R e fe re n ce 7 .5  ( - 1 9 .7 ,2 8 .5 ) -2.1 (-32.1 ,2 1 .1 ) 3 .3  ( -2 8 .6 ,2 7 .3 )
P -va lue 0 .5 53 0 .8 7 5 0 .8 1 8
Hospitalisations - 
clinical malaria
(n=337) (n=339) (n=347) (n=342)
E ve n ts /P Y A R ; R a te 5 7 /2 1 0 .9 :0 .2 7 6 1 /2 1 1 .4 ;0 .2 9 6 7 /2 2 1 .7 ; 0 .3 0 5 8 /2 0 6 .9 ; 0 .2 8
PE % (9 5 %  C l) R e fe re n ce -6 .8  (-61 .5 , 29 .4 ) -1 1 .8 (-6 7 .9 , 25 .5) -3 .7  ( -6 0 .6 ,3 3 .0 )
P -va lue 0 .7 5 6 0 .5 9 0 0.871
Hospitalisations - 
anaemia (Hb<8g/dL)
(n=337) (n=339) (n=347) (n=342)
E ve n ts /P Y A R ; R a te 4 4 /2 1 0 .9 :0 .2 1 4 1 /2 1 1 .4 ;0 .1 9 3 5 /2 2 1 .7 ;0 .1 6 4 1 /2 0 6 .9 ; 0 .2 0
PE % (95 %  C l) R e fe re n ce 7 .0  (-60.1 ,4 6 .0 ) 2 4 .3  ( -3 5 .2 ,5 7 .6 ) 5 .0  ( -6 4 .9 ,4 5 .3 )
P -va lue 0 .7 93 0 .3 4 7 0 .8 55
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Table 8: Incidences of the main outcomes during the first year of life - 
PPT
Outcome Placebo SP-AS3 AQ3-AS3 CD3
First or only 
episode of clinical 
malaria
(n=263) (n=264) (n=272) (n=251)
E ve n ts /P Y A R ; R a te 1 3 2 /1 3 1 .1 ;1 .0 1 9 9 /1 4 5 .4 ; 0 .6 8 1 1 5 /1 4 9 .0 ; 0 .7 7 1 1 3 /13 1 .7 ; 0 .8 6
PE %  (95 %  C l) R e fe re n ce 3 3 .3  ( 1 3 .5 ,4 8 .6 ) 2 6 .9 (6 .1  ,4 3 .1 ) 15.4 ( -8 .8 ,3 4 .2 )
P -va lue 0.002 0.014 0 .1 92
All episodes of 
clinical malaria
(n=263) (n=264) (n=272) (n=251)
E ve n ts /P Y A R ; R a te 2 1 7 /1 6 1 .3 ; 1.35 1 5 6 /1 6 4 .1 ;0 .9 5 1 7 9 /1 7 5 .3 ; 1.02 1 9 3 /1 5 5 .6 ; 1.24
PE  %  (95 %  C l) R e fe re n ce 2 9 .3  ( 9 .2 ,4 5 .1 ) 24.1 ( 3 .9 ,4 0 .1 ) 7 .8  ( -1 7 .0 ,2 7 .4 )
P -va lue 0.007 0 .0 2 2 0 .5 03
1st or only episode 
(>5000 par/pL)
(n=263) (n=264) (n=272) (n=251)
E v e n ts /P Y A R ; R a te 3 5 /1 6 3 .8 ; 0.21 1 3 /1 6 8 .5 ;0 .0 8 2 0 /1 7 9 .0 ; 0.11 2 9 /1 6 0 .2 ; 0 .1 8
PE  %  (95 %  C l) R e fe re n ce 6 3 .7  (3 1 .4 ,8 0 .8 ) 5 0 .5 ( 1 4 .3 ,7 1 .5 ) 16 .0  ( - 3 7 .4 ,4 8 .6 )
P -va lue 0.002 0.012 0 .4 88
Mild anaemia (n=247) (n=252) (n=252) (n=239)
(Hb<11g/dL)
E ve n ts /P Y A R ; R a te 1 9 0 /9 0 .4 ;2 .1 0 1 7 0 /10 2 .2 ; 1.66 1 7 7 /1 0 5 .1 ; 1.68 17 9 /93 .3 ; 1 .92
PE % (95 %  C l) R e fe re n ce 2 2 .6  ( 4 .8 ,3 7 .1 ) 2 3 .9  ( 6 .6 ,3 8 .1 ) 10 .2  ( - 1 0 .2 ,2 6 .8 )
P -va lue 0.015 0.009 0 .3 03
Moderate-to-severe (n=263) (n=264) (n=272) (n=251)
anaemia (Hb<8g/dL)
E ve n ts /P Y A R ; R a te 4 3 /1 5 8 .9 ; 0 .2 7 3 4 /1 6 4 .4 ; 0.21 3 5 /1 7 6 .6 ; 0 .2 0 35 /1 5 6 .6 ; 0 .2 2
PE  %  (9 5 %  C l) R e fe re n ce 2 3 .0  ( -2 0 .8 ,5 0 .9 ) 3 0 .8  ( - 8 .2 ,5 5 .7 ) 17 .9  ( - 2 8 .3 ,4 7 .4 )
P -va lue 0 .2 55 0 .1 0 6 0 .5 25
Out-patient visits (n=263) (n=264) (n=272) (n=251)
E v e n ts /P Y A R ; R a te 1 7 4 2 /1 7 1 .8 ;1 0 .1 4 15 7 7 /1 7 1 .6 ; 9 .9 8 1 8 3 1 /1 8 3 .5 :9 .1 9 1 7 54 /1 64 .9 ;
10 .63
PE  %  (95 %  C l) R e fe re n ce 9 .4  (2 .2 ,1 6 .0 ) 1.6 ( - 6 .4 ,9 .0 ) -4 .9  ( - 1 3 .3 ,2 .9 )
P -va lue 0.011 0 .6 8 5 0 .2 2 7
All hospitalisations (n=263) (n=264) (n=272) (n=251)
E v e n ts /P Y A R ; R a te 1 0 7 /1 7 2 .0 :0 .6 2 8 9 /1 7 1 .8 ;0 .5 2 1 1 1 /1 8 3 .7 ; 0 .6 8 6 /1 6 5 .1 ;0 .5 2
PE  %  (9 5 %  C l) R e fe re n ce 16.8  ( -1 2 .0 ,3 8 .1 ) 2 .9  ( - 2 8 .2 ,2 6 .4 ) 16.3 (-16.1 ,3 9 .7 )
P -va lue 0 .2 26 0 .8 3 7 0 .2 87
Hospitalisations • 
clinical malaria
(n=263) (n=264) (n=272) (n=251)
E ve n ts /P Y A R ; R a te 4 9 /1 7 2 .0 ; 0 .2 9 4 3 /1 7 1 .8 ; 0 .2 5 5 8 /1 8 3 .7 ;0 .3 2 4 2 /1 6 5 .1 :0 .2 5
PE %  (95 %  C l) R e fe re n ce 12.2  ( -4 0 .0 ,4 4 .9 ) -1 0 .8  ( -7 1 .3 ,2 8 .3 ) 10.7 ( -4 5 .5 ,4 5 .2 )
P -va lue 0 .5 85 0 .6 4 4 0 .6 49
Hospitalisations - 
anaemia (Hb<8g/dL)
(n=263) (n=264) (n=272) (n=251)
E v e n ts /P Y A R ; R a te 3 1 /1 7 2 .0 ;0 .1 8 3 0 /1 7 1 .8 ; 0 .1 7 2 0 /1 8 3 .7 ;0 .1 1 2 4 /1 6 5 .1 ;0 .1 5
PE  %  (95 %  C l) R e fe re n ce 3 .2  ( - 8 0 .3 ,4 8 .0 ) 3 9 .6  ( - 2 2 .4 ,7 0 .2 ) 19.4 (-55.1 ,5 8 .1 )
P -va lue 0 .9 2 0 .1 6 2 0 .5 19
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Figure 16: Kaplan-Meier plots showing the cumulative proportion of
children remaining free of clinical malaria episode between the first
dose of IPTi and 12 months of age.
- AQ3_AS3---------CD3
- PLACEBO--------SP AS
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Figure 17: Kaplan-Meier plots showing the cumulative proportion of
children remaining free of any anaemia (Hb <11 g/dL) between the
first dose of IPTi and 12 months of age.
From first dose until 12 months of age
—- AQ 3_AS3--------- CD3
--------- PLACEBO------------ SP AS3
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Figure 18: Kaplan-Meier plots showing the cumulative proportion of
children remaining free of moderate to severe anaemia (Hb < 8 g/dL)
between the first dose of IPTi and 12 months of age.
From first dose until 12 months of age
-  A Q 3 A S 3 --------- CD3
- PLACEBO ---------  SP AS3
1 1 0
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Post-dose efficacy against malaria
We analyzed the duration of the protective efficacy against clinical malaria 
with increasing time since each IPTi course using Survival analysis (Cox 
regression). The models were adjusted for age and sex.
0-30 days
To allow a comparison with previous studies of IPTi with SP, we first 
estimated the incidence and protective efficacy in the first 30 days after 
each course (Table 9, Page 117). This showed that the incidence was low 
after the first course and that the protective efficacy was highest with the 
sulphadoxine-pyrimethamine, followed by the AQ based regimen and then 
the CD regimen, as outlined below.
A very high protective efficacy was found against the first or only episode of 
clinical malaria within a period of 30 days after the first course of IPTi. This 
was highest at 88.7% (95% Cl: 50.9,97.4; p=0.004) in the SP-AS3 arm, 
and was 66.6% (95% Cl: 15.2,86.8; p=0.021) in the AQ3-AS3 arm, and 
66.1% (95% Cl: 14.0,86.6; p=0.023) in the CD3 arm, respectively.
The corresponding protective efficacies for the 30-days time period after the 
second course of IPTi were also highest in the sulphadoxine-pyrimethamine 
arm (89.9% [95% Cl: 66.7,96.9; p<0.001)], followed again by AQ3-AS3 at 
72.7% (95% Cl: 39.9,87.6; p=0.001), and 61.7% (95% Cl: 22.9,81.0; 
p=0.007) with CD3.
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By contrast, the protective efficacy for the 30-day time period after the third 
course of IPTi was much lower in all three interventions groups and was: 
32.7% (95% Cl: -32.4,65.8; p=0.251), 38.0% (95% Cl: -20.5,68.1; 
p=0.159), and 21.7% (95% Cl: -52.3,59.7; p=0.471) in the SP-AS3, AQ3- 
AS3 and the CD3 arms respectively (Table 9, Page 117).
When the post-dose analyses were conducted for the PPT population the 
results were similar for the first and second dose, showing greater 
protective efficacy by 30 days for SP-AS3, followed by AQ3-AS3 and then 
CD3. However, after the third dose much higher protective efficacy were 
observed for SP-AS3 and AQ3-AS3 (42.9% and 49.5%) than with the ITT 
analysis (32.7% and 38.8%), whereas the results for CD4 were lower 
(Table 10, Page 118).
Protective efficacy by week
The duration of post-treatment prophylaxis was then estimated in more 
detail by observing the waning protection offered during the second and 
third courses of IPTi in the first 84 days after each dose. The results from 
the weekly models represent data from the second and third course only. 
The first course had to be excluded from this analysis because the 
maximum possible observation time was limited to 30 days by which time 
the second course was scheduled to be given. Survival analysis (Cox 
regression) was used to estimate protective efficacy against the first or only 
episode of clinical malaria. The observations were made by calculating
protective efficacies within each consecutive period of 7 days after each of
1 1 2
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the relevant courses of IPTi. Infants were excluded from the analysis for a 
period of 28 days after each event, i.e. if a child had clinical malaria in the 
middle of a 7 day time period, it was excluded for the next 4 week-strata 
until a total of 28 days exclusion period had been reached, after which the 
infant contributed again to the analysis. Data are presented from the 
unadjusted models.
0-84 days (IPTi-2 and IPTi-3)
Figure 19 to Figure 24 show the protective efficacy against first-or-only 
episode of clinical malaria by the week since treatment for IPTi for courses 
2 and 3 only. The error bars indicate 95% confidence intervals. The 
analysis showed that the duration of protective efficacy was longest for the 
combinations based on sulphadoxine-pyrimethamine and amodiaquine 
reflecting their longer half-lives compared to CD3.
It also showed that the protective effect declined rapidly from 3 weeks 
onwards and was no longer evident after 2 months, suggesting that the 
effect of IPTi occurs only in the immediate period after drug dosing and 
appears to last as long as the direct pharmacological effect of the drug.
There was evidence of significant protection for at least [4] weeks with SP- 
AS3 and AQ-AS3, and at least [2] weeks for CD3. Importantly, there was no 
evidence of a sustained effect of IPTi after this initial period for any of the 
three drug combinations, neither was there any clear evidence of a rebound 
within the first 12 months of life.
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=igure 19: Weekly PEs post-IPTi 2 for SP-AS3
:igure 20: Weekly PEs post-IPTi 2 for AQ3-AS3
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:igure 21: Weekly PEs post-IPTi 2 for CD3
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:igure 23: Weekly PEs post-1 PTi 3 for AQ3-AS3
Figure 24: Weekly PEs post-1 PTi 3 for CD3
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Table 9: Incidences of the primary outcome 30 days after each course
of IPTi - ITT
Outcome Placebo SP-AS3 AQ3-AS3 CD3
First or only (n=337) (n=339) (n=347) (n=342)
episode of clinical
malaria after IPTi-1
E v e n ts /P Y A R ; R a te 1 7 /2 7 .1 ; 0 .6 3 2 /2 7 .8 ; 0 .07 6 /2 8 .3 ; 0.21 6 /2 7 .9 ; 0 .22
P E  %  (95 %  C l) R e fe re n ce 88 .7  (5 0 .9 ,9 7 .4 ) 6 6 .6 ( 1 5 .2 ,8 6 .8 ) 66.1 (1 4 .0 ,8 6 .6 )
P -va lu e 0.004 0.021 0 .0 23
First or only (n=309) (n=321) (n=318) (n=315)
episode of clinical
malaria after IPTi-2
E ve n ts /P Y A R ; R a te 2 7 /2 4 .4 ; 1.11 3 /2 6 .3 ; 0.11 8 /2 6 .0 ; 0.31 11 /25 .6 ; 0 .43
PE  %  (9 5 %  C l) R e fe re n ce 8 9 .9  ( 6 6 .7 ,9 6 .9 ) 7 2 .7  (3 9 .9 ,8 7 .6 ) 6 1 .7  (2 2 .9 ,8 1 .0 )
P -va lu e <0.001 0.001 0.007
First or only (n=187) (n=213) (n=235) (n=184)
episode of clinical
malaria after IPTi-3
E ve n ts /P Y A R ; R a te 1 9 /13 .6 ; 1.4 1 5 /1 5 .9 ;0 .9 4 1 6 /1 8 .0 ; 0 .8 9 16 /14 .3 ; 1.12
PE  %  (9 5 %  C l) R e fe re n ce 3 2 .7  ( -3 2 .4 ,6 5 .8 ) 3 8 .0  ( - 2 0 .5 ,6 8 .1 ) 21 .7  ( -5 2 .3 ,5 9 .7 )
P -va lu e 0.251 0 .1 5 9 0.471
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Table 10: Incidences of the primary outcome 30 days after each
course of IPTi - PPT
Outcome Placebo SP-AS3 AQ3-AS3 CD3
First or only (n=263) (n=264) (n=272) (n=251)
episode of clinical
malaria after IPTi-1
E ve n ts /P Y A R ; R a te 9 /2 1 .4 ;0 .4 2 1/21.6 ; 0 .0 5 5 /2 2 .3 ; 0 .2 2 3 /20 .6 ; 0 .1 5
P E  %  (9 5 %  C l) R e fe re n ce 89.1 (1 3 .8 ,9 8 .6 ) 4 6 .8  ( - 5 8 .9 ,8 2 .2 ) 6 5 .5  ( - 2 7 .3 ,9 0 .7 )
P -v a lu e 0 .0 36 0 .2 5 9 0.11
First or only (n=253) (n=260) (n=263) (n=247)
episode of clinical
malaria after IPTi-2
E ve n ts /P Y A R ; R a te 2 5 /1 9 .9 ; 1.26 2 /2 1 .4 ;0 .0 9 4 /2 1 .5 ;0 .1 9 9 /20 .2 ; 0 .4 5
P E  %  (9 5 %  C l) R e fe re n ce 9 2 .7  (69.1 ,9 8 .3 ) 8 5 .5  ( 5 8 .3 ,9 4 .9 ) 65 .0  (2 5 .0 ,8 3 .7 )
P -v a lu e <0.001 <0.001 0.007
First or only (n=212) (n=242) (n=246) (n=215)
episode of clinical
malaria after IPTi-3
E ve n ts /P Y A R ; R a te 1 5 /1 7 .0 ;0 .8 8 1 0 /1 9 .7 ;0 .5 1 9 /2 0 .0 ; 0 .4 5 1 4 /1 7 .4 ;0 .8
P E  %  (9 5 %  C l) R e fe re n ce 4 2 .9  (-27.1 ,7 4 .3 ) 4 9 .5  ( - 1 5 .4 ,7 7 .9 ) 9 .4 ( -8 7 .8 ,5 6 .2 )
P -v a lu e 0 .1 7 0 .1 0 5 0 .7 92
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:igure 25: Biweekly PEs post-1 PTi 2 for SP-AS3
Figure 26: Biweekly PEs post-IPTi 2 for AQ3-AS3
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:igure 27: Biweekly PEs post-IPTi 2 for CD3
Figure 28: Biweekly PEs post-IPTi 3 for SP-AS3
1 2 0
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Figure 29: Biweekly PEs post-1 PTi 3 for AQ3-AS3
rigure 30: Biweekly PEs post-IPTi 3 for CD3
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figure 31: Biweekly PEs pooled post-IPTi 2 and 3 for SP-AS3
-igure 32: Biweekly PEs pooled post-IPTi 2 and 3 for AQ3-AS3
1 2 2
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:igure 33: Biweekly PEs pooled post-IPTiJ2 and 3 for CD3
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Parasitaemia and anaemia at 12 months of age
Children were screened at the age of 12 months to determine the point 
prevalence of parasitaemia, clinical malaria and anaemia. A total of 1095 of 
the 1365 children (80.2%) were seen.
The point prevalence at 12 months of age for any parasitaemia was 19.8% 
in the placebo arm and lower across the 3 intervention arms: 12.4% in the 
SP-AS3 arm, 11.7% in the AQ3-AS3 arm, and 11.7% in the CD3 arm.
The corresponding figures for clinical malaria were 3.7% in the placebo arm 
and 5.3%, 4.6%, and 3.9% in the SP-AS3, AQ-AS3, and CD3 arm 
respectively. None of these differences was statistically significant.
The prevalence of moderate-to-severe anaemia (Hb <8.0g/dL) was low and 
only 4.8% in the placebo arm. They were slightly lower (not statistically 
significant) in the intervention arms (1.8%, 3.2%, and 2.7%, respectively) 
(Table 11, Page 125).
Thus, unlike the effect during the first year as measured by survival 
analysis, or the protective effect after each treatment course (clinical 
malaria only) measured by Poisson regression there was no evidence at 12 
months that the SP or AQ combinations had a greater or more sustained 
effect than observed with CD3.
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Table 11: Cross-sectional survey at 12 months of age
Prevalence Placebo SP-AS3 AQ3-AS3 CD3
(# at risk) (n=273) (n=283) (n=283) (n=256)
Parasitaemia (%) 5 4 (1 9 .8 ) 3 5 (1 2 .4 ) 3 3 (1 1 .7 ) 3 0 (1 1 .7 )
P R  (9 5 %  C l) R e fe re n ce 0 .6 3  (0 .4 2 ,0 .9 2 ) 0 .5 9  ( 0 .4 ,0 .8 8 ) 0 .5 9  (0 .3 9 ,0 .8 9 )
P -v a lu e 0 .0 1 9 0.010 0.013
Clinical malaria (%) 1 0 (3 .7 ) 1 5 (5 .3 ) 1 3 (4 .6 ) 1 0 (3 .9 )
P R  (9 5 %  C l) R e fe re n ce 1.45 ( 0 .6 6 ,3 .1 7 ) 1 .2 5  ( 0 .5 6 ,2 .8 1 ) 1.07 (0 .4 5 ,2 .5 2 )
P -va lu e 0 .3 55 0 .5 8 3 0 .8 84
Anaemia (Hb<8g/dL) 1 3 (4 .8 ) 5 (1 .8 ) 9 (3 .2 ) 7 (2 .7)
(% )
P R  (9 5 %  C l) R e fe re n ce 0 .3 7  (0 .1 3 ,1 .0 3 ) 0 .6 7  ( 0 .2 9 ,1 .5 4 ) 0 .5 7  (0 .2 3 ,1 .4 2 )
P -va lu e 0 .0 5 6 0 .3 4 3 0 .2 29
Rebound analyses
The rebound analyses included all study participants who had taken at least 
one dose of study drug and were still in the study 30 days after the third 
course of IPTi. The period under observation was from 30 days after the 
third course of IPTi until 24 months of age. The results did not show any 
statistically significant rebound for the first or only episode of clinical 
malaria, all episodes of clinical malaria, mild anaemia (Hb <11 .Og/dL), and 
moderate-to-severe anaemia (Hb <8.Og/dL). For a more specific case 
definition of the first or only episode of clinical malaria (with >5000 
parasites/pL of blood), the SP-AS3 and AQ3-AS3 arms did not show any
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statistically significant rebound but the CD3 arm did, -63.7% (95% Cl: -
142.5 , -10.5; p=0.014) (Table 12, Page 126).
Table 12: Incidences of some main outcomes between 10 to 24 
months of follow-up_________ ____________________________
Outcome Placebo SP-AS3 AQ3-AS3 CD3
First or only episode (n=282) (n=285) (n=296) (n=262)
of clinical malaria
E ve n ts /P Y A R ; R a te 1 5 1 /20 0 .2 ; 1 5 7 /2 1 1 .4 ;0 .7 4 1 6 2 /2 1 0 .1 ;0 .7 7 1 4 7 /1 7 9 .1 ;0 .8 2
P E  %  (9 5 %  C l) 0 .7 5 1.5 (-23.1 ,2 1 .2 ) -1.1 ( - 2 6 .3 ,1 9 .0 ) -7 .3  ( -3 4 .6 ,1 4 .5 )
P R e fe re n ce 0 .8 9 2 0 .9 2 0 0 .5 44
All episodes of (n=283) (n=286) (n=297) (n=262)
clinical malaria
E ve n ts /P Y A R ; R a te 4 5 6 /2 8 4 ; 1.61 4 6 4 /2 9 2 .9 ; 1 .58 4 7 5 /2 9 7 .4 ; 1.60 4 8 0 /2 5 6 .7 ; 1 .87
P E  %  (9 5 %  C l) R e fe re n ce 1.3 ( - 1 9 .8 ,1 8 .7 ) 1.0 ( -2 0 .8 ,1 8 .1 ) -1 6 .5  ( - 4 1 .2 ,3 .9 )
P -va lu e 0 .8 92 0 .9 5 7 0 .1 2 0
First or only episode (n=283) (n=286) (n=297) (n=262)
with >5000 par/pL
E v e n ts /P Y A R ; R a te 4 2 /2 8 8 .7 ; 0 .1 5 4 7 /2 9 8 .0 ; 0 .1 6 5 1 /3 0 0 .3 ; 0 .1 7 6 1 /2 5 5 .2 ; 0 .2 4
P E  %  (9 5 %  C l) R e fe re n ce -8 .6  ( - 6 4 .6 ,2 8 .4 ) -1 6 .7  ( -7 5 .6 ,2 2 .4 ) -6 3 .7 (-1 4 2 .5 , -1 0 .5 )
P -va lu e 0 .6 9 9 0 .4 5 8 0.014
Mild anaemia (n=279) (n=281) (n=295) (n=260)
(Hb<11g/dL)
E ve n ts /P Y A R ; R a te 2 3 9 /9 6 .7 ; 2 .4 7 2 3 8 /1 0 5 .5 ; 2 .2 6 2 5 4 /1 0 7 .3 ;2 .3 7 2 1 1 /9 3 .7 ;2 .2 5
P E  %  (9 5 %  C l) R e fe re n ce 8 .2  ( - 9 .8 ,2 3 .3 ) 3 .3  ( - 1 5 .4 ,1 9 .0 ) 6 .5  ( - 1 2 .5 ,2 2 .3 )
P -va lu e 0 .3 4 9 0 .7 0 7 0 .4 7 8
Moderate-to-severe (n=282) (n=285) (n=298) (n=261)
anaemia (Hb<8g/dL)
E v e n ts /P Y A R ; R a te 6 6 /2 5 7 .5 ; 0 .2 6 5 3 /2 6 8 .9 ; 0 .2 0 6 2 /2 7 4 .2 ; 0 .2 3 5 7 /2 4 3 .6 ; 0 .2 3
P E  %  (9 5 %  C l) R e fe re n ce 2 2 .2  ( -1 1 .7 ,4 5 .8 ) 11 .2  ( -2 5 .6 ,3 7 .2 ) 8 .0  (-31.1 ,3 5 .5 )
P -va lu e 0 .1 7 3 0 .5 0 2 0 .6 43
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Tolerability
Vomiting is an important factor because it has a tendency to cause 
complications in the control of malaria in very young infants. All children 
were therefore observed for a period of 30 minutes; if vomiting occurred 
during that period a repeat dose was administered and supervised at the 
healthcare unit by a study nurse.
Out of a total of 11,568 drug doses administered, only 2.1% were vomited. 
Overall, 4.6% of study subjects experienced at least one vomiting episode 
(Table 13, Page 129). Those taking study drugs were more likely to vomit 
than those taking placebo. The total rate of vomiting across the 3 courses 
was significantly higher with each drug intervention than with placebo: 
Relative risks in the SP-AS3 arm was 1.8 (95% Cl: 1.17,2.68; p=0.007); in 
the AQ3-AS3 arm this was 2.1 (95% Cl: 1.44,3.21; p<0.001), and in the 
CD3 arm 2.4 (95% Cl: 1.59,3.51; p<0.001). Thus, although vomiting was 
higher than in the placebo group, the three intervention drug combinations 
were well tolerated by most infants with relatively low rates of vomiting.
Safety and morbidity
There were 593 serious adverse events (SAEs) recorded during the 1st year 
of life. Of these, 55 were deaths, and 538 were hospitalizations. There was 
no significant difference in the number of SAEs recorded between the 
treatment arms and the placebo (Table 14, Page 130). No serious
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cutaneous adverse events were recorded. There were no cases of severe 
haemolysis recorded in any of the study arms. Though, it should be noted 
that observations were only made from a clinical impression because the 
study lacked a specific procedure for investigating haemolysis. From further 
analysis, it was observed that being a G6PD deficient male in the CD3 arm 
significantly increased ones’ chances of having moderate-to-severe 
anaemia (Hb <8.0g/dL) in the first year of life, -166.8% (95% Cl: -497.5 , - 
19.1; p=0.017). Other G6PD deficiency types (data not shown) did not 
show any statistically significant association between being in the CD3 arm 
and having moderate-to-severe anaemia (Hb <8.0g/dL) (Table 15, Page 
130).
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Table 13: Episodes of vomiting study drug
Dose Placebo SP-AS3 AQ3-AS3 CD3
IPTi course 1 (n=337) (n=338) (n=348) (n=342)
D o s e s  a d m in is te re d 1011 1014 1044 1026
V o m it e p is o d e s  (% ) 1 3 (1 .3 ) 20  (2 .0) 2 6  (2 .5) 26  (2 .5)
P a rtic ip a n ts  (% ) 11 (3 .3) 1 8 (5 .3 ) 24  (6 .9 ) 1 8 (5 .3 )
IPTi course 2 (n=328) (n=328) (n=333) (n=329)
D o s e s  a d m in is te re d 9 8 4 9 8 4 99 9 987
V o m it e p is o d e s  (% ) 7 (0 .7 ) 1 8 (1 .8 ) 24  (2 .4) 29  (2 .9)
P a rtic ip a n ts  (% ) 5 (1 .5 ) 1 3 (4 .0 ) 1 8 (5 .4 ) 23  (7 .0)
IPTi course 3 (n=292) (n=298) (n=308) (n=275)
D o s e s  a d m in is te re d 8 7 6 894 924 825
V o m it e p is o d e s  (% ) 1 3 (1 .5 ) 21 (2 .3) 23  (2 .5) 22  (2.7)
P a rtic ip a n ts  (% ) 9 (3 .1 ) 8 (2 .7 ) 1 8 (5 .8 ) 1 2 (4 .4 )
Total #  doses 1,2 ,3 2871 2 8 9 2 2 9 67 2838
V o m it e p is o d e  (% ) 3 3 (1 .1 ) 59  (2 .0 ) 73  (2 .5) 77  (2 .7)
P a rtic ip a n ts  (% ) 25  (2 .6 ) 39  (4 .0) 60  (6 .1) 53  (5 .6)
Rate Ratio* 1.8 2.1 2.4
(9 5 %  C l) R e fe re n ce ( 1 .1 7 ,2 .6 8 ) (1 .4 4 ,3 .2 1 ) (1 .5 9 ,3 .5 1 )
P -v a lu e 0.007 <0.001 <0.001
* Rate ratio of the total number of episodes divided by the number of
treatment given in the intervention group relative to that in the 
placebo group.
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Table 14: Summary of adverse events during the first year of life
Type of AE Placebo
(n=337)
SP-AS3
(n=339)
AQ3-AS3
(n=347)
CD3
(n=342)
Grade 2 or 1 AEs 2 1 1 2
Grade 3 AEs 4 1 1 4
SAEs
D e a th s 12 10 15 18
H o s p ita lis a tio n s 135 128 147 128
All SA
E ve n ts  
R a te  
R R  (95 
P-value
Es
/P Y A R
%  C l)
2
1 4 7 /1 5 3 3 .8
0 .1 0
R e fe re n ce
1 3 8 /1 5 3 0 .3
0 .0 9
0 .9 4  (0 .7 4 ,1 .1 9 )  
0 .6 1 7
1 6 2 /1 6 8 3 .9
0 .1 0
1 .0 0  ( 0 .7 9 ,1 .2 7 )  
0 .9 7 5
14 6 /1 5 4 9 .8
0 .0 9
0 .9 8  (0 .7 5 ,1 .2 7 )  
0 .8 9 6
SAEs possibly related 
to IPTi
5 6 5 4
Table 15: Association between CD3 and moderate-to-severe anaemia 
by G6PD status_________ ____________ ___________________
G6PD status Placebo
(n=263)
CD3
(n=251)
Anaemia (Hb<8g/dL) (%) 4 3 (1 6 .4 ) 3 5 (1 3 .9 )
Female Mild-deficient
P E  (95%  C l) 
P -va lu e
R e fe re n ce -1 8 4 .2  ( - 7 2 6 .0 ,2 .2 )  
0 .0 5 5
Deficient
PE  (95%  C l) 
P -va lu e
R e fe re n ce 0 .7  ( -1 4 0 .8 ,5 9 .0 )  
0 .9 8 8
Male Mild-deficient
P E  (95%  C l) 
P -va lu e
R e fe re n ce -5 2 .0  ( -2 2 0 .3 ,2 7 .9 )  
0.271
Deficient
P E  (95%  C l) 
P -va lu e
R e fe re n ce -1 6 6 .8  ( -4 9 7 .5 , -1 9 .1 )  
0.017
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Key findings
We determined the efficacy of short and long acting antimalarials to obtain 
a better understanding of the mode of action of IPTi in this area with stable 
perennial malaria transmission, high usage of ITNs (>70%), and a high 
level of P. falciparum resistance to SP. Our results indicate that use of the 
short-acting antimalarial combination drug, chlorproguanil-dapsone (CD3) 
provided less protection as IPTi against clinical malaria and anaemia than 
the two longer acting combinations: SP-AS3 and AQ3-AS3. As expected, 
episodes of clinical malaria were suppressed for longer with the regimens 
containing SP and AQ reflecting the longer duration of post-treatment 
prophylaxis compared to CD3. SP-AS3 and AQ3-AS3 also provided 
significantly higher protection against clinical malaria with >5000 par/pL of 
blood. Though, it should be noted that high density malaria was much more 
uncommon than clinical malaria and occurred (0.18 incidence rate per 
person year in placebo arm), and despite the high PE, the absolute number 
of high density infections that can be prevented by IPT is therefore small. 
We also found a statistically significant protective effect of AQ3-AS3 in the 
prevention of mild anaemia in the first year of life (PE 20%). The 
corresponding figure in the SP-AS3 arm was 16% (statistically non­
significant). Participants, recorded as having had poor iron compliance 
were 16.7% in the SP-AS3 arm, 17.9% in the AQ3-AS3 arm, 15.8% in the 
CD3 arm, and 16.0% in the placebo arm.
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Effect of SP-AS3 and comparison with previous SP trials
The IPTi Consortium recently completed the pooled analysis of the six trials 
with SP. This showed that SP is associated with a 30% reduction in the 
incidence of clinical malaria in the first year of life, a 37% reduction in 
hospitalizations of infants with malaria parasitaemia, a 23% reduction in all­
cause hospitalisations, and a 15% reduction in the risk of anaemia (IPTi 
Consortium, 2008).
The results of our study, where we used SP combined with AS3 is 
remarkably consistent with these summary estimates. The observed 
protective efficacy against clinical malaria provided by SP-AS3 was 26%; 
compared to 30% in the pooled analysis with SP alone. This level of 
protective efficacy against clinical malaria is remarkably consistent across 
the 6 SP trials and the current trial, despite considerable variation in the SP 
regimens used in the different trials, and in the degree of background SP 
resistance and level of ITN use. Macete etal. in Mozambique, using a 3, 4, 
and 9 month schedule reported a reduction in clinical malaria of 22% 
(Macete et al., 2006). In Ghana, Chandramohan et al. administered 4 
courses of SP-IPTi at months 3, 4, 9, and 12 and found a protective efficacy 
against all episodes of malaria of 25% up to 15 months of age 
(Chandramohan et al., 2005). The two other studies in Ghana, Kobbe et al. 
and Mockenhaupt et al., used a 3, 9, and 15 month schedule and reported 
20% (Kobbe et al., 2007) and 23% (Mockenhaupt et al., 2007) protective 
efficacy against clinical malaria up to 21 and 18 months of age respectively. 
In Gabon, Grobusch et al. administered SP-IPTi at 3, 9, and 15 months and
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reported a 22% protective efficacy against clinical malaria up to 18 months 
of age, although the results did not reach statistical significance (Grobusch 
etal., 2007b).
The smaller and non-significant effect of SP-AS3 (16%) on anaemia is also 
consistent with the pooled estimate found in the previous studies (15%). To 
date, only 2 of the previous 6 IPTi trials with SP have found a significant 
protective effect against anaemia: the original IPTi trial by Schellenberg et 
al in Tanzania (50%), and the trial by Grobusch et al in Gabon (22%) 
(Schellenberg et al., 2001, Mockenhaupt et al., 2007, Grobusch et al., 
2007b). Our trial and the SP trial in Tanzania differed from the other 5 
previous SP trials in that they provided 4 months of unsupervised daily iron 
supplementation and they had high coverage levels of ITNs (83% and 
68%). However, the Gabon trial which showed a reduction in anaemia did 
not provide any iron supplementation and ITN coverage was low (5%). The 
multifactorial nature of paediatric anaemia seems the most likely 
explanation for the heterogeneity in trial results with regard to protective 
efficacy against anaemia (Calis et al., 2008).
Effect of AQ3-AS3
Our results suggest that AQ may be a suitable alternative to SP for IPTi. 
However, as for SP, our results with AQ3-AS3 (PE 26% against clinical 
malaria) were less dramatic than the 65% protection with amodiaquine 
alone reported earlier from Tanzania by Massaga et al (Massaga et al., 
2003). This Tanzanian trial was quite different in that IPTi administration
133
Chapter 6: Discussion
was not linked to EPI and the 3 doses were given 60 days apart, beginning 
at 12-16 weeks of age. Importantly, we found that AQ3-AS3 was tolerated 
similarly well as the other IPTi drug combinations used in this trial. Although 
the acceptance of AQ is sometimes poor among adults and pregnant 
women being treated for clinical malaria (Tagbor et al., 2006, D'Alessandro 
and ter Kuile, 2006, Fanello et al., 2006, Rwagacondo et al., 2004), data 
from our blinded trial does not suggest that tolerability is a problem in 
infants.
Mechanism of action
Treatment effect and role of artemisinins
The observed differences between long and short-acting drugs suggest that 
the prophylactic effect is important for the mode of action of IPTi as 
discussed later. Nevertheless, the 16% reduction against clinical malaria 
observed with CD3, also suggests some contribution of efficacious 
clearance of existing infections (although none of the observed effects for 
CD3 were statistically significant). If the treatment effect provides some, 
albeit limited, contribution it still remains unclear to what extent the rapidly 
eliminated artemisinin derivates added any benefit. Any direct benefit could 
have resulted from the improved radical cure of existing infections over and 
above that of SP or AQ mono-therapy. The benefit would be greatest in 
children with higher density parasitaemias as low density infections are 
more likely to be cleared successfully even in the presence of mild to 
moderate resistant infections (Nosten and White, 2007). However, the
effect of this is likely to have been very small as few infants reported ill with
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clinical malaria at the time they were scheduled to receive IPTi, only 2-4% 
were symptomatic (i.e. those most likely to have higher parasite densities 
and thus to benefit from the added value of artemisinins over that of mono­
therapy). Thus the main benefit of adding an artemisinin derivative may be 
the prevention of abuse of monotherapies and the further development of 
resistance in the population (White, 2005). This needs to be weighed 
carefully against the added complexity if combination therapy for IPTi 
results in longer and more complex regimens (e.g. single dose SP vs. 3 
days SP-AS3).
The very high PEs in the 30 days after the first 2 courses of SP suggest 
that concerns about the potential impact of rising resistance of P falciparum 
to SP (when used for prevention) may not yet be evident at the current 
levels of SP resistance in western Kenya (46% treatment failure by day 28) 
(Obonyo et al., 2003), suggesting that SP may remain effective for 
prophylaxis despite clearly reduced efficacy as therapy. Since parasite 
density is a strong predictor of treatment failure irrespective of background 
immunity (Nosten and White, 2007), this difference can probably be 
explained by the differences in parasite densities in symptomatic children 
with malaria versus children receiving IPTi (Cairns et al., 2008). Given the 
short half-life of AS, it is unlikely that its addition to SP had substantial 
impact on its prophylactic protective efficacy against clinical malaria, but it 
may have contributed to the prevention of recrudescences. Unfortunately, 
without an SP alone arm, it is not possible to confirm this hypothesis.
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Relative efficacy by treatment course
The high PEs observed with SP-AS3 in the 30 days after the first and 
second courses of IPTi and the lower PEs in the 30 days after the third 
course are consistent with the findings of the other IPTi studies (Kobbe et 
al., 2007, Macete et al., 2006). The reason behind the observed reduction 
in PEs, which occurs after the 5 month period between the second and third 
courses of IPTi, is not well understood. It may be the result of a complex 
interplay of a combination of factors including the loss of maternal 
antibodies, the development of naturally acquired immunity by all children 
(including the healthy survivors in the placebo group, thereby diminishing 
any differences between those in the intervention and placebo arms) and 
limited exposure to malaria parasites (due to protection by high usage of 
ITNs). An additional explanation is the relatively lower dosage of 
intervention drugs received by the older at the third course (9 month of age) 
due to normal physiological age related weight gain between the first and 
second dose and the last course. The dosage provided was fixed for all 
three courses and based on age, not body weight, thus the older and 
heavier children received considerably less drug in mg/kg than children at 
the first and second course.
Prophylactic effect: duration of post-treatment prophylaxis
A closer look at cumulative PEs calculated every 7 days after each course 
of IPTi shows that the post-treatment prophylactic effect does not extend 
beyond 35 to 56 days after receiving SP or AQ. The results are very similar 
to a more detailed analysis of the duration of protection against clinical
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malaria provided by Cairns et al on the data from Navrongo. These also 
found that the duration of protective efficacy was short-lived and lasted for 4 
to 6 weeks only, reflecting the prophylactic effect of IPTi (the duration 
varied with the endpoint used in the analysis) (Cairns et al., 2008). Similar 
to our study, there was no evidence for a sustained effect thereafter (see 
also below).
Long term efficacy: Sustained protection/ Rebound
Current study
One of the other important questions that this study addressed was the 
impact of IPTi in the second year of life. We did not show a sustained 
protective efficacy effect of SP-AS3 or any of the other two interventions 
against the observed outcomes in the follow-up period starting from 10 to 
24 months. We also did not observe any significant increase or rebound in 
clinical malaria or mild and moderate-to-severe anaemia with either SP- 
AS3 or AQ3-AS3. These findings are consistent with the pooled analysis of 
the other SP trials (see below). We did record a statistically significant 
rebound effect with CD against clinical malaria with >5000 par/pL of blood. 
Though, the rate of high density malaria was higher in the CD arm than in 
the placebo arm, the rebound observed may be exaggerated due to the 
unfavourable significant differential loss to follow-up experienced in the CD 
arm. This loss to follow-up mostly occurred during the extended period 
between the second and third courses of IPTi and was mainly due to 
migration outside the study area. Another explanation is that this particular 
result may have occurred by chance and may reflect the fact that we
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compared multiple secondary endpoints (multiple comparisons), as there 
was no indication that this occurred for any of the other endpoints 
measured, or any of the other two interventions used. In addition, given its 
short half-life and unlikely influence on the acquisition of natural immunity, 
this unexpected finding may not be a true effect.
Comparison with results from IPTi Consortium:
These results concerning sustained protection for our longer acting 
combinations containing SP and AQ are consistent with the pooled analysis 
from the 6 SP trials in the IPTi Consortium, which found no significant 
rebound in episodes of clinical malaria, anaemia or hospital admissions 
over a period of 5 months after the IPTi intervention was completed (IPTi 
Consortium, 2008). Nevertheless, it is noteworthy that three studies in 
Ghana recorded some rebound, in high density clinical malaria (Navrongo), 
anaemia (Kumasi), and in severe malaria and severe anaemia (Tamale) 
(Chandramohan et al., 2005, Kobbe et al., 2007, Mockenhaupt et al., 2007). 
By Contrast, the initial study in Ifakara, Tanzania recorded a sustained 
protective effect of 36% against malaria in the second year of life 
(Schellenberg et al., 2005).
Thus, the remarkable effect of sustained protection well beyond the known 
pharmacological effect of SP to date has only been observed in the 
Tanzanian study. This difference with the other IPTi-SP trials has generated 
much debate. Gosling et al., recently published the results of a modelling 
study that attempts to offer a plausible explanation. The study uses models
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to show that the high PEs and sustained effect into the second year 
observed in Tanzania may have been due to a unique combination of the 
high incidence of malaria at the beginning of the study that declined 
thereafter and continued to do so over the period of follow-up, and the 
additive effect of high ITN coverage in driving down malaria transmission, 
and maternal immunity due to reduced exposure (Gosling et al., 2008). The 
models studied also predicted the observed lack of rebound as a situation 
of disappearing rebound parasitaemia in the face of decreasing 
transmission. It is interesting to note that maternal immunity seemed to be 
more strongly associated with the outcome of the model than the level of 
ITN coverage.
It is noteworthy, that IPTi trials which included iron supplementation in their 
design tended to show some protective effect on the prevalence of anaemia 
(Schellenberg et al., 2001, Chandramohan et al., 2005). Whereas, the trials 
which excluded iron supplementation (Macete et al., 2006, Kobbe et al., 
2007), with the exception of Gabon (Grobusch et al., 2007b), did not show 
any protective effect on anaemia. Iron supplementation in malaria endemic 
areas, in the light of recent findings (Sazawal et al., 2006, Richard et al., 
2006), is controversial, and provision of indiscriminate (no screening for iron 
deficiency) iron supplementation in malaria endemic areas is no longer 
recommended if children are not also protected from malaria. The decision 
to provide iron in this study was based on the results of a previous study 
from this same study site that demonstrated its beneficial effect in children 
using ITNs (Desai et al., 2003). In our study we also provided ITNs to all
Chapter 6: Discussion
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participants, and the trial itself provided a high level of free healthcare that 
reduced the danger of malaria infection to a minimum.
Since iron was given to all four arms of the study, the observed PE on the 
prevalence of anaemia is probably due to a true difference between the 
antimalarial effect of the study drugs (unless there is yet to be a defined 
drug interaction between iron and either of the antimalarial drugs used).
Drug choices
Adherence to multi-day regimens:
The choice of multi-day regimes in real-life implementation conditions 
introduces the complication of unsupervised doses and compliance issues. 
When such a drug is given to “well infants” for prevention rather than 
treatment, there is probably little motivation for the parent/guardian to 
comply with the full dosage of a multi-day regimen, particularly if the drug is 
difficult to administer (e.g. crushing of tablets) and is perceived to be not 
well tolerated (Sokhna et al., 2008). Reduced compliance is bound to have 
a negative impact on the efficacy of the drug and the duration of post­
treatment prophylaxis and increase chances of the exposure of parasites to 
sub-therapeutic levels that could encourage further development of 
resistance. It is possible that crushing adult tablets contributed to making a 
less palatable drug mixture that may have resulted in increased vomiting in 
the treatment arms as compared to placebo. At any rate, the level of 
vomiting is bound to increase with multi-day regimens as compared to a 
single dose, and this does not augur well for the acceptance of IPTi with
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such a drug in the community. Indeed, if not properly addressed, the issue 
of increased vomiting (such as is common with mefloquine in infants) 
(Luxemburger et al., 1996) could well have a negative impact on the uptake 
of EPI vaccines.
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The addition of AS:
The interpretation of our study results may be limited by the addition of AS 
to the two arms that contained the long-acting drugs, but not to the short­
acting CD arm. At the time, the inclusion of AS was dictated by the KEMRI 
National Ethical Review Committee (NERC). The NERC considered SP and 
AQ as failing drugs in terms of treatment efficacy, and were concerned that 
study participants in those arms should not be exposed to the risk of failed 
treatments. It remains unclear if AS confounded the treatment effects of SP 
and AQ as compared to CD. As it has been shown that SP and AQ are 
more efficacious with the addition of AS (Obonyo et al., 2003, Adjuik et al., 
2002, Doherty et al., 1999), it may be that the PEs observed in the study 
were in part due to the added benefit of AS. Another complication that could 
have been introduced by the addition of AS is directly linked to the 
supposed mode of action of IPTi. If the post-treatment prophylactic effect of 
a long-acting, but ‘failing’ drug (due to moderate levels of resistance) results 
in suppression and thus persistence of low-grade parasitaemia at levels 
that do not cause harm, it could boost the acquisition of natural immunity, 
similar to some vaccines. The addition of such an effective treatment 
component like AS may interfere with this process by rapidly clearing all the 
parasites.
141
Chapter 6: Discussion
Other alternatives:
Mefloquine was not selected due to concerns about vomiting rates (based 
on information from using a 25mg/kg dose) and irritability/restlessness in 
very young children treated with the drug (Luxemburger et al., 1996, ter 
Kuile et al., 1995, Slutsker et al., 1990). The Kilimanjaro IPTi study was 
already planning to study mefloquine.
Currently, another viable alternative may be DHA-piperaquine because it 
fits the profile of the more efficacious IPTi drugs because of the long half 
life of piperaquine. It may also be possible to develop a single dose 
regimen which would make it an ideal candidate for IPTi. Though, if we take 
the approach of using preventive drugs that are different from the 
recommended treatment drugs then we may have a dilemma with regard to 
DHA-piperaquine because it is considered a good candidate for a first-line 
treatment drug!
SP plus AQ is also a viable drug combination that has been tested for IPTc 
in a study in Senegal (Sokhna et al., 2008). In areas of Africa where 
resistance to both SP and AQ is still low, and a different drug is in use as 
the first line of treatment, SP+AQ3 may prove to be a good alternative 
because the combination has been found to be safe, efficacious and well 
tolerated (Sokhna et al., 2008).
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Study Limitations
Efficacy vs. effectiveness
The promising results obtained with the multi-day regimens administered 
under direct supervision in this trial should be interpreted with caution. The 
gap between efficacy and effectiveness is likely to be greater for IPTi with 
multi-day drug regimens than for SP, given that we supervised the 
administration of all study drugs, which would not be feasible if a multi-day 
regimen were ever adopted for programmatic use as IPTi. Notwithstanding, 
the fact that all the drugs used were well tolerated, paediatric formulations 
of the drugs (which were not available for use in this study) would likely 
have further reduced episodes of vomiting, improved the accuracy of 
dosages, simplified the process of drug preparation before administration, 
and generally contributed to greater acceptability of IPTi.
Investigation of the pharmacokinetic properties of the drugs used and their 
efficacy in parasite clearance was beyond the scope of this study. Another 
factor which may have affected the outcomes is that we facilitated 
hospitalization -- generally at the Provincial Hospital — for all participants. 
Our conservative approach to hospitalization may have resulted in a dilution 
of any effect of IPTi on hospitalization rates.
The results of this study can be generalized to other malaria endemic areas 
with stable malaria transmission, high coverage of ITNS and similar 
patterns of antimalarial drug resistance.
The design of this study could have benefited from a few improvements.
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The current design randomized children at the first EPI visit, i.e. 1 month 
before the first study drugs were dispensed (at the second EPI visit), thus 
some children died in the interim period, were lost to follow-up, or 
developed clinical malaria requiring treatment. This required us to use a 
‘modified’ ITT analysis. The one month period between recruitment and the 
first intervention visit could have been excluded, facilitating a simpler and 
more elegant ITT approach.
Migration was higher than expected and the sample size calculations could 
have been adjusted for loss to follow-up due to migration which is a 
significant phenomenon in this rural setting, affecting young parents and by 
extension the infant population.
We used dosing based on age and provided a single fixed dose in children 
2 to 11 month of age (e.g. all children in the SP group received 'A a tablet at 
each IPTi dose visit regardless of their bodyweight). The World Health 
Organization also recommends age based dosing using the same fixed 
dose for 2 to 11 months old infants. Given the rapid growth in infants, this 
will have resulted in the very young (and thus lighter) infants receiving a 
significantly higher dose in mg per kg bodyweight than the older (and thus 
heavier) infants. Our study did not measure drug levels, but it is not unlikely 
that these variations in dose will have resulted in variations in achieved 
drug levels, some of which may have been below the minimum inhibitory 
concentrations. This may have contributed to some of the variations in the 
30-day efficacy between the first two IPTi doses and the last dose. A weight
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based regimen would not necessarily have resolved this, even if a 
paediatric formulation such as dispersible tablets or syrup would have 
existed, as weight based regimens are also based on ‘strata’ and limited by 
the minimum tablet size (e.g. % or V2 tablet) or spoon size (e.g. 1/4 tea­
spoon) that would have been practical to give.
Another issue that may have had an impact on results for anaemia was the 
adoption of set cut-offs for deciding the level of anaemia and consequently 
adverse events due to low Hb levels. We used a fixed threshold to define 
anaemia and severe anaemia. This threshold is based on the experience in 
older children and adults and may not be the optimal definition in young 
infants, as it may have resulted in some mis-classification in infants due to 
the physiological changes in Hb levels in early infancy. In healthy children, 
physiological haemoglobin levels are relatively high at birth, decline rapidly 
to reach a nadir at 2 month of age, after which they increase gradually until 
6 months of age and remain relatively constant thereafter. Thus, the use of 
age-dependent cut-offs would have correctly determined the thresholds for 
anaemia in infants. Some of the episodes in the youngest infants aged 2 to 
6 months may thus have been classified as anaemia and that may have 
reflected to the normal (lower) physiological Hb levels at that age. This 
could have potentially biased the results of our study towards the null in the 
first 6 month of age (e.g. showing no, or smaller, differences between 
intervention arms).
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Pooled analysis:
In a pooled analysis like described in this thesis for the IPTi studies, data 
from individual records of each study subject in all the involved studies are 
pooled together and analyzed to compute a single estimate (individual 
patient data analysis). This is approach has obvious advantages in terms of 
increased power and sample size but it also has certain pitfalls that need to 
be taken into account. In the case of the IPTi analysis, these would include 
differences malaria transmission settings (and ITN use) between the 
studies, different intervention periods and dosing schedules (both in terms 
of duration and relation to the mean age of the cohorts), use and timing of 
iron supplementation, use of active versus passive follow-up of infants, and 
the background resistance to the intervention drug used. The results of 
such pooled analysis should thus be interpreted with caution in order to 
avoid implying effective outcomes where there may be none. In a situation 
where results from a single study differ markedly (heterogeneity between 
trials), e.g. Ifakara trial versus the subsequent trials, it would be best to 
present the results of the pooled analysis excluding that single trial 
alongside the complete pooled analysis and discussing any differences 
may allow for a better understanding of the results. Furthermore, it is not 
uncommon that a first trial that shows a very promising result, such as the 
IPTi study in Ifakara (Schellenberg et al., 2001) and the initial bednet trial in 
The Gambia (Alonso et al., 1991b), triggers a ‘donor’ response resulting in 
significant targeted funding of a series of subsequent trials to confirm the 
results. If significant heterogeneity between the first and subsequent trials is 
observed it may reflect that the first trial was an outlier and that the
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subsequent trials reflect regression toward the ‘true’ mean effect. Under 
such conditions, the results of the first trial may importantly affect the 
summary estimate of the pooled analysis, and it is perhaps best to omit the 
results of these initial ‘index’ studies, as the subsequent studies may never 
have taken place without the first study showing a promising result.
ITN coverage
The high usage of (ITNs) may potentially provide competing or added 
benefits in reducing clinical malaria and anaemia. It has been suggested 
that ITN usage may have a synergistic effect with IPTi (if used 
concurrently), though others have maintained that there would probably be 
an additive effect (Greenwood, 2007, Gosling et al., 2008). In our study, the 
effect of ITNs as a potential effect modifier could not be assessed because 
ITNs were provided to all participants at enrolment. This was done because 
the benefits of using ITNs had already been conclusively demonstrated in 
the same study area (Phillips-Howard et al., 2003b). Though, it was not 
possible to measure the impact of ITNs on IPTi in this study, the suggestion 
that synergy between high ITN use and IPTi may have resulted in the 
relatively high PEs observed in the Ifakara trial is likely inaccurate 
(Menendez et al., 2007b) because we did not observe such an effect under 
remarkably similar conditions.
Adverse events
There were no significant differences in the number of serious adverse 
events between any of the arms and the placebo. In particular, there were
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no serious cutaneous reactions, the main adverse reaction of concern with 
SP, and no cases of severe haemolysis recorded in the CD3 group, 
including among G6PD deficient male infants (although they were at a 
significantly increased risk of developing moderate-to-severe anaemia in 
the first year of life).
Our results regarding the lack of serious cutaneous reactions with SP will 
need to be interpreted within the limitations of the sample size. The rate of 
life-threatening cutaneous reactions with SP when given intermittently is a 
topic of much debate. Overall, over 4,000 infants in the six SP trials 
included in the meta-analysis conducted by the IPTi Consortium received 
12,000 doses of IPTi-SP and there were significantly fewer serious adverse 
events (19% to 22%) due to hospitalisations in the SP group than in the 
placebo group (IPTi Consortium, 2008). In the Kumasi study, two deaths 
were possibly attributed to IPTi, one from the SP group and the other from 
the placebo group (in this trial all events occurring within 40 days of IPTi 
were considered to be possibly related). Only two cases of SJS occurred in 
the SP group in the Kumasi study at 15 months of age and both children 
fully recovered. There was also one SJS case in the placebo arm 
considered not related to IPTi, and a dermatological SAE in the placebo 
group considered related to IPTi (Kobbe et al., 2007).
Implications for the implementation of IPTi in Kenya:
IPTi may be an appropriate strategy for the control of malaria in Kenya in 
the endemic areas with perennial transmission such as parts of the Kenya
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Coast line and the western region mostly around Lake Victoria. Although, 
these areas represent about 20% of the entire Kenyan population (after 
excluding Mombasa and Kisumu; the 2nd and 3rd largest cities in the 
country, which have more urban and thus lower transmission risk). Other 
strategies would be more relevant for the remaining parts of Kenya with 
malaria transmission that lies in arid/semi-arid epidemic prone and highland 
epidemic prone areas, and low-risk districts.
The implementation of IPTi as one of the tools of an integrated malaria 
control programme would require careful monitoring and evaluation. It 
would be necessary to monitor trends of possible increases or decreases of 
resistance to the IPTi drug with its initial implementation as recommended 
by the IOM (IOM, 2008). The development of any major increase in the 
level of resistance to SP should eventually have a negative impact on its 
efficacy (White, 2005). However the degree of resistance at which this 
occurs is not yet defined for SP. The difference in the impact of resistance 
to SP on case management and on preventive strategies such as IPTi is 
unclear. It is also unclear how best to monitor the impact of SP resistance 
on IPTi (and IPTp) effectiveness. It is no longer ethical to conduct in vivo 
studies in symptomatic children (or pregnant women) using SP as the 1st 
line treatment for case-management changed to ACT several years ago. 
One option is to conduct nested in- vivo follow-up studies among the 
recipients of IPTi who happened to be parasitemic (but asymptomatic) at 
the time they were scheduled to receive IPT. Furthermore, monitoring the 
presence of certain mutations known to confer resistance as molecular
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markers should be conducted. This requires that we establish a relationship 
that would link the efficacy of IPTi in prevention of clinical malaria or malaria 
associated anaemia, to the rate of parasite clearance in infants receiving 
IPT and to the presence of specific molecular markers in the population. 
This is not yet clearly understood and requires further study.
Also the effect of wide scale implementation of IPTi with SP on the level of 
SP resistance in the population is unclear (Schellenberg et al., 2006, 
O'Meara et al., 2006), although recent data from Ifakara in Tanzania 
showed that district wide implementation of IPTi with SP (in addition to SP 
use in pregnant women) did not affect the frequency of genetic markers in 
the DHFR and DHPS genes that encode resistance to SP (Schellenberg, 
2008).
In the face of successful malaria control programmes and decreasing 
malaria transmission due to other interventions such as successful vector 
control and case-management with ACTs (Fegan et al., 2007, Noor et al., 
2007), a shift may occur in the age spectrum of the disease burden from 
infants to older children, thereby rendering IPTi as currently designed less 
irrelevant. So a similar preventive strategy could be used for a wider age 
range as currently shown in West Africa, e.g. IPTc in infants as well as 
school going children. Though, exactly when IPTi or IPTc would become 
irrelevant is a difficult question that is yet to be answered. This is likely to be 
a moving target! The spectrum of disease relative to transmission intensity
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is like a continuum. Ideally, IPTi should only be seen as one of the 
strategies in a more integrated approach to malaria control.
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Delivery of IPTi via EPI:
Co-delivery of IPTi through EPI clearly has advantages in terms of 
increasing cost-effectiveness and the greater chances of acceptability. Data 
from a Tanzanian implementation study confirm the cost -effectiveness of 
IPTi (Manzi et al., 2008). It has also been shown to be acceptable and 
without any negative impact on the EPI system (Pool et al., 2006). The 
trials conducted with SP have demonstrated its safety and lack of 
interaction with EPI vaccines (Macete et al., 2006). This trial also collected 
data on the above mentioned issues which will become available soon. The 
distribution of EPI coverage in Kenya is closely linked with that of 
healthcare facilities capable of supporting the cold-chain that is so 
important for the preservation of vaccines.
Evaluation of IPTi with SP by WHO and IOM.
World Health Organization:
One of the main objectives of the IPTi Consortium is to facilitate the 
translation of research into policy within the shortest time possible if IPTi is 
found to be safe, efficacious and cost-effective. In October 2007, a 
technical expert group meeting (TEG) of WHO was convened in Geneva to 
discuss the findings presented by the IPTi Consortium at that time. The 
WHO TEG was presented with both published and unpublished data
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covering a wide range of issues around IPTi-SP. After reviewing the 
evidence provided, the WHO TEG noted: that alternative, feasible delivery 
strategies may have to be evaluated in areas with highly seasonal malaria 
transmission patterns or where EPI coverage is relatively low; that though 
SP has advantageous properties (inexpensive, single-dose and long-acting) 
that make it a pragmatic choice for IPTi, there was insufficient evidence to 
show how the duration of protective efficacy would change with time given 
the rising rate of resistance to SP; that the optimal dosage of SP for 
children remained uncertain and there was lack of information on the 
therapeutic efficacy or pharmacokinetics of SP in parasitemic infants; and 
that there were only two published IPT trials (at that time) that had 
evaluated alternative drugs to SP alone (WHO TEG, 2007). Therefore, the 
WHO TEG concluded that it was premature for it to comment on the relative 
advantage of SP for IPTi and opted to review further information that was to 
be availed in 2008 including on other antimalarials (the findings of the study 
reported in this thesis among others) (WHO TEG, 2007).
United States Institute of Medicine (IOM)
In June 2008, the United States Institute of Medicine (IOM) convened an 
expert committee, at the request of the Bill and Melinda Gates foundation, 
in order to evaluate the evidence concerning IPTi-SP and to provide 
guidance of its value as a continued investment for the Gates foundation 
(IOM, 2008). The IOM expert committee had access to a more 
comprehensive dossier of evidence collected by the IPTi Consortium 
including more published data from the six IPTi-SP trials and unpublished
152
data from the trial described in this thesis. The IOM committee evaluated 
the evidence presented and was satisfied that the pooled analyses were 
carried out appropriately, though the committee noted that some 
information on the quality assurance of study-level data and analyses 
included in the pooled analyses was lacking. The committee supported the 
notion that IPTi-SP was ready to move to the next level (on condition that 
the independent technical audit verified the accuracy of the presented 
evidence) (IOM, 2008). The committee concluded that if the decision were 
to be made to begin programmatic implementation, then it would 
recommend that IPTi-SP initially be implemented in perennial, high- or 
moderate-intensity transmission areas of sub-Saharan Africa where the 
burden of malaria is high in infancy and resistance to SP is relatively low, in 
order to maximise the public health impact (IOM, 2008). It also 
recommended that public health authorities should monitor trends of 
possible increases or decreases of resistance to SP wherever IPTi-SP was 
implemented and that the monitoring efforts would be better carried out 
together with initial implementation in certain districts and countries to 
gather evidence that would help the development of pragmatic guidelines 
for larger-scale implementation (IOM, 2008).
Policy Implications 
IPTi with SP
Given these positive results of the evaluation conducted by the IOM expert 
committee and the large implementation trials currently being undertaken 
by the IPTi Consortium in southern Tanzania involving 12,000 children per
Chapter 6: Discussion
153
Chapter 6: Discussion
year, and by UNICEF in six African countries (Benin, Mali, Senegal, Ghana, 
Malawi, Madagascar) involving 317,000 children per year, it is possible that 
some countries may consider adopting IPTi-SP as policy. If this were to 
become a reality, then the most likely beneficiaries in the early stages of 
programmatic implementation would probably be countries or regions in 
West Africa, with high to moderate malaria transmission, where resistance 
to SP is still low and the first-line drug for malaria treatment is not SP. A 
different strategy of delivery would have to be designed for the areas with 
highly seasonal transmission.
In these regions with moderate SP resistance, SP should best be reserved 
for IPT strategies (IPTi, IPTp and perhaps IPTc) and not used as part of the 
first line combination therapies. In fact, this is currently happening in most 
countries for IPTp, as almost all countries in Africa currently recommend 
the use of either AQ-AS or artemether-lumefantrine. None are 
recommending SP plus artesunate. Under such conditions, the decreasing 
use of SP for malaria treatment and in turn reduced drug pressure may 
lessen the threat of rising resistance to SP and allow its effective use for 
prophylaxis.
SP resistance and alternative antimalarials
Countries or regions with high levels of SP resistance may consider the 
immediate implementation of IPTi with alternative drugs or drug 
combinations to SP alone and eventually re-consider if sensitivity to SP 
were to increase given the increasing use of ACTs at the expense of SP
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monotherapy. Our findings suggest that AQ3-AS3 and SP-AS3 are similarly 
safe and efficacious and AQ3-AS3 could thus be used as suitable 
alternatives to SP for IPTi. However, as pointed out earlier in this 
discussion, the three-day regimen introduces a practical complication in 
terms of supervised drug administration that may have an impact on cost of 
delivery and worries over compliance with the full regimen (Kachur et al., 
2004).
As for CD, it is too short-acting, not suitable and furthermore, is no longer 
available as the manufacturer ceased its production. Other alternative 
drugs with potential for use as IPTi include: mefloquine (MQ) which is 
currently under investigation by another Consortium IPTi trial in Kilimanjaro, 
Tanzania; and dihydroartemisinin-piperaquine (DHA-PIP) which so far has 
not been tested for use as IPTi. Both MQ and DHA-PIP are long-acting 
drugs that according to our findings may be suitable for use as IPTi if found 
to be safe and efficacious.
IPTi and integrated malaria control
IPTi may become a useful tool in the integrated malaria control strategy of 
relevant countries in which the infant populations would stand to benefit 
from such an intervention (i.e. relatively intense transmission that places 
the burden on infants). As it becomes more and more obvious that no one 
single intervention is likely to eliminate the threat of malaria in sub-Saharan 
Africa and elsewhere (except for, maybe a cheap, abundantly available and 
highly effective vaccine), IPTi with the appropriate drug choice should be
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considered for implementation alongside other control measures such as 
vector control including ITNs and IRS. Such programmatic implementations 
should be carefully monitored and data gathered for preparing guidelines to 
aid further large-scale implementation (IOM, 2008).
Due to the current increased level of interest in malaria control and its 
elimination shown by the international community, including some funding 
agencies, there is renewed optimism among public health practitioners that 
great strides may be achieved against malaria in the near future. In the 
event that the UN’s vision of an immediate massive up-scaling of LLITN 
coverage and the use of IRS in all malaria endemic areas actually becomes 
a reality, leading to the marked reduction in deaths from malaria by 2010 
(BBC, 2008), it would be important to monitor the decreasing transmission, 
incidence rates and inevitable age-shift of the burden of disease beyond 
infants, in order to identify the appropriate target population for IPTi.
It may well be possible that with successful vector control and the 
widespread use of ACTs, IPTi may no longer be needed or be cost- 
effective in the near future (e.g. 5 years). The current study and the 
previous analysis by Cairns et al (Cairns et al., 2008) suggest that the effect 
of IPTi is relatively short-lived (4 to 6 weeks). The relative impact will thus 
depend on the level of malaria transmission. It will thus be important to 
carefully monitor the role of the different IPT strategies (IPTi,p,c,s) over 
time when transmission hopefully decreases due to successful integrated 
control. However, until such successful programs are in place, it makes
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sense to employ IPTi in areas with intense transmissions as one of the 
effective tools currently available to fight malaria, in order to stem the tide of 
unacceptable deaths due to this treatable and preventable disease.
Chapter 6: Discussion
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This study was conducted under the auspices of the IPTi Consortium from 
March 2004 to March 2008, and was one of the first IPTi proof of concept 
trials to investigate the mode of action of IPTi using long and short-acting 
drug combinations. In conclusion, our results suggest that long-acting 
regimens are more suitable for IPTi than short-acting regimens in areas of 
perennial malaria transmission and high ITN coverage. These data also 
provide a strong indication that the post-treatment prophylactic effect of a 
long-acting drug provides the bulk of the protective effect of IPTi. There was 
no evidence for a sustained effect of IPTi beyond the direct 
pharmacological effect provided by protective drug levels with any of the 
drug combinations tested, suggesting that these IPTi regimens did not 
boost the development of protective immune responses in infants . Neither 
did they increase the risk of malaria or anaemia due to potential rebound 
malaria once the immediate protective effects of the drugs had waned.
The observed difference between the effect of long versus short-acting
combinations is also relevant for other IPT strategies such as IPT in
pregnancy (IPTp) and IPT in children (IPTc). These results contribute to
efforts to develop a target product profile for alternative drugs to be used for
IPT, which is one of the aims of the IPTi Consortium. There is a pressing
need to investigate the potential gap between efficacy and effectiveness for
multi-day regimens, to test other long-acting combinations (potentially with
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paired long-acting antimalarials such as SP plus AQ) and to examine 
whether the artesunate component of these regimens is of any additional 
benefit to justify inclusion in preventive strategies that appear to rely 
primarily on a chemo-prophylactic effect.
For future IPTi studies or implementation programmes, we would 
recommend the following:
1. If conducted in rural areas; that the design is appropriately adjusted to
account for the existing patterns of migration.
2. That the design avoids any significant period between the enrolment of
study participants and the commencement of the intervention.
3. That a paediatric formulation of the given drug or drug combination be
used, rather than crushing a proportion of adult tablets.
4. That more accurate dosing regimens be developed, probably by better
understanding of the pharmacokinetic properties of the given drug.
5. That a rigorous investigation of the effectiveness of multi-day regimens
be carried out in a real-life implementation setting.
6. That the added benefit of IPTi as one of several tools employed in an
integrated malaria control programme be evaluated.
7. That SP could be reserved for IPT strategies (IPTi and IPTp)
Finally, on the strength of the results of this study and others mentioned in 
the text, the author is convinced that IPTi, despite its imperfections and 
drug-choice issues, may become one more useful tool for the prevention of 
malaria morbidity. A recent commentary in the Lancet suggests that others
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share this view (Editorial, 2008). However, the current uncertainties 
surrounding the IPTi strategy need to be addressed (White, 2008b), and 
more evidence provided from ongoing studies and future studies with more 
suitable alternative drugs.
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Flesch-Kincaid Reading Score: 8.1
Parental/Guardian Permission form -  Malaria and Anemia Prevention Study 
(IPTi)
Background: The Kenya Medical Research Institute (KEMRI) and the Centers for 
Disease Control and Prevention, USA (CDC) are doing a research study to find 
the best prevention for lack of blood (anemia) and malaria. As part of this study 
we want to compare different ways to prevent lack of blood and malaria. One 
drug we are giving children is iron. The other drugs are Fansidar® with 
artesunate, amodiaquine with artesunate, and Lapdap®. All three of these drug 
regimens are used to treat malaria. You can buy iron, amodiaquine, and Fansidar 
in many shops in Asembo. Artesunate and Lapdap are not widely sold. We want 
to know if Fansidar + artesunate, amodiaquine + artesunate, or Lapdap, when 
given with iron, is better than iron alone for preventing lack of blood in infants.
We also would like to know if these drugs change the way the body responds to 
vaccines. About 1500 infants will be enrolled in the study.
Treatment groups: As part of this study, all children who join the study will 
receive treatment with iron for 4 months. Children will also receive one of four 
different types of pills. One group of children will get a crushed sugar pill with no 
medicine (placebo). One group will get Fansidar + artesunate. One group will get 
amodiaquine + artesunate. One group will get Lapdap. Children in each of the 
groups will receive crushed pills in syrup at 10 weeks of age, 14 weeks of age, 
and 9 months of age. Some pills will be taken in clinic, with another dose the 
next day and a third dose the day after that. Someone will come to your house to 
give the drug on the second and third day. Neither the study team nor you can 
pick the treatment group as this could affect the study results. The treatment will 
be chosen at random (like flipping a coin). Neither the study team nor you will 
know which of the drugs your child is receiving until the study is over.
Follow-up Visits: As part of this study, you will bring your child to this clinic a total 
of 7 additional times during the study (at 10, 14 & 18 weeks, and at 9, 12, 18 and 
24 months of age). At each visit a health worker will ask questions about your 
child’s health and examine the child. At some visits, the study staff will take the 
weight and height of the child. At some visits, she will also prick your child’s heel 
or finger to obtain a blood sample. At some visits, your child will be given the 
study drug. Each visit should take about 30 minutes.
Study drugs: At the 10-week, 14-week, and 9-month vaccine visit, your child will 
get medication to take in clinic. A study team member will visit your house the 
next two days to give the 2 other doses of medicine. Each time your child is 
given a study drug, our study staff will watch the child for 30 minutes to make 
sure he does not vomit the drug or become ill. You will also get a bottle with 
medicine (iron) at 10 weeks, and again at 14 & 18 weeks. We would like you to
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give this medicine to your child every day. When your child is 6 months old, we 
will visit your house to check to see if your child has been given all the iron.
Blood samples: We will prick your child’s heel or finger to obtain a blood sample 
today, and again at 10 weeks, 18 weeks, 9 months and 12 months of age. The 
amount of blood we will take is small, about % of a teaspoon. The blood will be 
stored. Some of the blood will be used to see whether your child had an 
adequate response to the vaccines. Some of the blood will be used to test for a 
condition in the blood called sickle cell. You will be informed if your child has 
sickle cell disease. We will provide counseling to help you understand how to 
seek medical care for your child and how to care for your child at home. Some of 
the blood will be used to test for other traits that may cause anemia in children, 
such as G6PD deficiency.
At the 10 week and 12 month visits, we will put a few drops of your child’s 
blood onto a small piece of paper. We will test the blood on this paper to learn 
more about how well the drugs that are used to treat malaria are working in your 
community.
At 12, 18 and 24 months, we will take 5 drops of blood to check if your 
child has malaria and/or anemia (lack of blood). We will provide treatment if your 
child has anemia or malaria and a history of hot body at these visits.
Nasal swab: At the visit at 9 months of age, we will use a cotton swab to go 
inside your child’s nose. We will check to see whether your child is carrying any 
bacteria that cause acute upper respiratory disease. All children are vaccinated 
against this disease, so even if your child has this bacteria, it does not mean that 
he or she is sick. We are testing to see whether your child has an adequate 
response to the vaccine.
Sick visits: We ask you to bring your child to this clinic if your child is ill at 
any time during the study. In the event of an emergency, you should bring your 
child to the nearest health facility or hospital. We also have staff in the following 
health clinics: Abidha, Ongi’elo, Lwak, and Saradidi. In case of illness after the 
clinic closes,at night, or on the weekend, we will have a nurse on-call at St. 
Elizabeth’s Lwak Hospital to see your child. If your child requires hospitalization, 
we will provide transport for the child to be taken to New Nyanza General 
Provincial Hospital. We will pay for the child’s hospitalization at these hospitals 
for malaria, lack of blood, worms, diarrhea, and pneumonia illnesses.
We would prefer you not to buy any routine treatment for malaria or 
treatment for lack of blood from shops or clinics during the study unless 
necessary. We ask this because extra medicine may result in side effects for 
your child. Other drugs may also reduce the effect of the study drugs. We supply 
all other drugs for malaria, lack of blood, worms, diarrhea, and pneumonia free of 
charge at the health clinic. Therefore, it will usually not be necessary to buy 
other medicines for those conditions.
Risks: All medicine has side effects.
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General: There is some chance of vomiting after any of the study drugs.
If this occurs within 30 minutes, then your child will be given another dose 
of the drug. If the vomiting occurs later than 30 minutes, no additional 
drug will be given.
Iron: Some children do not like the taste of iron. Some children complain 
of nausea and not feeling like eating after taking iron. In some children the 
teeth will become darker. In other children the stool will become darker or 
greener than normal. This is a normal reaction to treatment with iron. The 
teeth and stool color will become normal again after the iron treatment is 
completed. Iron is also toxic if taken in large doses (more than 
recommended amount).
Fansldar: Sometimes a child may get a rash after treatment with 
Fansidar®, one of the study medicines. If this occurs, we will stop the 
medicine and recommend that your child be treated with different malaria 
medicines in the future.
Amodiaquine: There are no known specific risks of amodiaquine when 
taken intermittently to treat malaria.
Artesunate: There are no known specific risks of artesunate.
Lapdap: Sometimes a child can get a temporary anemia following 
Lapdap. We believe this risk to be small. However, as this is a newer 
drug, and has not been used often in children in Africa, the risks are not 
completely known. .
Sugar pills: We expect no side effects with sugar pills.
Heel or finger prick: A small bruise or mild pain on the heel or finger from 
where the blood is taken may develop. There is also a chance of infection 
when blood is drawn. This chance is very small because we always use 
clean materials.
Nasal swab: There is a chance of local irritation, bleeding, or infection 
from the nasal swab.
Costs/compensation: If the event of any problem from the heel or finger prick or 
the nasal swab that a doctor needs to look at, or a severe reaction to the malaria 
drug treatment, we will provide transport to the hospital. In the hospital your child 
will be treated free of charge. No such incident has occurred since the beginning 
of the CDC studies in Asembo since June 1992.
Lab tests: All blood samples will be tested in Kisian for malaria. Part of the blood 
and the nasal swab may be stored and sent to labs in Europe and the USA. In 
the USA, further studies may be done that will help us to know more about how 
your body protects itself against malaria and lack of blood. This includes a study 
of how your child’s body responds to vaccines. The nasal swab will be tested for 
bacteria. The blood may be tested for iron, response to iron, or response to 
malaria. Part of the blood will be sent to France to study your child’s response to 
vaccines. If we get any results from these studies that may affect the health of
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your child, we will inform you. Results of the G6PD test will not be given. All the 
lab tests will be done free of charge.
Privacy: If you want your child’s blood sample taken out of storage, please let our 
study staff know. We will destroy the sample. This will have no effects for you or 
your child. The facts we collect in the study and the results of the lab tests will be 
kept private to the extent allowed by law. The child’s name will not be used on 
any of the study reports or study samples. Only study personnel will have 
access to these records and samples.
Severe illness: This study involves children who are healthy. Children with severe 
illness today will not be included in this study but referred to one of the hospitals 
in the study area. Also if your child becomes very ill during the study because he 
has had a severe reaction to one of the study drugs we have given your child 
your child’s participation in the study will need to be stopped.
Withdrawal from the study: Some children may be prescribed daily treatment 
with cotrimoxasole by a clinician. Cotimoxasole may cause a serious reaction 
with one of our study drugs. Therefore, if your child begins taking daily 
cotrimoxasole, we will have to withdraw him or her from the study. This 
withdrawal will be done to safeguard the health of your child.
Stopping the study: You are free to choose for your child to be part of this study.
If you do not want your child to be in the study, you have the right to refuse. If 
you do not want your child to go on with this study you can also stop anytime.
This will have no effects for you or your child. You and your child can continue to 
receive regular care from this clinic.
Benefits: Your child will likely benefit from being in this study. Your child will 
receive free health care for malaria, lack of blood, worms, diarrhea, and 
pneumonia illnesses for a period of 24 months starting from the first day of this 
study. You will be given a “health passport” which allows your child to receive 
free treatment for these conditions in one of the study clinics for this period. The 
child will be seen by a special study nurse, which may result in shorter wait times 
for medical care. Inpatient hospital costs at Lwak and New Nyanza General 
Provincial hospitals will also be covered for enrolled children for medical 
conditions listed in sick visits section. Any other medical costs (such as specialty 
care or hospitalization for conditions not listed above or not resulting from one of 
the study medications) are not covered by the project. The free treatment and 
care at the hospital will help improve the health of your child. The free iron your 
child receives will probably help prevent lack of blood. Because your child will 
visit the clinic regularly during the course of the study, your child is also likely to 
have malaria detected and treated more quickly than usual. Your child will also 
be receiving malaria tests for febrile illnesses, which may allow for better 
treatment of these illnesses. You will be informed if your child has sickle cell
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disease, which may help you seek needed care. We hope the results of this 
study will help to improve the treatment for malaria and lack of blood in this area.
Alternatives: You can choose not to have your child in this study. If you choose 
not to have your child in the study, your child will be seen by the regular staff in 
this clinic. He/she will get the standard MOH care and pay any standard fees.
No further visits would be required.
Contacts: If your child has any problems from the study that you want a doctor to 
look at, you can contact Dr. Juliana Otieno at New Nyanza Provincial General 
Hospital. The telephone number is 23200. Should any further questions arise, 
or if you want to quit the study, please contact Dr. Larry Slutsker, Mr. Peter 
Otieno or Mr. Frank Odhiambo, at the CDC office in Kisian. The office is at 
Kisian, on the Kisumu-Busia Road. The telephone number is 22929, 22959, or 
22983. If you have any questions about your rights as a study patient, or if you 
want to talk about the study with someone who is not part of this research 
project, please contact Dr. Margaret Oloo. Dr. Oloo is a special doctor for 
children and is not part of the study. You can also contact Dr. Margaret Oloo if 
you think your child has been injured because of this study. She works in the Aga 
Khan Hospital in Kisumu and can be reached by phone. The phone number is 
057 41031.
Thank you very much for your time.
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Malaria and Anemia Prevention Study:
The above has been explained to me and 1 have read the permission form or it has 
been read to me. 1 agree for my child to take part in the study. 1 have been told that 1 am 
free to choose for my child to be part of this study. 1 also have been told that if 1 do not 
want my child to go on with this study 1 can stop at anytime. This will have no effect on 
future care that 1 might receive for my child or me. 1 agree for my child’s blood to be 
tested for malaria, lack of blood and factors that may protect against malaria, lack of 
blood, or bacterial infections. 1 agree for my child’s nasal swab to be tested for bacteria.
Parent/Guardian
Name.........................
Initials...............
Signature............................
Mark*
Date.......................
IPTi Registrar
Name.........................
Signature............................ Date.......................
Independent
witness*
Name.........................
Signature............................
Mark**
Date.......................
*A paren t can sign o r m ake  a m ark and have h is /he r perm iss ion  confirm ed b y  the s ignature  o f a witness.
** A m ark is m ade by  the p a ren t o r guard ian by  thum bprin t (p lacing th e ir thum b on an inkpad  and pressing  dow n in 
the space above)
Either mother or father or guardian can sign. All not required. Witness 
only required for those who cannot sign. All pages of the consent form 
must be initialed by the mother, father, or guardian (the person who signs 
the consent form).
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Lonq-term storage and future studies:
We would like to store your child’s leftover blood to do more tests related to malaria in 
the future. No HIV or genetic testing is planned. It is your choice to let us keep the 
blood after the study ends. You can still be part of the study if you do not want us to 
store the blood. At the end of this study, we will take your name off of all forms. 
Therefore, we cannot report any new test results on the stored blood to you.
If you change your mind about saving blood while the study is ongoing, we can destroy 
the blood. To do this, contact Mr. Peter Otieno, Mr Frank Odhiambo, or Dr. Mary Hamel 
at the CDC office in Kisian. The office is at Kisian, on the Kisumu-Busia Road. The 
telephone number is 22929, 22959, or 22983
Parent/Guardian
Name..........................
Initials...............
Signature............................
Mark*
Date.......................
IPTi Registrar
Name..........................
Signature............................ Date.......................
Independent
witness*
Name..........................
Signature............................
Mark**
Date.......................
*A paren t can s ign  o r  m ake a m ark and  have h is /he r perm iss ion  confirm ed b y  the s ignature o f a witness.
** A m ark is m ade by  the p a ren t o r  guard ian by thum bprin t (p lacing th e ir thum b on an inkpad  and pressing  dow n in 
the space above)
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Registrar code
IPTi - Malaria Prevention Study 
01 - Screening Form
Screening date (dd/mm/yyyy)
Scanned & 
Verified
/ /
O Female
Part 1: Screening
1.00 Infant’s gender O Male
1.01 Is the infant here to get Pentavalent 1 or OPV 1?
Check the ir im m unization  card.
1.02 Is the infant between 5 and 16 weeks of age?
1.03 Is the infant with his/her parent or guardian?
A sk  the guardian the nam e o f  the village they s tay  in
1.04 Is the village listed in the catchment area?
Look up the nam e on the list o f  c lin ic catchm ent areas,
1.05 Are the guardian and the infant regular residents of that 
village?
1.06 Is the parent or guardian willing to join the study?
O yes O no
If  'yes', i f  'no '.STO P . DO N O T  EN R O LL
continue go to 3.04a.
1.07 Does the infant have a sulfa allergy or any known 
allergies to any of the following drugs: Fansidar, 
Cotrimoxazole, sulphadoxine/pyrimethamine, quinine, 
or amodiaquine)?
1.08 Is the infant taking cotrimoxazole (prophylactically 
indefinitely) on a daily basis?
1.09 Will the infant be away from the study area (Asembo) for 
more than 6 months during the next two years?
Part 2: Examination
Nurse code
Health facility 
O Lwak O Abidha
O Ong'ielo O Saradidi
2.01 Has the infant had convulsions (talarieya) within the 
last day?
2.02 Does the infant have diarrhoea?
2.03 Does the infant have any difficulty feeding?
2.04 Does the infant appear seriously ill?
2.05 Is the infant being referred to the hospital today?
Screening / File Number
□ n
date_01
regcode
hfac_01
gender
L
O yes O no pentopvl
O yes O no age5_14
O yes O no parent
O yes O no catcharea
O yes O no sleep
I f  a ll the answ ers  
o f  questions  
1.01-1.05 are 'yes', 
go to 1.06. 
CO NTINUE
If  a n y  answers o f  
questions  
1.01-1.05 are 'no, 
STOP. DO N O T  
ENROLL
willing_01
O yes O no allergy
O yes O no cotrimox
O yes O no away
I f  any  answ ers to  
question 1.07-1.09  
are 'yes', STOP. 
DO N O T  EN R O LL
If  a ll the answers  
o f  questions  
1.07-1.09 are 'no', 
take to the nurse. 
CO N TIN UE
nursecode
O yes O no convulsion
O yes O no diarrhoea
O yes O no feeding
O yes O no ill_serious
I f  any  o f  the  
answers o f  
questions  
2.01-2.04 are 'yes', 
use IM C I 
algorithm  to  
assess.
I f  a ll the answers  
o f questions  
2.01-2.04 are 'no', 
C O NTINUE
Oyes 
I f  "yes', DO  
N O T  EN R O LL  
go to 3.01
O no 
If 'n o ', 
continue
hosp_ref
filenum_01
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Part 3: Consent
Registrar code
regcode2
3.01 Is the child eligible (1.01-1.05 are'yes'and 1.07-1.09 O yes 
and 2.05 are 'no')? I f  'yes'
continue
O no
I f  'no', S TO P  
D O  N O T  EN R O LL
3.02 Is the parent or guardian willing to join the study?
Have the guardian re ad  the con sen t form , o r  read  the 
consent form to the guard ian . Then, go through an  
A ssessm ent o f  P artic ipan t C om prehension form .
O yes O no
If 'y e s ' if 'n o ',S T O P ,
continue DQ N Q T  E N R 0 L L
go to 3.04a.
3.03 Does the guardian comprehend the study? O yes
(based on answers on the Assessment of Participant 
Comprehension form).
O no
If 'n o 'S T O P .
D O  N O T  EN R O LL
3.04 Does the guardian give consent to participate in the 
study?
O yes O no 
I f  yes' 
go to Part 4.
3.04a Why does the guardian not want to participate?
O needs to speak to husband 
O worried about risk of HIV 
O worried about risk of anaemia 
O worried about effects of study drugs 
O do not like or trust CDC 
O other
O no reason
*  Note: R em em ber to  re fe r the  in fan t fo r im m unization
Part 4: Assignment of IPTi ID number
I f  the infant is e lig ib le  a n d  the guard ian  has given  IPTi Participant ID number
consent, draw the n ex t S tu d y  ID  C ard and record  the
num ber here. Then re co rd  the  n u m b er on the Enro llm ent  -------------- ------- -------  -------—
Form, blank S tudy ID  Form  a n d  C lin ic  Intake Log.
Take 2 photos o f the in fan t a n d  guardian a n d  attach them  
on the Study ID  C ard  a n d  Form . A ttach  an IP T i Partic ipant 
sticker to the C h ild  H ea lth  C ard (M O H  Im m unization Card).
eligible
willlng_02
comprehend
consent
husband
HIV
anaemia
drugs
CDC
other
other_reason 
no reason
idnum
Screening / File Number
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Registrar code
IPTi Participant ID number
IPTi - Malaria Prevention Study
02 - Enrollment Form
Interview date (dd/mm/yyyy)
/ m /
R ecord  the num ber from the infant's  s tu d y  ID  card.
S c a n n e d  
& V e rifie d □ 1
Health facility regcode
date_02
O Lwak O Abidha
hfac 02
O Ong'ielo O Saradidi
idnum
Part 1: Family information
1.01 Infant's gender o  Male O Female 
1.03 Infant's name
1.02 Infant's date of birth (dd/mm/yyyy)
/ /
1.04 Mother's name
C hristian n a m e
Ju o k  nam e
Fath er's  Ju o k n a m e
Head of compound name 
C hristian  n a m e
Ju o k  nam e
Fath er's  J u o k  n a m e
C h ris tia n  n a m e
.06 Guardian's name ( I f  n o t  m o t h e r  o r  h e a d  o f  c o m p o u n d )  
C h ris tia n  n a m e
J u o k  n a m e
F a t h e r /  H u s b a n d 's  J u o k  n a m e
1.07 What is the relationship of the guardian to the infant?
O mother O father O compound head O other relative O not related 
If  mother, continue. O therw ise go to 2.01.
1.07a During your last pregnancy, did you receive 
2 doses of SP (Fansidar, Orophan,
Metakelfin, etc..) to prevent malaria during O yes O no O unknown 
pregnancy?
Part 2: Location information
2.01 Which village do guardian and infant reside?
Name Number
2.02 Can the mother's permanent ID be found? O yes O no
I f  yes, go to 2.03
sex
dob
name
namem
mname
mnamem
Iname
Inamem
cfname
gfname
cjname
gjname
clname
glname
guardian
dose
villname
village
midfound
2.02a How long has the mother resided in Asembo?
O less than 1 month 0  1-4 months O greater than 4 months O unknown
2.03 Mother's Permanent ID
□
2.04 Compound
2.05 Which landmarks does the child live near? 
Complete Village Landm ark  Codemap. 
File / Enrollment number
landmarkl
L
House ( If  unknow n
□
Iandmark2
leave blank)
Iandmark3
reside
mindividid
compound
house
landmarkl 
Iandmark2 
Iandmark3 
filenum 02
IPTi - 02-Enrollment Form - FINAL-Version 1.0
(This form has been designed so that the first page can be removed for anonymization of data)
Page 1 of 2 J
2 3 8 0 0 0 1 3 4 1 02 - Enrollment Form
Interview date (dd/mm/yyyy)
/
IPTi Participant ID number
Part 3: Bednet Use
3.01 Do you have any bednets in your house?
3.02 Did the child sleep under the bednet last night?
3.03 Was the bednet treated with insecticide within the 
last year?
O yes O no O unknown 
I f  no, com plete B ed n e t Voucher 
and  go to p a rt 4
O yes O no O unknown 
I f  no, p robe a n d  com plete B ednet 
Voucher i f  necessary
O yes O no O unknown
Part 4: Immunizations
date_02_2
idnum2
bednet
sleep
treated
Send the In fant to receive h is /h er im m unizations and  ask them  to return here a fte r they  are  
finished. Using the in fant's  M O H  card, note the im m unizations tha t were g iven  today:
O OPV1 O Pentì
Part 5: Samples
Nurse Code Interviewer Code
5.01 Is the child ill today?
5.02 Does the child appear ill today?
I f  5.01 and 5.02 are both no, go  to 5.09
5.03 Has the child had a hot body in the last 48 hours?
5.04 Temperature
5.05 Does the child have palmar pallor or other signs of 
anemia?
O none opvipentì
notimmunized
nursecode
intcode
O yes O no ill_today_02
O yes O no ill_now_02
O yes O no O unknown hotbody_02
°C temp_02
O yes O no O unknown pallor_02
IF  hot body in la s t 48  hours OR tem p >=37.5 OR signs o f anem ia do Haem oglobin , OptiMal, and  
B lood Slide tests.
5.06 Hemoglobin 5.07 OptiMal result
] .  Q  g/di
If  < 1 1 .0  g ive iron
A LL PARTICIPANTS
OBTAIN M IC RO TA IN ER  SA M PLE
(red  top)
5.09 Blood sample number
Place label here:
O positive O negative 
I f  positive, note on S tudy ID  
C ard and  give to Pharm acy  
Technician
5.09a Was blood sample taken
before or after immunization?
O before O after
Part 6: Treatment
6.01 Was any antimalarial treatment (quinine) given? q yes q no
5.08 Blood slide done hb_02
O yes O no optimai_02
bloodslide
bsampnum_0:
taken
antimalaria 0;
6.02 Was iron (ferrous sulfate) given? q yes q no
Bring the in fan t b ack  to the R egistrar. R ecord  the dates o f  Date of next visit (dd/mm/yyyy) 
the next IPTi v isit on the IP T i S tudy ID  card  an d  S tudy ID  
Form. Give ID  to guardian. / /
iron
nvisitdate_02
File / Enrollment number
L 1 1 1 1 1 1 IPTi - 02-Enrollment Form - FINAL-Version 1.0 Page 2 of 2
4 7 6 2 0 2 5 2 9 7 IPTi - Malaria Prevention Study S c a n n e d  & V e rifie d
Registrar code
03 - Scheduled Visit Form
Interview date (dd/mm/yyyy) Health facility 
O Lwak O Abidha
O Ong'ielo O Saradidi
IPTi Participant ID number R ecord  the num ber from  the infant's s tu d y  ID  card. I f  the guardian has
n ot b rought the ID  card, p lease ask them  to retrieve the card. If  the ID 
-------— L— —  ------- -------  card  has been lost, look up the child  in the files and  create a new  ID card.
regcode 
date_03 
hfac 03
idnum
Part 1. Study Visit -  a l l  v is it s
Which study visit is the in fan t here  fo r today?
O Visit 2: Study drug 1 (OPV 2/Pent 2) O Visit 5: Study drug 3 (Measles) O Visit 7: Follow up (18 months)
O Visit 3: Study drug 2 (OPV 3/Pent 3) O Visit 6: Follow up (12 months) O Visit 8: Follow up (24 months)
O Visit 4: Follow up (18 weeks) visitcode
O Visit 9: Missed medication ,W hich s tudy drug was this v isit for?  O Study drug 1 O Study drug 2
O  Study drug 3 missdrug
Write the visit num ber on the top o f  a ll pages o f this form.
Part 2. Location Information - a l l  v is it s
2.01 Child's name
Christian name J u o k  name F a th e r 's  J u o k  n a m e
Child's DSS Permanent ID
□ n r individid
2.02 What is the relationship of the caregiver to the infant?
O mother O baby sitter O other relative O unknown
O father O maid (japidi) O other not
If  m other o r fa th er go to 2.04
2.03 Are you (the caregiver) 15 years old or older?
Show  the caregiver the vilage Landm ark Code Map in the 
participant's file.
2.04 Has the infant moved to a new location since 
the last visit?
2.04a In which village does infant and caregiver reside? 
Name
related
O yes O no O unknown 
I f  'no ', p lease te ll them  that they m ust get 
an o ld er re lative.STO P COM PLETION O F  
THE FORM . D IR E C T  TO IM M UNIZATION  
D ESK  IF  A PPR O PR IA  TE.
O yes O no O unknown 
I f  "yes', record  relocation inform ation  
below  and  on a new  Village Landm ark  
Codem ap. I f  'n o 'g o  to Part 3.
Number
caregiver
cage15
moved
villnam e
village
2.04b Have you moved:
O new house and new compound in same village 
O new village within clinic catchment 
O new village in catchment of another clinic 
O outside study area
C ontact S tudy C oord inator before continuing
2.04c What is the name of the current head of 
compound?
C h ris tia n  n a m e
2.04d Compound House:
□
File number
L
2.04e Which landmarks does the infant live near?
landmarkl Iandmark2 Iandmark3
J u o k  n a m e
F a th e r 's  J u o k  n a m e
wheremove
cfname
cjname
cíñame
compound
house
landmarkl
Iandmark2
Iandmark3
IPTi - 03-Visit Form - FINALt-Version 2.8 
(T h is  fo rm  h a s  b e e n  d e s ig n e d  so  th a t th e  first p a g e  c a n  b e  re m o v e d  fo r  a n o n y m iz a tio n  o f  d a ta )
Page 1 of 4 J
3 7 7 1 0 2 5 2 9 6
Interview date (dd/mm/yyyy)
03-Visit Form
IPTi Participant ID number
Visit Number n
/ /
Part 3: Immunizations - a l l  v is it s
U sing the infant's M O H  card, n o te  the im m unizations tha t w ere given TODAY.
NO TE: I f  visit 5, b lo o d  sam ple  m u st be taken before m easles im m unization is given.
O  BCG O OPV1 O OPV2 O OPV3 O Pentl O Pent2 O Pent3 O Measles O None
Part 4: Symptoms - a l l  v is it s
Nurse code
4.01 Is the infant ill today? O yes O no
4.02 Has the infant had convulsions within the last day? O yes O no
4.03 Does the infant vomit everything? 0  yes O no
4.04 Is the infant not able to drink or breastfeed? O yes O no
4.05 Does the Infant appear ill today? O yes O no
I f  any  o f  the answ ers o f I f  a ll the answ ers o f
4 .01-4.05 are 'yes', questions 4.01-4.05
com plete Sick Visit Form. are 'no', go to 5.01.
date_03_2
idnum2
beg °Pv1 
opv2 opv3
pentl Pent2
pent3
measles
notimmunized
nursecodel
ill_today 
convulsion 
vomit 
feeding 
ill now
Part 5: Treatment History - a l l  v is it s
I f  S ick Visit form com pleted, do n o t fill part 5. Go to Part 6:
5.01 Was the child admitted to a hospital since the last time 
you visited an IPTi clinic? (since the last time you visited 
the IPTi study staff in this clinic, or another IPTi clinic).
5 01a Was this admission facilitated by IPTi staff?
5.01b Has your child had a blood transfusion since the 
last visit?
5.02 Has your child taken any medications in the past 2 
weeks other than those given by study staff?
What was your child given?
Show careg iver M ed ication  R eference Sheet
and the probe fo r specific  m edications.
O yes O no O unknown 
I f  'no', go to 5.02.
admitted
O yes O no O unknown 
I f  no o r unknow n, fill H ospital D ischarge Form.
O yes O no O unknown
facilitated
SP
Amodiaquine
Septrin (CTX)
Chloroquine
Quinine
Co-artem
Cotexin/alaxin
Cosumate
Analgesics
Antibiotic
Antihelminthic
Valium
Other:
Specify 
File number
O yes 
O yes 
O yes 
O yes 
O yes 
O yes 
O yes 
O yes 
O yes 
O yes 
O yes 
O yes 
O yes
O no 
O no 
O no 
O no 
O no 
O no 
O no 
O no 
O no 
O no 
O no 
O no 
O no
O unknown 
O unknown 
O unknown 
O unknown 
O unknown 
O unknown 
O unknown 
O unknown 
O unknown 
O unknown 
O unknown 
O unknown 
O unknown
O yes O no O unknown 
I f  'no', go to Part 6.
Where was it obtained?
1=this clinic, 2=other clinic, 3=hospital, 
4=duka, 5=other
0 4
transfusion 03
medication
O 1 
O 1 
O 1 
O 1 
O 1 
O 1 
O 1 
O 1 
O 1 
O 1 
O 1 
O 1 
O 1
0 2
0 2
0 2
0 2
0 2
02
0 2
0 2
0 2
0 2
0 2
0 2
0 2
0 3  
O 3 
0 3  
0 3  
0 3  
O 3 
0 3  
0 3  
0 3  
0 3  
0 3  
0 3  
0 3
0 4
0 4
0 4
0 4
0 4
0 4
0 4
0 4
0 4
0 4
0 4
0 4
0 5  
O 5 
0 5  
0 5  
0 5  
0 5  
0 5  
0 5  
0 5  
0 5  
0 5  
0 5  
0 5
sp
sp_obt
aqobt
clx_obt
cc|_obt
qu
qu_Obt
coartem
co_artem_obt
cotexin
cotexin_obt
cosumate
cosumate_obt
anal
anal_obt
antib
antib_obt
antih
antih_obt
valium
valiumobt
other 
other_obt 
other name
L t IPTi - 03-Visit Form - FINALt-Version 2.8 Page 2 of 4 J
0 0 2 4 0 2 5 2 9 4
Visit Number
Part 6: Intervention Drug - Iron -  v is it s  2, 3, a n d  4
Visit 2: Give 2 bottles o f  iron. V isit 3: Give 2 bottles o f iron. Visit 4: Give 4 bo ttles  o f  iron.
6.01 Was iron given? O yes O no
iron
Part 7: Intervention Drug - Antimalarial -  v is it s  2, 3, s a n d  9
7.01 Was study drug given as a Missed Medication dose 
(Visit 9) in the last 2 weeks?
(check partic ipant fo ld er to note i f  any  V isit 9)
O yes O no
I f  yes, do not give s tudy drug.
mm2wks
7.02 Has the infant taken SP (Fansidar, Oraphan, 
Metakelfin, etc) in the last 2 weeks?
(refer to question  5.02)
O yes O no O unknown 
I f  yes  o r unknown, do n o t g ive  s tudy  drug.
sp2wks
7.03 Has the infant taken Amodiaquine(AQ) or 
chloroquine in the last 2 weeks?
(refer to question 5.02)
O yes O no O unknown
I f  yes  o r unknown, do n o t g ive  s tudy drug.
aq2wks
7.04 Has the infant taken Quinine, in the last 2 weeks? 
(refer to question 5 .02 and  check i f  in fan t had  
an unscheduled s ick  v is it in the last 2 weeks)
O yes O no O unknown
I f  yes o r  unknown, do n o t g ive  s tudy drug.
qu2wks
7.05 Has the infant taken Septrin(SEP), in the last 2 
weeks? (refer to question  5.02)
O  yes O no O unknown
I f  yes o r unknown, do n o t g ive  s tudy drug.
I f  no go  to 7.06
ctx2wks
7.05a Is the infant taking Septrin (prophylactically 
for an indefinite period) daily?
O  yes O no O unknown
I f  yes, W ITH D R A W  child  from  study.
ctxdaily
I f  the infant w a s  given a s tu d y  drug o r has taken SP, AQ, Quinine, chloroquine o r SEP in the past 2 
weeks (but is not taking S E P  daily), calculate the date 2 w eeks from  the m ost recen t date one o f the 
drugs was adm inistered and  w rite  it a t the bottom  o f the next page as the nex t v is it date. I f  the 
caretaker says she does n o t kno w  when the drug was adm inistered, calculate the date  2 w eeks from  
today.
I f  the infant has not taken s tu d y  drug, SP, AQ, Quinine, chloroquine o r SEP in the last 2 weeks, 
give the study drug.
7.06 Was the s tudy drug given? O  yes O  no studydrug
Observe the in fant fo r 30 m inutes to determ ine i f  the dose was tolerated. I f  the dose was vom ited, 
repeat the dose and  observe the in fan t for another 30 m inutes. Record a ll in form ation  about 
vom iting below:
7.07 Did the infant vomit the study drug?
7.07a Was a second dose of study drug given?
7.07a1 Was the second dose of study 
drug vomited?
O yes O no O left without being observed 
I f  yes, g ive a second dose.
I f  no, go to part 8
O yes O no
I f  no, record  w hy not given in  Treatm ent B ook
O yes O no O left without being observed 
I f  yes, do not give a th ird  dose.
Part 8. Bednet use -  a l l  v is it s
vomit sd1
studydrug2
vomit sd2
Interviewer code
intcode2
8.01 Do you have any bednets in your house? O yes 
I f  'no',
O no O unknown bednet 03
g o  to Part 9.
8.02 Did your child sleep under a bednet last night? O yes O no O unknown sleep_03
8.03 Was the bednet "treated" with insecticide within the O yes O no O unknown nettreatJD3
last year?
File number
L [ x n IPTi - 03-Visit Form - FINALt-Version 2.8 Page 3 of 4
5 6 2 0 0 2 5 2 9 1 Visit Number
Part 9: Iron Taking Behavior - v i s i t s 3 a n d 4
3.01 Does the infant have any difficulty taking the iron?
3.02 Do you have any difficulty giving the iron?
9.03 How often has the infant been given the iron?
9.04 Did you spill any of the iron since the infants last 
study visit?
9.05 Did you share the iron with other children or 
adults?
9.06 Did you have the iron bottle with you?
Write down the am o un t o f  iron rem aining in the  
bottle
Part 10: Clinical measurements -  v is it s  2, 6 , 7, a n d  8
O yes O no O unknown 
O yes O no O unknown O NA 
O never O rarely O occasionally
O most days O daily O unknown 
O yes O no O unknown
O yes O no O unknown 
Bottle 2
O yes O no 
Bottle 1
mm mm
10.01 MU AC ( If  < 8  OR >20 Re-M easure)
10.02 Length/ height ( If  < 4 0  OR >110 Re-M easure)
10.03 Weight ( if  < 2 OR >13 Re-M easure)
Part 11: Samples
IF  VISIT 5
cm
cm
Length board number
Weighing scale number
kg
PERFORM NP SW AB
11.01 NP swab number
IF  V IS IT  6, 7 A N D  8 
TEST H EM O G LO B IN
11.02 Hemoglobin
IF  V IS IT  4, 5, A N D  6
O B TA IN  M IC R O TA IN ER  SAM PLE  
(red  top)
11.03 Blood sample number
g/di
Place label here:
IF  VISIT 2 AND 6 
OBTAIN EDTA SA M PLE  
(Purple top)
11.04 Blood sample number
I f  <8.0 and  >=5.0 re fe r to 
N urse fo r iron treatm ent. 
I f  <5.0, re fe r to Nurse for  
hosp ita l referral
11.02a Was iron given?
O yes O no
Place label here:
Place label here:
IF  VISIT 2 A N D  6
OBTAIN FILTER PA P ER  SA M PLE
11.07 Filter paper done?
O yes O no
Calculate the date o f  the nex t study visit:
File number
IF  V IS IT  6, 7 A N D  8 
M AKE B LO O D  SLIDE
11.05 Blood slide done 
O yes O no
IF  V IS IT  6, 7 A N D  8 
TAKE TEM PER A TU R E
11.06 Temperature
I f  > =37.5  °C com plete  
Sick V isit Form  i f  not 
a lread y  com pleted
Date of next IPTi visit (dd/mm/yyyy)
/ /
n
fe_dif1_03
fe_dif2_03
fe_often_03
fe_spill_03
fe_share_03
fe_bottle_03
fe_mm_03
fe_mm_03_2
muac
height
boardnum
weight
scalenum
npswabnum
hb_03
micronum
IF  V IS IT  5
11,03a Was measles vaccination 
given before or after blood 
sample was taken?
O before O after
fegiven
before
edtanum
bloodslide
tempV6
filter
nvisltdate 03
L IPTi - 03-Visit Form - FINALt-Version 2.8 Page 4 of 4 J
r S c a n n e d  ,------, I8273328711 IPTi _ Malaria Prevention Study & V e rifie d  I I05 - Compliance Monitor - Intervention Form
IPTi Participant ID number 
Nurse code
Part 1. Location Information
R ecord  the details b e low  from  the S tudy ID  Form.
1.01 Child's name 
C hris tian  n a m e
J u o k  n a m e
F a th e r's  J u o k  n a m e
In fan ts ' D a te  o f  b ir th (d d /m m /y y y y )
_____ /_______ I__________
1.03 Village Compound House
Health facility idnum
O Lwak O Abidha date_05
O Ong'ielo O Saradidi hfac_05
nursecode
1.02 Head of Compound
C hn'stian  n a m e  
J u o k  n a m e  
F th e r 's  J u o k  n a m e
1.04 Which landmarks does the infant live 
near?
Landmark 1 Landmark 2 Landmark 2
Date (dd/mm/yyyy)
/ /
filenum 05
L IPTi - 05-Compliance monitor- Intervention Form -FINAL-Version 2.0 T h is  fo rm  h a s  b e e n  d e s ig n e d  s o  th a t th e  firs t p a g e  c a n  b e  re m o v e d  fo r  a n o n y m iz a tio n  o f  d a ta  ^ a9 e  ^ o f  2  J
9 1 3 5 3 2 8 7 1 9 IPTi - Malaria Prevention Study
05 - Compliance Monitor - Intervention Form
IPTi Participant ID number Date (dd/mm/yyyy)
- /  / idnum2
W hich study visit is  this in tervention  for?
O Visit 2: Study drug 1 (OPV 2/Pent 2) O Visit 3: Study drug 2 (OPV 3/Pent 3) visticode
O Visit 5: Study drug 3 (Measles)
W as iron given?
Day 2
O Visit 9: Missed medication 
O yes O no If visit 9, copy filing number 
from Scheduled Visit Form
Attempt Date
(dd/mm/yyyy)
Compliance Is child If no, why not? 
Monitor found?
1
2
/ /
/ /
O yes O no
O yes O no
filenum03
irong
attempi day2
cmcode2_1
found2_1
attemp2day2 
cmcode2 2
found2 2
I f  c h ild  no t found a fte r 2nd  attem pt, begin a ttem pting  to give D ay 3 treatm ent
idnum2_1 
given2_1 
vomit2_1 
given2_2
vomit2_2 
treatcode2
dosedate2
I f  1s t dose is vom itted return to c lin ic to g e t the 2nd  dose (if  w eekend o r ho liday  bring  the child  to Lwak)
IPTi ID number
Study
drug
given?
1st 
Dose 
Vomit?
2nd
Dose
Given?
2nd
Dose
Vomit?
Intervention
Observed
ID code
Date (dd/mm/yy)
/  /
O yes 
O no
O yes 
O no
O yes 
O no
O yes 
O no
Day 3
Attempt Date Compliance Is child If no, why not?
(dd/mm/yyyy) Monitor Found?
1 O yes O no attemp1day3 
cmcode3_1 
found 1
2 O yes O no attemp2day3 
cmcode3_2 
found3 2
I f  ch ild  no t found a fte r 2nd  attem pt, n o tify  F ie ld  Supervisor
idnum3_1 
given3_1 
vomit3_1 
given3_2 
vomit3_2 
treatcode3 
dosedate3
I f  1s t dose is vom itted return to clin ic to g e t the 2nd  dose (if  w eekend o r ho liday  bring  the child  to Lwak)
IPTi ID number
Study
drug
given?
1st 
Dose 
Vomit?
2nd 
Dose 
Given?
2nd
Dose
Vomit?
Intervention
Observed
ID code
Date (dd/mm/yy)
/  /
O yes 
O no
O yes 
O no
O yes 
O no
O yes 
O no
IPTi - 05-Compliance monitor- Intervention Form -FINAL-Version 2.0 Page 2 of 2
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5554580989 IPTi - Malaria Prevention Study
12- Withdrawal/Suspension Form
S c a n n e d  
& V e rifie d
IPTi Participant ID number Date (dd/mm/yyyy)
- / /
Clinic Staff Code
Health facility 
O Lwak O Abidha
O Ong'ielo O Saradidi
Part 1: Child is to be withdrawn/suspended
1.01 Is this child:
O No longer an active participant (suspended)?
C om p le te  q u e s tio n  1.02
O Withdrawing from the study?
C om p le te  q u e s tio n  1.03 Date deceased(dd/mm/yyyy)
O Deceased?
1.02 Active looking (suspension) for the child has stopped
O The child has missed 1 scheduled visit and the Compliance Monitor was unable to locate the child 
and suspects the child has moved out of the catchment area
O Caregiver has informed us that the child has moved outside the study area
1.03 This child is being withdrawn from the study because:
O Adverse reaction to study drugs
O Guardian refuses further participation without further explanation 
O Infant is taking daily cotrimoxazole prophylaxis indefinitely 
O Guardian refuses further participation with explanation:
O Other:
Part 2: Suspension is to be lifted
2.01 File number of the suspension form
2.02 Reason suspension is lifted
O Child has moved back into the study area 
O Child has started coming to clinic again
File/withdrawal number
IPTi -12- Withdrawal Form -FINAL-Version 1.1
□ n
idnum 
date_12 
hfac_12
intcode
active
dod
stopped
withdrawn
explanation
filenum_12_2
reasonjift
filenum_12
J
8 0 3 6 6 2 0 9 1 5 IPTi - Malaria Prévention Study
15 - Parental Consent Form
IPTi Participant ID number
ID Code
Oboke Mar Yudo Thuolo Koa Kuom Janyuol Kata Jarit Nyathi Ma Oyie Ni 
Nyathine Odonji E Nonro Mar Geng'o Malaria Kod ‘Nok Mar Remo’ Ne 
Nyithindo (IPTi)
Wach motelo
Kenya Medical Research Institute (KEMRI) to kod Centers for Disease 
Control and Prevention, USA (CDC) timo nonro mar ng'eyo yo maber mogik 
mar geng'o ‘nok mar remo’ (anemia) kod malaria.E nonroni wadwaro pimo 
yore mopogore opogore minyalo geng' go tuo mar malaria kod ‘nok mar 
remo’. Achiel kuom yedhe ma wamiyo nyithindo en yadh remo ma iluongo ni 
iron.Yedhe mamoko gin Fansidar® kod artesunate, amodiaquine kod 
artesunate, kod Lapdap®. Adek gi duto gin yedhe ma osepuodhi, kendo ma 
itiyogo e thiedho malaria. Fansidar, amodiaquine, kata yadh remo (iron) gin 
yedhe mayudore mayot kendo inyalo ng’iewgi e duke mang'eny ei Asembo 
ka. Artesunate kod Lapdap to ok us e duke mang'eny.Wadwaro ng'eyo ni ka 
Fansidar + artesunate, amodiaquine + artesunate, kata Lapdap, kochiw kod 
yadh remo to nyalo bedo maber moloyo kochiw yadh remo kende kuom 
geng'o ‘nok mar remo’ kuom nyithindo mayom.Bende dwaher ng'eyo kapo ni 
yedhe gi kelo lokruok e yo ma dend nyathi winjore gi chenjo. Nonroni biro 
kawo nyithindo mayom madirom elufu achiel gi mia abich (1500).
Grube maq thieth
Nyithindo duto ma okaw e nonroni ibiro pogi e grube ang’wen ka okwanygi 
radha radha ma jo nonro kata janyuol nyathi ok bi yiero bende ok bi ng’eyo ni 
nyathi bedo e grup mane nikech ma nyalo chando duoko mawuok e nonro. 
Grup ka grup biro yudo yadh malaria ma opogore. Grup moro biro yudo 
Fansidar gi artesunate, moro biro yudo amodiaquine kod artesunsate, 
machielo biro yudo Lapdap, moro bende biro yudo placebo (gima olosi ma 
oriw gi sukari to yath onge e iye). Kata kamano nyithindogi duto te ibiro thiedhi 
kod yadh remo (iron) kuom dweche ang’wen.
Nyithindo ei grube ang'wen gi te ibiro mi yedhe ma oregi e yor amadha ka gin 
gi jumbe 10, jumbe14 kod dweche 9. Yedhe moko ibiro mi nyathi e od thieth, 
to moko obiro muonyo chieng’ maluwo mano kendo moko omuonyo chieng' 
mar adek. Jatich nonro biro limi dala mondo okelne nyathini yedhegi chieng' 
mar ariyo gi chieng' mar adek. Jotich nonro kata in janyuol/jarit nyathi ok bi 
ng’eyo yedhe ma nyathini yudo nyaka chop nonro rum.
Kaka ibiro kelo nyathi
E nonroni wabiro kwayi mondo ikel nyathini e od thieth ka nya dibiriyo (ka 
nyathini ni gi jumbe 10,14 kod 18 kendo kochopo dweche 9,12,18 gi 24). E 
limbe ka limbe jatich nonro biro penji penjo kaluwore gi ngima mar nyathini 
kendo obiro nono nyathi. E limbe moko jatich mar nonro biro pimo pek kod 
bor mar nyathi. E limbe moko jatichni biro chuoyo lith Iwedo kata ombong' 
tiend nyathini mondo okaw remo matin. Kendo e limbe moko ibiro mi nyathini 
yadh nonro. Limbe ka limbe biro kawo thuolo madirom dakika 30.
Nukta mochung ne nying Janyuol/Jarit
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Yedhe nonro
E limbe mar chenjo mar nyathi e juma mar10,14 kod mar dweche 9, nyathini 
biro yudo thieth e od thieth. Bang’e, jatich nonro biro limi dala kuom ndalo 
ariyo moluwore mondo ochiw ne nyathi yath modong'. Seche duto ma orni 
nyathini yadh nonro, jatich nonro biro ng'iye kuom dakika 30 mondo ong'e 
adieri ni nyathi ok ong'ok kata obedo matuo. Ibiro yudo chupa mar yadh remo 
(iron) e juma mar10, mar 14 kendo mar 18. Dwaher ni imi nyathini yadhni pile 
pile. Ka nyathini ni gi dweche 6, wabiro limo odi mondo wanon ka nyathini 
osemi yedhe remo gi duto te.
Remo ma wakawo
Kawuono wabiro chuoyo ombong' tiend nyathini kata lith Iwete mondo wakaw 
remo ma wapimo. Wabiro timo kamano kendo ka en ja jumbe 10,18 kod ka en 
ja dweche 9 kod 12. Remo mawabiro kawo tin, madirom 1/4 mar kijiko chai 
kende. Remoni wabiro kano. Moko wabiro tiyogo mondo wang'i kaka dend 
nyathini rwako chenjo. Moko kuom remo ni wabiro tiyogo mondo opimgo tuo 
mar remo milwongo ni amara (sickle cell). Ibiro nyisi ka po ni nyathini ni gi 
amara.Wabiro chiwo johocho mondo okonyi ng'eyo kaka inyalo manyo ni 
nyathini yore thieth kendo kaka inyalo rito nyathini e dala. Remo moko ibiro 
tigo kuom pimo gigo mamoko e del mányalo kelo ‘nok mar remo’ ne nyithindo, 
kaka tin mar G6PD.
E limbe mar juma mar 10 to kod mar dwe mar 12, wabiro tono remb nyathini 
matin e kalatas moro matin. Wabiro pimo remo ma oton e kalatasno mondo 
okonywa ng’eyo mang’eny kaka yedhe ma itiyogo kuom thiedho malaria tiyo e 
gweng’u ka.
Ka nyathi ochopo dweche 12, 18 kendo gi 24 wabiro kawo oton mar remo 
madirom ondeng’ 5 mondo wapim kadipo ni nyathini nigi malaria kod / kata 
‘tin mar remo’. Wabiro chiwo thieth ka nyathini ni gi tin mar remo, malaria, 
kata del ma ore. Ma wabiro timo e seche ma ibiro e limbe gi.
Ramien Um
E limbe mar dweche 9 bang' nywol nyathi, wabiro soyo pamba e urne.Wabiro 
ng’iyo ka nyathini ni gi kute mányalo kelo tuoche mamako kor, kata machando 
yueyo mar nyathi. Nyithindo duto yudo chenjo mar tuoni, omiyo kata ka 
nyathini oyudi gi kute gi, ok onyiso ni obiro yudo tuoni. Bende wabiro pimo 
nyathi mondo wane kaka dende rwako chenjo.
Limbe ka nyathi tuo
Wakwayi ni ikel nyathini e od thieth saa a saya ma nyathini tuo kapod nonroni 
dhi nyime. Kadipo ni nyathini obedo matuo kendo odwaro thieth mapiyo to 
itere kar thieth kata osiptal machiegni kodi mogik. Nonroni ni kod jotich e 
kuonde thieth mag Abidha, Ong'ielo, Lwak kod Saradidi. Ka tuo dipore ne 
nyathi gotieno ka ose lor od thieth, kata chieng’ jumamos gi jumapil, wabiro 
bedo gi jathieth e osiptal mar St Elizabeth Lwak, ma nyalo thiedho nyathino. 
Ka nyathini dwaro thieth momedore ma dwaro ni orwake e osiptal mondo 
othiedhe to wabiro chung'ne eyo mányalo tere New Nyanza General 
Provincial Hospital. Wabiro kawo chudo mar ospitai ka nyathini orwak kuro
Nukta mochung ne nying Janyuol/Jarit
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Kapod nonroni dhi nyime, wabiro kwayi ni kik inyiew ne nyathini yedhe 
mag thieth mar malaria kata nok mar remo e duke kata od thieth , mak mana 
kochuno ahinya.Wakwayo kama nikech medo yedhe moko e wi magwa nyalo 
kelo chandruok ni nyathini.Yedhe mamoko bende nyalo duoko teko mar 
yedhe nonroni piny.Wachiwo yedhe dutomoko go te mag malaria, ‘nok mar 
remo’, njofni, to kod Numonia (kor mathung') maonge chudo moro amora e od 
thieth. Kuom mano, biro bedo maonge tiende nyiewo yedhe mamoko mag 
tuoche gi.
Chandruok manvaio bedo:Yedhe duto ni kod richo gi
Kuom yedhe duto: Nyalo pore ni ng'ato ng'ok bang' kawo yedhe moro amora 
mar nonro. Ka ma otimore kochopo kata kapodi kochopo dakika 30 to ¡biro mi 
nyathini yadhno kendo. Ka ong'ok bang' dakika 30 to ok bi mede yath moro.
Yadh remo(lron).Nyithindo moko ok ohero bilo yadh remo. Nyithindo moko 
wacho ni giwinjo ka chuny gi lew to kendo giwinjo kama ok gidwar chiemo 
bang' madho yadh remo. E nyithindo moko, lake gi lokore marateng’. To moko 
oko maduong' mar gi lokore marateng’ kata majan moloyo pile. Ma en gima 
timore pile ma ok Neh ka ng'ato ithiedho gi yadh remo. Rangi mar lak kata oko 
maduong' biro duogo e wang'e ka thieth gi yadh remo ose tieki. Yadh remo be 
en sum kendo onyalo hinyo ng'ato kokaw mang'eny mokalo karom 
madwarore.
Fansidar: Seche moko dend nyathi nyalo rwodho bang' thieth gi Fansidar®, 
ma en achiel kuom yedhe mar nonroni. Ka ma otimore, wabiro chungo miyo 
nyathi yadhno kendo wabiro golo paro ni nyathini othiedh gi yedhe malaria 
mopogore ndalo mabiro.
Amodiaquine: Onge chandruok ma ong'ere maluwore gi muonyo amodiaquine 
e seche mopogore opogore kuom thiedho malaria.
Artesunate: Onge chandruok mong'ere maluwore gi muonyo artesunate.
Lapdap: Seche moko nyathi nyalo bedo gi nok mar remo kuom saa matin 
bang' kawo Lapdap. Wan gi paro ni chandruok machalo kama nyalo bedo 
matin nono. Mak mana ni yadhni en yath manyien, kendo pod ok oti kode 
mang'eny kuom nyithindo e Afrika ka, omiyo ok wanyal ng'eyo chandruok te 
manyalo bede kuom tiyo kode.
Gima olosi gi sukari maneno kaka yath to yath onge e iye: Ok wapar ni 
chandruok moro amora biro wuok e tiyo gi gini.
Chuoyo ombong’ tielo kata lith Iwedo: Kama ochuo e ombong' tielo kata lith 
Iwedo kuom kawo remo nyalo dong' gi alama matin kendo be inyalo winjo rem 
matin. Nyalo timore ni tuoche moko nyalo donjo e del kogol remo kama. Mak 
mana ni timruok kuom gima kama tin ahinya to nikech watiyo gi gik maler pile.
Nukta mochung ne nying Janyuol/Jarit
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Ramien um: Nyalo timore ni rewni moro matin nyalo wuok kama ramien urn 
biro kale. To bende chwer kata tuo nyalo donjo kaluwore gi tiyo gi ramien um.
Thieth ma onqe Chudo:
Kaponi nitiere chandruok mowuok kuom chuowo ombong’ tielo/lith Iwedo kata 
yueyo um gi pamba ma dwarore ni daktari ong’i, kata ka rach moro owuok 
kuom muonyo yedhe malaria mawathietho go, wabiro chung’ni e yor wuoth 
kendo wabiro tero jatuo e ospitai. E osiptal nyathini ¡biro thiedho nono 
maonge chudo moro amora. Onge chandruok machalo kamano mose wuok 
kata timore chakre jo CDC chak nonrogi ei Asembo e dwe mar auchiel e higa 
1992. E limbe mag klinik duto ma ochiki, ¡biro miyi pesa mar wuoth ma oromi 
biro e Klinik kendo dok dala ka itiyo gi ngware kata boda boda. Kamano 
bende ¡biro miyi pesano e saa asaya ma ikelo nyathi e klinik nikech ong’ogo 
yath nonro.
Pimo Tuoche (Lab tests)
Remo duto mokaw ¡biro ter e od pimo tuoche ma Kisian mondo opim ka gin 
kod malaria. Remo moko gi pamba mar ramien um inyalo kan mondo obi oori 
e kar pimo tuoche (lab) manitiere Europe kod USA. E piny mar USA, nonro 
matut inyalo tim mabiro konyowa ng’eyo mang’eny moloyo kuom kaka dend 
nyathini geng’o tuoche mag malaria kod nok mar remo. Ma oriwo nonro kuom 
kaka dend nyathini winjore gi chenjo.Ramien um bende ¡biro pim mondo one 
kanikod kute makelo tuo. Remo bende inyalo pimgo kar rom yadh remo 
manie del (iron), lokruok manitiere bang’ tiyo gi yadh remo(iron) kata kaka 
dend nyathi kedo ka malaria odonjo. Remo moko ¡biro ter e piny mar France 
mondo onon kaka nyathini winjore gi chenjo. Kawayudo duoko moro amora 
kuom pimgi manyalo bedo gi wach kuom ngima nyathini to wabiro wachoni. 
Duoko mar pim mar G6PD to ok bi chiw. Pim tuoche duto ¡biro tim nono 
maonge chudo moro amora.
Kano wach ma opondo
Kaponi idwaro ni remb nyathini ogol e kar keno to yie mondo inyis jotich 
nonro.Wabiro ketho remo go kendo ok bi kan gi. Ma ok bi kelo rach moro ne 
nyathini kata ne in. Weche ma wachoko e nonroni to gi duoko ma wayudo e 
pim mar tuoche ¡biro kan maber kendo ok bi landi kaluwore gi chik Sirikal. 
Nying nyathi bende ok bi tigo e nonro kata duoko mabiro wuok kuom nonro. 
Jo matiyo e nonro kende e mabiro bedo gi thuolo mar neno gik mawayudo ka 
nonro dhi nyime.
Nvithindo ma tuo ahinva:
E nonroni ibiro kaw nyithindo ma ngima gi ber. Nyithindo ma tuo ahinya 
kawuono ok bi kaw e nonroni to ibiro nyis gi mondo gimany thieth e osiptal 
manitiere machiegni. E seche ma nonroni dhi nyime, ka nyathi ma osekaw e 
nonro obedo matuo ahinya nikech dende ok owinjore gi yedhe nonro ma 
wamiye to wabiro chunge mondo kik odhi nyime gi nonro.
Wuok e nonro
Nyithindo moko nyalo bedo ma laktar ondiko mondo omigi yath ma iluongo ni 
cotrimoxasole pile pile. Yath mar cotrimoxasole ok winjre maber gi achiel 
kuom yedhe
Nukta mochung ne nying Janyuol/Jarit
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ma wabiro chiwo e nonroni. Omiyo ka nyathini oketi e yath mar cotrimoxasole 
mondo omuony pile pile to wabiro gole oko e nonro. Ma wabiro timo mondo 
wakony ngima nyathini.
Chunqo nonro: In kod thuolo mar yie kata dagi mondo nyathini obed e 
nonroni. Ka okidwar ni nyathini obed e nonroni to in kod adieri mar tamori. 
Bende ka okidwar ni nyathini odhi nyime gi bedo e nonroni to inyalo chunge 
saa asaya. Ma ok bi kelo rach moro amora ne in kata ne nyathini. In kata 
nyathini podi ubiro yudo thieth makare e od thieth ni.
Ber mawuok e nonroni: Nitiere ber ma nyathini nyalo yudo kuom bedo e 
nonroni. Obiro yudo thieth manono mar malaria, nok mar remo, njofni, diep gi 
tuoche mag kor mathung’ kuom dweche 24 kochakore chieng’ mokuongo mar 
nonroni. Ibiro miyi otiko mar yudo thieth mabiro miyo nyathini yudo thieth ma 
nono ka en gi tuo moro amora kuom ma wasewachogo e kuonde thieth ma 
nonroni timoree. Nyathini ibiro thiedhi gi jathieth mar nonroni kendo ma biro 
miyo ka rito thieth kawo seche matin moloyo pile.
Ka nyathi ma enonroni oruaki e wuod e osiptal ma Lwak kata New Nyanza 
General Provincial hospital ka en gi achiel kuom tuoche ma ondiki ebwo 
“limbe ka nyathi tuo”, nonroni biro chulo chudo madwarore kuom nyathino. 
Kata kamano chudo mag thieth kuom tuoche moko ma opogore gi ma 
wasewacho go (kata ma ok obiro nikech tiyo gi yedhe nonro) to nonroni ok bi 
chulo. Thieth manono gi rit biro konyo ngima nyathini bedo maber. Yadh 
remo(iron) manono biro geng’one nyathini bedo gi tuo mar nok remo. Nikech 
nyathini biro limo od thieth kuom ndalo mang’eny ka nonroni dhi nyime, biro 
bedo mayot moloyo mondo oyud ka en kod malaria kendo ibiro tim ne thieth 
mapiyo moloyo pile.
Nyathini bende ibiro timne pirn mar malaria ka en kod tuoche maluwore kod 
del maoore to mani nyalo miyo oyudi thieth maber moloyo kuom tuoche gi. 
Ibiro nyisi bende ka nyathini ni kod tuo mar amara (sickle cell) to ma nyalo 
konyi mondi ¡many yore mag rit kuom tuo ni ma dwarore. Wageno ni duoko 
mar nonroni biro konyo mondo thieth mar malaria kod nok mar remo obed 
maber moloyo e gweng’ni.
Paro Machielo: In thuolo yiero mondo kik nyathini obedi e nonroni. Ka iyiero 
mondo kik nyathini obedi e nonroni to ibiro nene gi jotich matiyo ka pile kendo 
obiro yudo thieth mowinjore kaka migawo mar rito ngima oyango, ka ichulo 
pesa ma owinjore. Limbe mag nonroni koro ok bi chan nii.
Joma inyalo tudori go: Ka nyathini ni gi chandruok moa kuom nonroni 
madiher ni laktar ong’i wachne to inyalo tudori gi Dr. Juliana Otieno ma tiyo 
New Nyanza Provincial General Hospital e namba simo mar 057 2023200. 
Kapod in kod penjo moko, kata ka idwaro mondo iwuogi e nonroni, to tudri 
kod Dr. Larry Slutsker, Mr. Peter Otieno kata Mr. Frank Othiambo e ofis CDC 
manitiere Kisian. Ofis ni nitiere Kisian e ndara maduong' ma wuok Kisumu ka 
dhi Busia. Namba simo gin 057 2022929, 057 2022959, kata 057 2022983.
Ka in kod penjo ma oluwore gi adieri mari kaka achiel kuom jogo ma itimo ne
Nukta mochung ne nying Janyuol/Jarit
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gi nonro, kata ka idwaro loso kuom nonroni kod ng'ano ma ok omakore gi 
nonroni to tudri gi Dr. Margaret Oloo. Dr. Oloo en jathieth manimba 
mochung'ne nyithindo to ok en achiel kuom jogo matimo nonroni. Bende 
inyalo tudori kod Dr. Margaret Oloo ka iparo ni nyathini ohinyore nikech 
nonroni. En otiyo Aga Khan Hospital ei Kisumu kendo inyalo yude e namba 
simo ma 057 20 41031.
Ero kamano kuom kawo sechegi.
Nonro mar gengo Malaria kod Nok mar Remo
Mondik malo gi te oselerna kendo asesomo oboke mar ayie kata osesome ni 
an. Ayie ni nyathina obed e nonroni. Owachna ni an kod thuolo mar yiero 
mondo nyathina obedie nonroni. Owachna ni bende ka ok adwar mondo 
nyathina odhi nyime gi bedo e nonro to anyalo chunge saa asaya. Ma 
kotimore to onge wach moro amora mabiro tamo nyathina kata gi an kuom 
yudo rit makare ndalo mabiro. Ayie ni opim remb nyathina kanikod 
malaria,’nok mar remo’ kod gigo mányalo geng’e kuom yudo malaria, ‘nok 
mar remo’ kata tuoche mokel gi kute. Ayie ni ramien moa e urn nyathina opim 
kanikod kute makelo tuo.
Janyuol/Jarit Nyinge Sei Tarik
/  /
Nukta ma ochung ne 
nyinge
Alama*
Ja ndiko 
mar IPTi Nyinge Sei Tarik
/  /
Ja neno* Nyinge Sei Tarik
/  /
Alama**
*Janyuol nya lo  ke to  sey i kata keto alama kod janeno  bende biro keto sey i m are m anyiso ni 
¡anyuol/jarit n ya th i oyie.
** Alam a m ike to  g i ja n yu o l kata ja r it nyath i en m a r Iwedo (placing the ir thum b on an inkpad  
and p ress ing  dow n in the space above)
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Kano remo mar tiyogo e nonro e kinde mabiro
Dwaher mondo wakan remb nyathini moko modong’ mondo watimgo nonro e 
kinde mabiro e weche momakore gi tuo mar malaria. Ok wapim kute mag 
Ayaki kata chwech remo. In thuolo yiero mondo iyienwa wakan remb nyathini. 
To pod inyalo mana bedo e nonroni kata ka ok iyie mondo wakan remb 
nyathini mar tiyogo e nonro e ndalo mabiro. E rumb nonroni, wabiro golo 
nyingi e oboke duto mag nonroni, omiyo ok wabi duokoni duoko moro amora 
mowuok kuom pim mar remo ma okan.
Ka iloko pachi ni ok idwar mondo wakan remb nyathini e kinde ma nonroni dhi 
nyime to itudri gi Mr Peter Otieno, Mr Frank Odhiambo, kata Dr Mary Hamel e 
ofis CDC ma Kisian mondo kik wakan remono. Ofis CDC ma Kisian ni e bath 
ndara maduong’ mawuok Kisumu ka dhi Busia. Namba simu en 22929,
22959, 22983
Janyuol/Jarit Nyinge Sei Tarik
/  /
Nukta ma ochung ne 
nyinge
Alama*
Ja ndiko 
mar IPTi Nyinge Sei Tarik
/  /
Ja neno* Nyinge Sei Tarik
/  /
Alama**
*Janyuol nyalo  keto  sey i kata keto a lam a kod janeno  bende biro ke to  se y i m are m anyiso ni 
janyuol/jarit n ya th i oyie.
** Alama m ike to  g i ja n yu o l kata ja r it nya th i en m a r Iwedo (placing the ir thum b on an inkpad  
and p ress ing  dow n in the space above)
Achiel kuom mama kata baba kata jarit nyathi nyalo keto seyi. Ok dwar seyi mag 
gi giduto. Janeno dwarore mana kuom joma ok nyal keto seyi.Otas te mar oboke 
ni nyaka ketie alama mar mama, baba kata jarit nyathi( ng’ano ma oketo seyi e 
oboke mar Ayie)
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16 - Sick Visit Form
S c a n n e d  
& V e rifie d a n
Registrar code Interview date (dd/mm/yyyy) Health facility
I I  O Lwak O Abidha
O Ong'ielo O Saradidi
IPTi Participant ID number R ecord  the num ber from  the infant's s tu d y  ID  card. I f  the guardian has
n o t brought the ID  card, p lease ask them  to retrieve the card. I f  the ID  
— — — —  -------—  card  has been lost, look up the ch ild  in the files a n d  create a new  ID card.
Parti. Study Visit
Which type o f s tu d y  v is it is  the ch ild  here fo r today?
O Unscheduled sick visit O Scheduled visit when the child was found sick 
Begin with P art 2. B egin with P art 3.
Visit number
regcode 
date_16 
hfac_16
idnum
visitcode
visitus
Part 2. Location Information
2.01 Child's name
C h ris tia n  n a m e  J u o k  n a m e  F a th e r 's  J u o k  n a m e
Date of birth (dd/mm/yyyy)
/ /
Child is
2.02 What is the relationship of the caregiver to the infant?
O mother O baby sitter O other relative
O father O maid (japidi) O other not related
O Less than 2 months old 
O Equal to or greater than 2 months old
O unknown
2.03 Are you (the caregiver) 15 years old or older?
Show the careg iver the village Landm ark Code M ap in the  
participant's file.
2.04 Has the infant moved to a new location since 
the last visit?
2.04a In which village does infant and caregiver reside? 
Name
O yes O no O unknown
I f  'no', Nurse m akes assessm ent w hether
an o ld er relative sho u ld  be brought in
O yes O no O unknown 
If  ‘yes', record  re location  inform ation  
below  and  on a new  Village Landm ark  
Codem ap. I f  'no' go to Part 3.
Number
2.04b Have you moved:
O new house and new compound in same village 
O new village within clinic catchment 
O new village in catchment of another clinic 
O outside study area
C ontact S tudy C oord inator before continuing
2.04c What is the name of the current head of 
compound?
C h ris tia n  n a m e
2.04d Compound House:□
2.04e Which landmarks does the infant live near?
landmarkl Iandmark2 Iandmark3
File/Sick visit number
L
J u o k  n a m e
F a th e r 's  J u o k  n a m e
dob
childage
caregiver
cage15
moved
villname
village
wheremov
cfname
cjname
cíñame
compound
house
landmarkl
Iandmark2
Iandmark3
IPTi - 16-Sick Visit Form - FINAL-Version 2.5 
(T h is  fo rm  h a s  b e e n  d e s ig n e d  so  th a t th e  firs t p a g e  c a n  b e  re m o v e d  fo r  a n o n y m iz a tio n  o f  d a ta )
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Nurse code Interview date (dd/mm/yyyy) IPTi Participant ID number
/ / -
nursecode 
date 16 2
Part 3: Treatment History
idnum2
3.01 Was the child admitted to a hospital since the last time 
you visited an IPTi clinic? (since the last time you visited 
the IPTi study staff in this clinic, or another IPTi study 
clinic).
3.01a Was this admission facilitated by IPTi staff?
3.01b Has your child had a blood transfusion since the 
last visit?
3.02 Has your child taken any medications in the past 2 
weeks other than those given by study staff?
O yes O no O unknown 
I f  'no', go to 3.02.
admitted
O yes O no O unknown 
I f  no o r unknow n, fill H ospita l 
D ischarge Form
facilitated
O yes O no O unknown transfusion_16
O yes O no O unknown medication
I f  'no', go to P art 4.
What was your child given?
Show caregiver M edication  R eference Sheet 
and  probe fo r  specific  m edications.
Where was it obtained?
1=this clinic, b u t n o t from  IP Ti staff, 
2=other clinic, 3=hospital, 4=duka, 5=other
SP O yes O no O unknown O 1 0 2 0 3 0 4 0 5 spsp_obt
Amodiaquine O yes O no O unknown O 1 0 2 0 3 0 4 0 5 Icjobt
Septrin (CTX) O yes O no 0  unknown O 1 0 2 0 3 0 4 0 5 ctx_obt
Chloroquine O yes O no O unknown O 1 0 2 O 3 0 4 0 5 ccjobt
Quinine
Co-artem
Cotexin/alaxin
O yes 
O yes 
O yes
O no 
O no 
O no
O unknown 
O unknown 
O unknown
O 1
O 1 
O 1
0 2
0 2
0 2
0 3  
0 3  
O 3
0 4
0 4
0 4
0 5  
O 5 
O 5
qu
qu_obt
co artem 
co_artem_obt
cotexin
cotexin_obt
Cosumate O yes O no O unknown O 1 0 2 O 3 0 4 O 5 cosumatecosumate_obt
Analgesics O yes O no O unknown O 1 0 2 O 3 0 4 O 5 analanal_obt
Antibiotic O yes O no O unknown 0  1 0 2 0 3 0 4 0 5 antibantib_obt
Antihelminthic O yes O no O unknown O 1 0 2 0 3 0 4 O 5 antih
antih_obt
Valium O yes O no O unknown O 1 0 2 O 3 0 4 0 5 valium
valium_obt
Other: O yes O no O unknown O 1 0 2 O 3 0 4 O 5 other
Medication name treatname
Other: o  yes O no O unknown 0 1  0 2  0 3  0 4  0 5 other2 
other obt2
Medication name treatname2
File/Sick visit number
....... ...................................
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Part 4: Examination
4.01 Vital signs Pulse 
Temperature
r n
I f  > 150 call CO  Respiratory rate
breaths/minute
I f  >60 call CO
□ o p  I f  T<35.6 o r  T> 37.4 and  <2m onths, u  I f  T>39.5 c a llC O
4.02 Is the child able to drink or breastfeed at all? O yes O no -
— * severe disease  
> If  'no', severe disease
4.03 Does the child vomit everything with each feeding? O yes O no
O yes O no 
O yes O no} I f  'yes', severe disease
O yes O no 
I f  'no', go to 4.07.
days
I f  <2m onths and  >59 bpm  severe disease
O  yes O  no 2-12m onths and  >49 bpm  1 breaths
> pneum oniaJ12-59m onths a n d  >39 b p m .
O yes O no— > I f  'yes', severe disease
O yes O no— t I f  'yes', and  <2months, severe disease
stridor
4.04 Is the child lethargic or unconscious?
4.05 Is the child convulsing now?
4.06 Does the child have cough or difficult breathing?
4.06a How long has the child had the cough?
4.06b Does the child have fast breathing?
4.06c Chest indrawing?
4.06d Nasal flaring?
4.06e Stridor when calm?
4.06f Wheezing?
4.07 Does the child have diarrhea?
4.07a How long has the child had diarrhea?
4.07b Is there blood in the stools?
4.07c Has the child ever had 2 or more episodes c 
diarrhea lasting 14 days or more?
4.07d Is the child restless or irritable?
4.07e Does the child have sunken eyes?
4.07f Is the child not able to drink or drinking 
poorly?
4.07g Is the child drinking eagerly, thirsty?
4.07h After pinching the skin does it go back?
If  2 of: lethargic, unconscious, sunken eyes,drink poorly, o r skin p inch  very s lo w ly — * severe disease
pulse
respiration
temp_2
breastfeed2
vomit
lethargic
convulsion
cough
coughdays
indrawing
flaring
O yes O no— * I f  'yes', severe disease
O yes O no
O yes O no
I f  'no', go to 4 .07d
wheezing
diarrhea
days diarrheadays
O yes O no stool
O yes O no episodes
O yes O no restless
O yes O no sunkeneyes
O yes O no poordrink
O yes O no thirsty
O  very slowly O  slowly O  normally pinch
File/Sick visit number
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4.08 Does the child have measles now, or in the past 
3 months?
4.09 Does the child have a stiff neck?
4.10 Does the child have bulging fontanelle?
4.11 Does the child have a runny nose?
4.12 Does the child have a rash?
4.12a Is it a localized heat or diaper rash?
4.13 Does the child have red eyes?
4.14 Does the child have mouth ulcers?
4.14a Are they deep and extensive?
O yes O no
O yes O no - —♦ I f  'yes', severe disease
O yes O no - —♦ I f  'yes', severe disease
O yes O no
O yes O no
I f  'no', go to 4.13
O yes O no
I f  'no', fill the Skin R eaction Form
O yes O no
O yes O no ( If  'no', go  to 4.15)
I f  'yes', fill the Skin R eaction  Form
O  yes O no — ♦ I f  'yes', severe disease
measles3mon
stiffneck
fontonelle
runnynose
rash
diaperrash
redeyes
mouthulcers
deepulcers
puseyes
4.15 Does the child have pus draining from the eye(s)? O yes O no — > I f  'yes' and  <2m onths, severe disease
4.16 Is there clouding of the cornea? O yes nn ___. cloudingI f 'y e s 'a n d  measles, severe disease
4.17 Does the child have an ear problem?
4.17a Is there pus draining from the ear?
O yes O no earproblem 
I f  'no', go to 4.18.3 pusear 
O yes O no — * I f  'y e s 'a n d  <2m onths severe disease
4.17b Is there tender swelling behind the ear? O yes O no — ♦ I f  'yes', severe disease tenderswell
4.18 Is there visible severe wasting? O yes O no — ♦ I f  'yes', severe disease wasting
4.19 Is there oedema of both feet? O yes O no — ♦ I f  'yes', severe disease oedema
4.20 Weight for age: O very low O not very low weight
4.21 Is the growth faltering?(weight curve flattening 
or dropping for at least 2 consecutive months)
O yes O no
faltering
4.22 Is the child jaundiced? O yes O no jaundice
4.23 Are there enlarged lymph nodes at 2 or 3 of the 
following sites (neck, axillae, groins)
O yes O no lymphnodes
4.24 Oral thrush? O yes O no oralthrush
4.25 Any signs of anemia 
4.25a Palmar pallor? O yes O no palmarp
4.25b Nail bed pallor? O yes O no nailp
4.25c Conjuctiva/lip/tongue pallor? O yes O no otherp
4.26 Has the child had hot body in the last 48 hours or is 
the temperature >37.4 now?
O yes O no hotbody
* j | f  Note: If  child  has severe  disease, give urgent p re-refera l treatm ent, re fe r the ch ild  and  
notify Clinic O fficer
File/Sick visit number
...........................................
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Part 5: Samples
1
IF  hot body in las t 48 hours OR tem p >37.4 OR signs o f anem ia do H aem oglobin , OptiMal, and  
B lood Slide.
HAEM OGLOBIN TEST
5.01 Hemoglobin
”  g/dl□
PERFO RM  OPTIM AL TEST
5.02 OptiMal result
O positive O negative
If  visit 6, 7, 8 co p y  onto  
Scheduled Visit Form  p a rt 11
*  IF  <5.6 g /d l ca ll CO,
*  IF  <5.1 g/dl, Refer, ca ll CO
*  IF  <8.0 g/dl, G ive Treatm ent Iron
If  'positive', note on S tudy  
ID  card  and  give to 
Pharm acy Technician
M A K E B LO O D  SLIDE
5.03 Blood slide done
O yes O no
I f  v is it 6, 7, 8 copy onto  
Schedu led  Visit Form  p art 11
hb_16
optimal_16
bloodslide
I f  visit 2, 4, 5 o r 6 go  to p a rt 11 o f  Scheduled Visit Form  and  co llect appropriate b lo o d  sam ple. 
Part 6: Diagnosis I f  ch ild  is < 2m onths old, re fe r to IM C I gu idelines to m ake diagnosis
6.01 What do you diagnose the child with?
Malaria O yes Meningitis O yes svmeningitis
Severe malaria O yes Otitis media O yes svsmalariasvotitis
Pneumonia O yes Conjunctivitis O yes svpneumoniasvconjuctiva
Severe pneumonia O yes Gastroenteritis O yes svspneumoniasvgastroent
Upper Respiratory Tract Infection(URTI) O yes Diarrhoea O yes svurti
svdiarrhoea3
Wheezing/bronchospasm O yes Dehydration O yes svbronchospasmsvdehydration
Anemia O yes Dysentery O yes svanemiasvdysentery
Severe anemia O yes Ring worm O yes svsanemia
svringworm
Malnutrition O yes Intestinal worms O yes svmalnutrition
svworms
Severe malnutrition O yes Wound O yes svsmalnutritionsvwound
Measles O yes Septic wound/ulcers O yes svmeasles
svulcers
Oral candidiasis O yes Burn O yes svcandidiasissvburn
Scabies O yes Diaper rash O yes svscabies
svdiaperrash
Rash O yes Heat rash O yes svrashdct/hoofrach
Fever >39.5, no other signs of illness 
Otherl
O yes
Other2
O yes 
O yes
6.02 If there is any error in part 6.01, shade these two circles O yes O yes
Part 7: Medication
7.01 Did you or will you give antimalarial treatment 
7.01a What was given?
O Quinine sulfate O Special antimalarial treatment per protocol O co-artem
O yes O no 
I f  'no', go  to 7.02.
O Other
File/Sick visit number
svfever39_5
svotherdl
svothercodel
svotherd2
svothercode2
anyerror
antimalaria 16
specialantimal
othername
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R efer to 4.02: O ptiM al results. I f  result is positive, P harm acy Technician is preparing  
treatment. A d m in is te r treatm ent once ready.
7.02 What other medications were given today?
Albendazol syrup O yes Sallbutamol/ventolin O yes
Amoxicilline syrup O yes Benzyl benzoate emulsion O yes
Benzoic /slicyl acid ointment O yes Ceftriaxone injection O yes
Clotrimazole cream O yes Clotrimazole oral paint O yes
Cloxacillin syrup O yes Piriton/chlorophenilamine O yes
Erythromycin syrup O yes Ferrous sulphate(vit B complex) O yes
Gentamycin eye drops O yes Gentian violet crystals O yes
Metronidazole suspension O yes Multivitamin syrup O yes
Oral rehydration salts O yes Paracetamol O yes
Praziquantel (biltricide) O yes Quinine injection O yes
Sulphadiazine cream O yes Tetracycline eye ointment O yes
Vitamin A O yes Valium injection O yes
Valium tablets O yes Hydrocortisone cream O yes
Cough expectorant O yes Chloramphenicol IM O yes
Other 1 O yes
Other 2 O yes
malbendaz
msalbutamol
mamoxicil
mbenzyl
mbenzoic
mceftriax
mclotcream
mclotpaint
mcloxacill
mpiriton
merythrom
mferrous
mgentamycin
mgentian
mmetronidaz
mmultivit
mors
mparacetam
mpraziquant
mquinjection
mletracyc
msulphadiaz
mvitamia
mvaliumini
mvaliumtaD
mhydrocort
mcoughexpect
mchloramphim
motherl
mothernamel
mother2
mothername2
7.02a If there is any error in part 7.02, shade these two circles o  yes O yes anyerror2
Part 8: Disposition
8.01 Based on IMCI classification the child has?
8.02 What is the disposition of the child ?
O mild disease 
O moderate disease 
O severe disease 
O home O PGH
Give p re -re f era! trea tm en t, 
re fe r the child  and  call CO
O Lwak O other
imci
disposition
otherdisp
X  If  hospita lized  fo r  observation o r  treatm ent no tify  CO.
A ll children being  referred  m ust be sen t with a referral form. 
I f  ch ild  is being  referred  to hospital, do n o t g ive intervention  
drug
Return to p a rt 6 o f  Schedu led  Visit Form  i f  ch ild  is p resent fo r  a S cheduled  visit. 
I f  child  is referred  to a hospital, do n o t g ive intervention drug.
Part 9: Adverse Event Classification
Clinical Officer code
9.01 Is Grade 3 AE or SAE suspected ? O yes O no
I f  'yes', fill A E  Investigation form  
Write A E  Form  file  num ber here
cliniccode
SAE
SVAEnumber
File/Sick visit number
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17 - Immunization Schedule Form
Participant ID Number
idnum 
hfac 17
Immunization
BCG O given O missed
OPVO O given 0  missed
OPV1 O given O missed
PENT 1 O given 0  missed
OPV 2 O given 0  missed
PENT 2 O given 0  missed
OPV 3 O given 0  missed
PENT 3 O given O missed
Measles O given O missed
Vitamin A : Dose 1 O given O missed
Vitamin A : Dose 2 O given 0  missed
Vitamin A : Dose 3 O given O missed
Vitamin A : Dose 4 O given O missed
Date(dd/mm/yyyy)
/ begbegdate
opvO
opvOdate
/
/
/
/
/
/
/
/
/
/
/
opv1
opvldate
pentì 
pentì date
opv2
opv2date
pent2
pent2date
opv3
opv3date
pent3
pent3date
measles
measdate
vitaminal 
vitamina 1 date
vitamina2 
vita mina 2d ate
vitamina3
vitamina3date
vitamina4
vitamina4date
IPTi -17- Immuniztion Schedule Form - FINAL-Version 1.2
filenum 17
Page 1 of 2
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17 - Immunization Schedule Form 1
Date form completed (dd/mm/yyyy)
/ /
date 17
Notes:
IPTi - 17- Immuniztion Schedule Form - FINAL-Version 1.2
Page 2 of 2
r S c a n n e d  ,------, " I8588296983 IPTi - Malaria Prevention Study & verified . :  \19 - Hospital Discharge Form
Staff code IPTi Participant ID number Date (dd/mm/yyyy) AE number
- / /
C opy from  the A E  
Investigation Form  
Filing  N um ber
staffcode
idnum
date_19
aenumber_1i
Part 1. Identifying Information
1.01 Child's name
C h ris tian  n a m e
1.02 Child's date of birth
d d /m m /y y y y hddob 19
J u o k  n a m e
F a th e r 's  Ju o k  n a m e
File/Discharge number
IPTi -19- Hospital Discharge Form - FINAL-Version 2.3 
(T h is  fo rm  h a s  b e e n  d e s ig n e d  so  th a t th e  firs t p a g e  c a n  b e  re m o v e d  fo r  a n o n y m iz a tio n  o f  d a ta )
Page 1 of 7
r 7H6296989 19- Hospital Discharge Form
IPTi Participant ID number AE number Date(dd/mm/yyyy)
- / /
Part 2: Discharge
2.01 Date admitted
C opy from  the A E  
Investigation  Form  
Filing  N um ber
/ /
2.02 Hospital O Lwak O Bondo O NGPH 
O other___________________
date_19_2
aenumber_19_2
idnum2
hdadmdate
hdhospital
hdhospother
2.02a If admitted to NPGH,Write hospital number here 
(Found on outside cover o f  hosp ita l chart)
2.03 Did the child receive blood transfusion during admission? 
2.03a If yes, date of transfusion
O yes O no
/ /
hdipnum
hdtransfusion
hdtransdate
2.04 Was a malaria blood slide done during the hospital admission? o  yes O  no 
2.04a If yes, date of slide 
2.04b If yes, where was the slide done?
/ /
O  Walter Reed O  Main Hospital Laboratory 
O  CRC lab
O  Other
2.04c If slide was made, what was the result? O  Positive O  Negative
O  Indeterminate O  Unknown
2.04d If blood slide was positive, what was the species?
O P falciparum O P falciparum gametocyte only 
O  P malariae O  Mixed infection P falciparam+P malariae
O Other
hdbsdone
hdbsdate
hdbslab
hdbslabother
hdbsresult
hdpfalciparum
hdpfalciparumgarr
hdpmalariae
hdpfmmixed
hdspcother
hdspcothername
2.04e If yes, what was the disposition of the slide? O  CRC-lab O  Sent to Kisian for re-reading hdbsdisposition
O  Discarded O  unknown
2.05 Was a complete hemogram done during this admission? q  yes O no 
2.05a If yes, where was the test performed? O  Walter Reed O  Main Hospital Laboratory 
O  CRC lab
O  Other
hdhgdone
hdhglab
hdhglabother
File/Discharge number
L 1 11 1 1 1 IPTi -19- Hospital Discharge Form - FINAL-Version 2.3 Page 2 of 7
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2.05b If yes, record results below
NO TE: If  m ore than one hem ogram  done
duringadm ission, record  one with the low est 
hem oglobin value.
WBC
RBC
Hgb
Hct
MCV
MCH
MCHC
Pit
LY%
LY#
■
X10A3/uL
X10A6/uL
g/dL
%
fL
pg
g/dL
X10A9/L
. □ %
X10A3/uL. □
hdwb
hdrbc
hdhb
hdhct
hdmc
hdmc
hdmc
hdplt
hdly_percent
hdly_
2.06 Was a hemocue measurement done during admission? O yes O no O unknown hdhqdone
2.06a If yes, record the value
NOTE: I f  m ore than one hem ocue
m easurem ent was taken during adm ission, 
record  one with the low est hem oglobin  value.
hdhq
2.07a Did the child have a measured axillary temperature of > 37.4 
during this hospital admission?
O yes O no O unknown hdaxiltemp
2.07b Did the child have prostration? O yes O no O unknown hdprostate
2.07c Did the child have impaired consciousness? O yes O no O unknown hdconscious
2.07d Did the child have respiratory distress or acidotic breathing? O yes O no O unknown hddistress
2.07e Did the child have 2 or more convulsions? O yes O no O unknown hd2convulse
2.07f Did the child have circulatory collapse? O yes O no O unknown hdcollapse
2.07g Did the child have radiographically confirmed pulmonary 
oedema?
O yes O no O unknown hdpoedema
2.07h Did the child have abnormal bleeding? O yes O no O unknown hdableeding
2.07i Did the child have jaundice? O yes O no O unknown hdjaundice
2.07j Did the child have haemoglobinura? O yes O no O unknown hdhglobinura
2.07k Did the child have hypoglycemia? O yes O no O unknown hdglycemia
2.07I Was blood glucose measured? O yes O no O unknown hdglucose
W rite down the am ount 
o f g lucose in  b lood
mmol/L hdglucosevm
File/Discharge number
L 111111 IPTi -19- Hospital Discharge Form - FINAL-Version 2.3 Page 3 of 7
0 9 1 3 2 9 6 9 8 7
2.08 Did the child receive antimalarial treatment during admission? o  yes O no O unknown hdantimaiariaMi
2.08a If yes, What date was antimalarial treatment begun? 
( If  m ore than one antim alaria l g iven  record  date  
first antim alaria l g iven)
hddateantimal
2.08b If yes, fill in circle for each antimalarial that 
was given
O SP / Fansidar / Metakelfin O Amodiaquine
O Quinine Injection 
O Quinine tablets 
O other
O Cotexin/Alaxin 
O Malarone
O Cosumate 
O Co-artem 
O unknown
2.08c If there is any error in part 2.08b, shade these two circles O yes O yes
hdsp
hdamodiaquine
hdcosumate
hdquinineinj
hdcotexin
hdcoartem
hdquininetab
hdmalarone
hdnotknown
hdothermaldrug
hdotherdrugname
hdanyerror
2.09 Did the child receive any sulfa-containing antibiotics 
during admission (septrin/cotrimoxazole) O yes O no O unknown
hdsulfantibiotic
2.10 Did the child receive any antimalarials to take at home upon O yes O no O unknown 
discharge?
hdantimalhome
2.10a If yes, what antimalarials were given on discharge? (Shade a ll tha t apply)
Medication No days How Dispensed
(1=Pllls g iven 2=Prescription W ritten 3=O ther)
O  SP/ Fansidar / Metakelfin
O Amodiaquine 
O Quinine tablets 
O Cosumate 
O Cotexin/Alaxin 
O Co-artem
O Malarone 
O other
2.10b If there is any error in part 2.10a, shade these two circles
O 1 0 2 O 3
O 1 0 2 O 3
O 1 0 2 O 3
O 1 0 2 0 3
O 1 0 2 0 3
O 1 0 2 0 3
O 1 0 2 0 3
O 1 0 2 0 3
o yes O yes
hdsph
hdsp_day
hdsp_disp
hdaqh
hdaq_day
hdaq_disp
hdquh
hdqu_day
hdqu_disp
hdcosh
hdcos_day
hdcos_disp
hdcoth
hdcot_day
hdcot_disp
hdcoarth
hdcoart_day
hdcoart_disp
hdmalh
hdmal_day
hdmal_disp
hdothh
hddrgna
hdoth_day
hdoth_disp
hdanyerror3
File/Discharge number
L ..... IPTi -19- Hospital Discharge Form - FINAL-Version 2.3 Page 4 of 7
2 9 5 8 2 9 6 9 8 8
2.11 Did the child receive any sulfa-containing antibiotics to 
take at home upon discharge (septrin/cotrimoxazole)? O yes O no O unknown hdsulfantibh
2.11a If yes, what antibiotics were given on discharge? (Shade a ll that apply)
Medication No days
(If recom m ended to take m edication  
indefin ite ly  code n u m b er o f days as 99)
O Septrin/cotrimoxazole
O Other
How Dispensed
(1=Pills g iven  2=Prescription W ritten 3=Other)
O 1 0 2 0 3
O 1 0 2 0 3
2.11b If there is any error in part 2.11a, shade these two circles O yes O yes
2.12 What were the hospital discharge diagnoses?
(These m ay be d ifferent from  the CO ju d g em en t o f  A E  diagnoses on form s 29&30)
Malaria O yes
Severe malaria O yes
Pneumonia O yes
Severe pneumonia O yes
Upper Respiratory Tract Infection(URTI) O yes
Wheezing/bronchospasm O yes
Anemia O yes
Severe anemia O yes
Malnutrition O yes
Severe malnutrition O yes
Measles O yes
Oral candidiasis O yes
Scabies O yes
Otherl
Other2 ________________________________________
2.12a If there is any error in part 2.12, shade these two circles
Meningitis O yes
Otitis media O yes
Conjunctivitis O yes
Gastroenteritis O yes
Diarrhoea O yes
Dehydration O yes
Dysentery O yes
Intestinal worms O yes
Wound O yes
Septic wound/ulcers O yes
Burn O yes
Rash O yes
---------- O yes
---------- O yes
O yes O yes
2.13 Outcome O alive O absconded
O dead O transferred
2.14 Date of discharge/death/absconding (dd/mm/yyyy)
hdseph
hdsep_day
hdsep_disp
hdothph
hdothp_day
hdothp_disp
hdanyerror4
hdmalaria
hdmeningitis
hdsmalaria
hdotitis
hdpneumonia
hdconjuctiva
hdspneumonia
hdgastroent
hdurti
hddiarrhoea3
hdbronchospasm
hddehydration
hdanemia
hddysentery
hdsanemia
hdworms
hdmalnutrltlon
hdwound
hdsmalnutrition
hdulcers
hdmeasles
hdburn
hdcandidiasis
hdrashd
hdscabies
hdotherdl
hdothercodel
hdotherd2
hdothercode2
hdanyerror2
hdoutcome
hddischargdate
File/Discharge number
L 111111 IPTi -19- Hospital Discharge Form - FINAL-Version 2.3 Page 5 of 7
5 0 3 2 2 9 6 9 8 4
3.01 Notes:
File/Discharge number
IPTi -19- Hospital Discharge Form - FINAL-Version 2.3
Page 6 of 7
File/Discharge number
IPTi -19- Hospital Discharge Form - FINAL-Version 2.3
Page 7 of 7 I
I 7851448221 IPTi - Malaria Prevention Study
29 - Adverse Events Investigation Form
Scanned 
& Verified n  “ I
IPTi Participant ID number Clinical officer code Interview date
Note: C lin ical O fficer o r  designated m edical s ta ff shou ld  fill this form  fo r a ll c lin ical AEs.
idnum 
cliniccode 
date 29
Part 1: Identifying information
1.01 Infant's name
Christian name
Juok name
Father's Juok name
.02 Infant's date of birth
(dd/mm/yyyy) name
QXD
1.03 Infant's gender o  Male O Female mname
sex
1.04 Infant's date of enrollment lname
(dd/m m /yyy)
/  /  enrolldate
idnum
File / AE number
IPTi - 29-Adverse Events Investigation Form - FINAL-Version 2.5 
(This form has been designed so that the first page can be removed for anonymization of data)
Page 1 of 6
7 6 2 1 4 4 8 2 2 6 29 - Adverse Events Investigation Form
Clinic Officer code IPTi Participant ID number Interview date (dd/mm/yyyy)
- / /
Was this AE preceded by a sick visit?
If yes, write Sick Visit Form filing number here
O yes O No
idnum2
cliniccode2
date_29_2
AElpreceed
AElfilenum
Part 2: Investigation
2.01 Notification of Adverse Event was received from whom? AEisource
O IPTi Nurse O IPTi coordinator O Non IPTi clinic staff
O DSS staff o  PGH staff O IPTi clinical officer
O Other
AElothersourc«
2.02 Onset date
/ /
2.03 Date of awareness by IPTi staff
/ /
AEldateonset
AElawaredate
2.04 AE diagnosis name(s) 
(check a ll that apply)
Malaria O yes Meningitis O yes aeimalariaaeimeningitis
Severe malaria O yes Jaundice O yes aeismalariaaeijaundice
Pneumonia O yes Conjunctivitis O yes
aeipneumonia
aeiconjuctiva
Severe pneumonia O yes Gastroenteritis O yes aeispneumoniaaeigastroent
Wheezing/bronchospasm
Anaphylaxis
Stevens Johnson syndrom/TEN
Drug rash 
Anemia
Severe anemia
Malnutrition
Measles
Fever >39.5, no other signs of illness 
O Other
O yes Diarrhoea O yes
O yes Dehydration O yes
O yes Dysentery O yes
O yes Neutropenia O yes
O yes Stomatitis/oral ulcers O yes
O yes Temperature >39.5 O yes
O yes Septic wound/ulcers O yes
O yes Burn O yes
O yes
Code
O Other Code
aeibronchospasm
aeidiarrhoea3
aeianaphylaxis
aeidehydration
aeisten
aeidysentery
aeidrashd
aeineutropenia
aeianemia
aeistomatitis
aeisanemia
aeitemp_39_5
aeimalnutrit
äeiulcers
aeimeasles
aeiburn
aeifever39_5
aeiname 
aeiotherd 1 
aeiothercodel
aeiname2
aeiotherd2
aeiothercode2
2.04a If there is any error in part 2.04, shade these two circles O yes O yes AElanyerror
File / AE number
....... .............................
IPTi - 29-Adverse Events Investigation Form - FINAL-Version 2.5 Page 2 of 6
3 7 6 1 4 4 8 2 2 7r
2.05 Was client hospitalized? O yes O no
2.06 Dates 1 st dose of study drug was given
/  / to / /
O study drug not yet administered
2.07 Dates 2nd dose of study drug was given
/ / to / /
O study drug not yet administered 
2.08 Dates 3rd dose of study drug was given
/ / to / /
O study drug not yet administered
2.09 Does the participant need to be withdrawn from the study? 
O yes O no O already withdrawn O N/A
2.10 At the time of completing this report, determine status of adverse event
O Resolved O Not resolved O N/A 
Go to 2 .12
1
AElhospitalized
AEldosedatel
AEldosedatelb
AElsdruggivenl
AEIdosedate2
AEIdosedate2b
AEIsdruggiven2
AEIdosedate3
AEIdosedate3b
AEIsdruggiven3
AElwithdrawIsm
AEI resolved
2.11 If event is resolved determine outcome Go to 2.13
O Died, participant history and cause known o  Event resolved with disability
O Event resolved without disability O N/A AEistatusi
O Other
AElotherstatusI
2.12 If event is not resolved, determine status
O Participant hospitalized O Participant home: event ongoing O N/A
O Participant in clinic: event ongoing o  Participant died, history or cause not known
O Other
If  event is n o t resolved, continue to fo llow  participant, fill A E  Update Form  when necessary  
and  untill A E  is reso lved
AEIstatus2
AEIotherstatus2
File / AE number
L 1 1 1 1 1 IPTi - 29-Adverse Events Investigation Form - FINAL-Version 2.5 Page 3 of 6
9 9 8 5 4 4 8 2 2 1
2.13 Narrative of event:
Include history of present illness, symptoms, other medication usage, other medical history, 
pertinent physical findings, laboratory/X-ray diagnosis, treatment of adverse event, and follow up 
required. Also include any protocal violations or erroneous drug administration that may have 
contributed to the event.
File / AE number
L 1 1 1 1 1 IPTi - 29-Adverse Events Investigation Form - FINAL-Version 2.5 Page 4 of 6
1 4 1 7 4 4 8 2 2 3
File /AE number
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Part 3: Categorization/Reporting: (t o  b e  c o m p l e t e d  b y  t h e  p r i n c i p a l  in v e s t i g a t o r )
Investigator code
7 1 I
3.01 DSMB
Categorization of Event 
O SAE - death
O SAE - hospitalization for unexpected or unusual cause, __
, including critica l anem ia(hb<5.0) OR  
re lated to study drug
O SAE - hospitalization for common childhood illness __
O SAE - Life threatening event, not hospitalized —
O SAE - Event resulting in disability, not hospitalized —
O AE - Grade 3 AND related to study drug __
O AE - Grade 3 AND NOT related to study drug,No hospitalization 
OR refused hospitalization
O Grade 1 or 2AE, or not an AE or SAE —
Reporting Timeline 
Within 7 days of event
Within 7 days of event
Quarterly report 
Within 7 days of event 
Within 7 days of event 
Within 7 days of event 
Not reported 
Not reported
AElPIcode
AEldsmgrade
3.02 CDC/KEMRI IRB/ERC
Cartegorization of Event Reporting Timeline AElcdcgrade
O SUAEP- Serious unexpected event resulting in death o r  * Informal E-mail within 2 working days
hospitalization, AN D  a t least poss ib ly  re la ted  to study drug Formal report within 7 days of event
O AAE- Deaths o r  hosp ita lizations from  com m on > Yearly renewal report
ch ildhood illness
°  Not an AAE, or SUAEP  » Not reported
3.03 Determine the causal relationship to investigation drug administration
O definite (most probable) O probable O possible O unlikely O not related O unclassified AEiprobabie
3.04 Should the participant be withdrawn from the study?
O yes O no O already withdrawn O died AEiwithdrawpi
3.05 Signature of investigator
sign
3.06 Date of signaturem/nr 2 0 0 AElsigndate
File / AE number
L 1 1 1 1 1 IPTi - 29-Adverse Events Investigation Form - FINAL-Version 2.5 Page 6 of 6
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S c a n n e d  ,------ ,
& V e rifie d  I___ IIPTi - Malaria Prevention Study
30 - Adverse Events Update Form
AE number Clinical officer code IPTi Participant ID number Interview date (dd/mm/yyyy)
Note: C lin ical O fficer o r  designated  m edical s ta ff shou ld  fill this form  fo r  a ll unresolved AEs.
staffcode
AEnumbei
idnum
date 30
cliniccode
Part 1: Identifying information
1.01 Infant's name 1.02 Infant's date of birth
C h ris tia n  n a m e
J u o k  n a m e
F a th e r 's  Ju o k n a m e
(d d /m m /y y y y )
/ /
1.03 Infant's gender o  Male O Female
1.04 Infant's date of enrollment
(dd/m m /yyy)
/ /
name
dob
mname
sex
Iname
enrolldate
idnum
Filenum/Pagelink
IPTi - 30-Adverse Events Update Form - FINAL-Version 2.4
(T h is  fo rm  h a s  b e e n  d e s ig n e d  s o  th a t th e  firs t p a g e  c a n  b e  re m o v e d  fo r  a n o n y m iz a tio n  o f  d a ta )
Page 1 of 5
5 0 3 1 2 1 0 6 4 2 30- Adverse Events Update Form
AE number Clinical officer code IPTi Participant ID number Interview date (dd/mm/yyyy)
/ m /
AEnumber2 
idnum2 
date 30_2
cliniccode2
Part 2: Update on Event
2.01 Has the event:
O increased in severity O decreased in severity O no improvement
AEUseverity
2.02 AE diagnosis name(s) F inal A E  diagnoses shou ld  be assigned based  on CO ju d g em en t
ra th er than hosp ita l d ischarge diagnoses.
O yes Meningitis
O yes
Malaria
Severe malaria 
Pneumonia 
Severe pneumonia 
Wheezing/bronchospasm
O yes 
O yes 
O yes
Jaundice
Conjunctivitis
Gastroenteritis
Diarrhoea
O yes 
O yes
O yes
O yes
O yes
Anaphylaxis
Stevens Johnson syndrom/TEN
Drug rash 
Anemia 
Severe anemia 
Malnutrition 
Measles
Fever >39.5, no other signs of illneess
O yes Dehydration O yes
O yes Dysentery O yes
O yes Neutropenia O yes
O yes Stomatitis/oral ulcers O yes
O yes Temperature >39.5 O yes
O yes Septic wound/ulcers O yes
O yes Burn O yes
O yes
O Other 
O Other
Code
Code
2.02a If there is any error in part 2.02, shade these two circles O yes O yes
aeumalaria
aeumeningitis
aeusmalaria
aeujaundice
aeupneumonia
aeuconjuctiva
aeuspneumonia
aeugastroent
aeubronchospasrr
aeudiarrhoea3
aeuanaphylaxis
aeudehydration
aeusten
aeudysentery
aeudrashd
aeuneutropenia
aeuanemia
aeustomatitis
aeusanemia
aeutemp_39_5
aeumalnutrition
aeuulcers
aeumeasles
aeuburn
aeufever39_5
aeuname
aeuotherdl
aeuothercodel
aeuname2
aeuotherd2
aeuothercode2
aeuanyerror
2.03 Date that most recent dose of study drug was given
/ / to / /
O study drug not yet administered
AEUdosedatel
AEUdosedatelb
AEUsdruggivenl
Filenum/Pagelink
L 1 1 1 Li IPTi - 30-Adverse Events Update Form - FINAL-Version 2.4 Page 2 of 5
9 5 1 1 2 1 0 6 4 9r
2.04 Does the participant need to be withdrawn from the study?
O yes O no O already withdrawn
2.05 At the time of completing this report, determine status of adverse event
O Resolved O Not resolved 
Go to 2 .07
2.06 If event is resolved determine outcome Go to 2.08
O Died, participant history and cause known q  Event resolved with disability 
O Event resolved without disability O N/A
O Other
AEUwithdrawIsm
AEU resolved
AEUstatusI
AEUotherstatusI
2.07 If event is not resolved, determine status
O Participant hospitalized O Participant home: event ongoing
O Participant in clinic: event ongoing o  Participant died, history or cause not known 
O Other
I f  event is no t resolved, continue to fo llow  participant, fill A E  Update Form  when necessary  
and  untilI A E  is reso lved
AEUstatus2
AEUotherstatus
2.08 Describe update on the event
Filenum/Pagelink
IPTi - 30-Adverse Events Update Form - FINAL-Verslon 2.4 Page 3 of 5
r 8 3 5 5 2 1 0 6 4 4
Filenum/Pagelink
L 1 1 1 1 1 IPTi - 30-Adverse Events Update Form - FINAL-Version 2.4 Page 4 of 5
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Part 3: Categorization/Reporting: ( t o  b e  c o m p l e t e d  b y  t h e  p r i n c i p a l  in v e s t i g a t o r )
Investigator Code
7
3.01 DSMB
Final Categorization of Event 
O SAE - death
O SAE - hospitalization for unexpected or unusual cause, 
,including critica l anem ia(hb<5.0) OR  
re lated to study drug
O SAE - hospitalization for common childhood illness
Reporting Timeline
Within 7 days of event
O SAE - Life threatening event, not hospitalized ___
O SAE - Event resulting in disability, not hospitalized ___
O AE - Grade 3 AND related to study drug ___
O AE - Grade 3 AND NOT related to study drug,No hospitalization,
OR refused hospitalization 
O Grade 1 or 2AE, or not an AE or SAE
Within 7 days of event
Quarterly report 
Within 7 days of event 
Within 7 days of event 
Within 7 days of event 
Not reported 
Not reported
3.02 CDC/KEMRI IRB/ERC
Final Carteqorization of Event
O SUAEP- Serious unexpected event resulting in death o r
Reporting Timeline
AEUPIcode
AEUdsmgrade
AEUcdcgrade
Informal E-mail within 2 working days 
hospitalization, AND at leas t possib ly  re lated to study drug  Formal report within 7 days of event
O AAE- Deaths o r  hospita lizations from  com m on  
ch ildhood illness
O Not an AAE, or SUAEP
Yearly renewal report 
-» Not reported
3.03 Has the determination of causal relationship changed since AE Investigation form was completed? 
O yes O no AEUcausecha
3.03a If yes, record new proposed causal relationship
O definite (most probable) O probable O possible O unlikely O not related O unclassified AEUprobabie
3.04 Should the participant be withdrawn from the study?
O  yes O  no O  already withdrawn O  Died AEUwithdrawpi
3.05 Signature of investigator
sign
3.06 Date of signature
/ / 2 0 0
L
Filenum/Pagelink
IPTi - 30-Adverse Events Update Form - FINAL-Version 2.4
AEUsigndate
Page 5 of 5 J
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Malaria Prevention Study 
36 - STUDY Form
Health Facility:
Head of compound's name
C h ris tia n  n a m e
J u o k  n a m e  
F a th e r 's  J u o k  n a m e
Infant's name
C h ris tia n  n a m e
J u o k  n a m e
F a th e r 's  J u o k  n a m e
Mother / Father / Guardian's name 
C h ris tia n  n a m e
J u o k  n a m e
F a th e r 's  J u o k  n a m e
Village
DSS Permanent ID DSS Permanent ID
□  [
Date seen
□
Date of next 
visit
Visit 1 Enrollment
Visit 2 Pent 2 (iPTii)
Visit 3► Pent 3 (lPTi2)
Visit 4 18 weeks
Iron Visit
Visit 5
i
' Visit 6
Measles (iPTi3)
12 months
Visit 7 18 months
Visit 8 24 months
Missed medication _______
Missed medication ------------
Missed medication
Infant's date of birth (dd/mm/yyyy)
L [
OptiMal 
+ / - /ND
_  □
_  □
Study Drug Given
Day 1 Day 2 Day 3
□□
□
□□□□
/ /
IPTi -36- Study Form - FINAL-Version 1.1 J
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